Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

 
<< vorige    volgende >>
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             2413 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1001 PGI23 COST OF INFLAMMATORY BOWEL DISEASE MANAGEMENT IN THE KINGDOM OF SAUDI ARABIA Al Jedai, A.
22 S3 p. S620
 artikel
1002 PGI13 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE Fioratti, C.
22 S3 p. S618
 artikel
1003 PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE Fioratti, C.
22 S3 p. S618
 artikel
1004 PGI10 COST-UTILITY ANALYSIS OF USTEKINUMAB VS VEDOLIZUMAB IN CROHN DISEASE IN ITALY Povero, M.
22 S3 p. S617-S618
 artikel
1005 PGI15 COST-UTILITY AND BUDGET IMPACT ANALYSES OF INFLIXIMAB AND ITS BIOSIMILAR IN THAI PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE CROHN'S DISEASE Phisalprapa, P.
22 S3 p. S618-S619
 artikel
1006 PGI3 DEPRESCRIBING OF LONG TERM UTILIZATION OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS BASED ON ENDOSCOPIC ANALYSIS Chandrabhiroop, M.
22 S3 p. S616
 artikel
1007 PGI46 DISEASE BURDEN, SYMPTOMS ASSOCIATED WITH TREATMENT-SEEKING AND REMISSION DEFINITION: A QUALITATIVE STUDY IN ADULT AND ADOLESCENT PATIENTS WITH CROHN'S DISEASE Kitchen, H.
22 S3 p. S624
 artikel
1008 PGI56 EVALUATION OF MORTALITY ASSOCIATED WITH PROTON PUMP INHIBITORS AND H2 BLOCKERS: A REAL WORLD EVIDENCE STUDY Luciano, S.
22 S3 p. S626
 artikel
1009 PGI2 EVALUATION OF PATIENTS DEPRESCRIBED OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS USING KWAS QUESTIONNAIRE Chandrabhiroop, M.
22 S3 p. S616
 artikel
1010 PGI32 EVALUATION OF THE COST-UTILITY OF THE YORK FAECAL CALPROTECTIN CARE PATHWAY Holmes, H.
22 S3 p. S622
 artikel
1011 PGI22 HEALTH ECONOMIC EVALUATION OF EARLY LAPAROSCOPIC CHOLECYSTECTOMY FOR THE PATIENT WITH GALLSTONE DISEASE. A MICRO-COSTING ANALYSIS Turri, J.A.
22 S3 p. S620
 artikel
1012 PGI24 IBD INTEGRATED MODEL OF CARE LEADS TO COST SAVINGS: A BUDGET IMPACT MODEL FOR A RUSSIAN REGION Bezdenezhnykh, T.
22 S3 p. S620
 artikel
1013 PGI60 IDENTIFYING PROGRESSING PATIENTS IN AN ARTIFICIAL INTELLIGENCE (AI) BASED COHORT OF NONALCOHOLIC STEATOHEPATITIS (NASH) Bandaria, J.
22 S3 p. S627
 artikel
1014 PGI59 INCREASED AVAILABILITY OF REIMBURSED INTERFERON-FREE TREATMENTS FOR HCV IN POLAND AND ITS COST Stańczak-Mrozek, K.
22 S3 p. S627
 artikel
1015 PGI52 INTERNATIONAL ADAPTATION AND LINGUISTIC VALIDATION OF NASH-CHECK, A NOVEL PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS Doward, L.
22 S3 p. S625
 artikel
1016 PGI20 MULTIMATRIX VERSUS TIME-DEPENDENT DELIVERY OF MESALAZINE FOR ULCERATIVE COLITIS THERAPY IN KAZAKHSTAN: A HEALTH ECONOMIC EVALUATION Almadiyeva, A.
22 S3 p. S620
 artikel
1017 PGI57 NON-BIOLOGIC TREATMENT OF GERMAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASSESSMENT OF HEALTH CARE RESOURCE USE AND COST ASSOCIATED WITH DISEASE ACTIVITY Hardtstock, F.
22 S3 p. S626
 artikel
1018 PGI14 PHARMACOECONOMIC ASPECTS OF TREATMENT OF ACUTE PANCREATIS IN CENTRAL PART OF SERBIA - COST OF ILLNESS STUDY BASED ON DATA FROM TERTIARY REFERRAL HOSPITAL Stefanović, K.
22 S3 p. S618
 artikel
1019 PGI51 PSYCHOMETRIC EVALUATION OF NASH-CHECK, A PATIENT-REPORTED OUTCOME MEASURE FOR NONALCOHOLIC STEATOHEPATITIS Twiss, J.
22 S3 p. S625
 artikel
1020 PGI47 PSYCHOMETRIC VALIDATION OF THE INTESTINAL GAS QUESTIONNAIRE (IGQ) FOR MEASURING GAS RELATED SYMPTOMS AND THEIR IMPACT ON DAILY LIFE Duracinsky, M.
22 S3 p. S624
 artikel
1021 PGI55 QUALITY OF LIFE AND PATIENT PREFERENCE AMONG DANISH PATIENTS WITH ULCERATIVE COLLITIS - RESULTS FROM A SURVEY STUDY Hagelund, L.
22 S3 p. S626
 artikel
1022 PGI37 REDUCTION IN CO-THERAPY COSTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH BIOLOGICAL DRUGS Kostev, K.
22 S3 p. S623
 artikel
1023 PGI61 REGULATORY AND HTA ENGAGEMENT IN NEURODEGENERATIVE DISEASE RESEARCH: A DECISION TOOL O'Rourke, D.
22 S3 p. S627
 artikel
1024 PGI44 SCREENING STRATEGIES FOR HEPATITIS C VIRUS ELIMINATION IN ITALY Kondili, L.
22 S3 p. S624
 artikel
1025 PGI31 SENSITIVITY OF INCREASING BODY WEIGHT IN PATIENTS WITH COLLITIS ULCEROSA TO TOTAL COST OF TREATMENT Pilgaard, T.
22 S3 p. S622
 artikel
1026 PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES Le Pen, C.
22 S3 p. S621
 artikel
1027 PGI35 THE CLINICAL AND ECONOMIC IMPACT OF TDM (THERAPEUTIC DRUG MONITORING) ON CROHN DISEASE MANAGEMENT IN ITALY Povero, M.
22 S3 p. S622
 artikel
1028 PGI7 THE CLINICAL IMPACT OF THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE ─ A CRITICAL LITERATURE REVIEW AND META-ANALYSIS Povero, M.
22 S3 p. S617
 artikel
1029 PGI33 THE COST-EFFECTIVENESS OF FAECAL MICROBIOTA TRANSPLANTATION VS. ANTIBIOTICS FOR PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: A SYSTEMATIC REVIEW Hammeken, L.
22 S3 p. S622
 artikel
1030 PGI30 THE MEDICAL COSTS OF INFLAMMATORY BOWEL DISEASE IN RUSSIA FROM A PUBLIC PAYER PERSPECTIVE Ignatyeva, V.
22 S3 p. S621-S622
 artikel
1031 PGI42 THE NEW WAVE OF ULCERATIVE COLITIS BIOLOGICS: CONSTRAINED BY THE COST-CONSCIOUS EUROPEAN MARKETS OR CHALLENGING THE TREATMENT PARADIGM? Privolnev, Y.
22 S3 p. S623
 artikel
1032 PGI36 THE RECENT CHANGE IN EPIDEMIOLOGY OF CHRONIC LIVER DISEASE IN JAPAN: AN ANALYSIS OF CLAIMS DATABASE Yoshida, M.
22 S3 p. S622-S623
 artikel
1033 PGI50 THE RELATIONSHIP BETWEEN DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS IN JAPAN Kuwabara, H.
22 S3 p. S625
 artikel
1034 PGI6 TREATMENT FAILURE AND REMISSION IN MODERATE TO SEVERE ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD) IN EUROPE Achra, M.
22 S3 p. S617
 artikel
1035 PGI45 WORK PRODUCTIVITY AND COSTS RELATED TO PATIENTS WITH INFLAMMATORY BOWEL DISEASE Walter, E.
22 S3 p. S624
 artikel
1036 PIH13 A COST-EFFECTIVENESS ANALYSIS OF ENTERAL LACTOFERRIN SUPPLEMENTATION FOR VERY PRETERM INFANTS: THE ELFIN TRIAL Fusco, F.
22 S3 p. S629-S630
 artikel
1037 PIH55 A MULTIVARIATE APPROACH TO EXPLORE THE DRIVERS OF MEDICINE ACCEPTABILITY IN PEDIATRICS Vallet, T.
22 S3 p. S637
 artikel
1038 PIH10 ANALYSING PRESCRIBING PATTERNS AND COSTS OF DRUG TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS IN THE NETHERLANDS Schreijer, M.A.
22 S3 p. S629
 artikel
1039 PIH28 A REAL WORLD ANALYSIS OF PREVALENCE OF SYMPTOMS AND HEALTHCARE UTILIZATION IN WOMEN WITH MENOPAUSE Sharman Moser, S.
22 S3 p. S632
 artikel
1040 PIH40 ASSESSING HEALTH DISPARITY IN THE ELDERLY POPULATION WITH DIFFERENT ECONOMIC STATUS IN SOUTH KOREA: FOCUSING ON HIP FRACTURE Seo, M.S.
22 S3 p. S634
 artikel
1041 PIH37 ASSESSMENT OF PRECLINICAL MARKERS "MOBILITY LIMITATIONS” AND "COGNITIVE IMPAIRMENT” AMONG GERIATRIC INPATIENTS: EVIDENCE FROM THE CROSS SECTIONAL STUDY Rashid, I.
22 S3 p. S634
 artikel
1042 PIH20 A TARGETED LITERATURE REVIEW OF THE ECONOMIC BURDEN ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME Rajora, P.
22 S3 p. S631
 artikel
1043 PIH31 BURDEN OF SHINGLES IN THE OVER 80'S IN THE UK Matthews, I.
22 S3 p. S633
 artikel
1044 PIH43 CAN USING POINT OF CARE BLOOD TESTS HELP INFORM DECISION MAKING FOR PATIENTS WITH ACUTE FRAILTY SYNDROME? A BUDGET IMPACT ANALYSIS Stainthorpe, A.
22 S3 p. S635
 artikel
1045 PIH30 CHALLENGES FACED BY PEOPLE WITH PHYSICAL DISABILITIES IN ACCESSING SEXUAL AND REPRODUCTIVE HEALTH SERVICES IN EASTERN REGION OF NEPAL Subedi, L.
22 S3 p. S632-S633
 artikel
1046 PIH41 CHANGES OF CAESAREAN SECTION RATES IN EUROPEAN COUNTRIES BETWEEN 1990-2014 Elmer, D.
22 S3 p. S635
 artikel
1047 PIH47 COMPARISON OF CAESAREAN SECTION RATES IN GEOGRAPHICAL AREAS OF WHO EUROPEAN REGION Elmer, D.
22 S3 p. S636
 artikel
1048 PIH46 COST EFFECTIVENESS ANALYSIS FOR A MULTI-FACTORIAL INTERVENTION FOR ELDERLY INPATIENTS WITH DELIRIUM, UTILIZING REAL WORLD DATA Ohde, S.
22 S3 p. S636
 artikel
1049 PIH17 COST-EFFECTIVENESS OF INTERVENTIONS PREVENTING FALLS IN OLDER ADULTS: A SYSTEMATIC REVIEW Schmidt, M.
22 S3 p. S630
 artikel
1050 PIH21 COST-EFFECTIVENESS OF ORAL CARE IN INSTITUTIONALIZED OLDER PEOPLE Werbrouck, A.
22 S3 p. S631
 artikel
1051 PIH24 COST-UTILITY ANALYSIS OF NEWBORN SCREENING PROGRAM BY TANDEM MASS SPECTROMETRY IN JAPAN Konomura, K.
22 S3 p. S632
 artikel
1052 PIH23 ECONOMIC BURDEN OF TRANSFUSION DEPENDENT THALASSAEMIA (TDT) PATIENT IN MALAYSIA: A SOCIETAL PERSPECTIVE Wong, J.H.Y.
22 S3 p. S631
 artikel
1053 PIH11 ECONOMIC EVALUATION OF OSPEMIFENE FOR THE TREATMENT OF VULVOVAGINAL ATROPHY IN THE UNITED KINGDOM Dymond, A.
22 S3 p. S629
 artikel
1054 PIH32 EPIDEMIOLOGIC FACTORS PREDISPOSING TO PEDIATRIC OBESITY: A SYSTEMATIC REVIEW OF THE LITERATURE Pacheco-Fuentes, Á.
22 S3 p. S633
 artikel
1055 PIH22 ESTIMATING THE PRODUCTIVITY BURDEN OF PEDIATRIC PNEUMOCOCCAL DISEASE IN THAILAND Ounsirithupsakul, T.
22 S3 p. S631
 artikel
1056 PIH48 EVALUATING COVERAGE EXPANSION FOR NON-INVASIVE PRENATAL TESTING THROUGH A PERFORMANCE-BASED RISK SHARING AGREEMENT McQueen, R.B.
22 S3 p. S636
 artikel
1057 PIH39 EVALUATION OF PROPRANOLOL OFF-LABEL USE IN INFANTILE HEMANGIOMA AND EFFECTIVENESS OF RISK MINIMISATION MEASURES TO MITIGATE ADVERSE REACTIONS: A FRENCH AND GERMAN DRUG UTILIZATION STUDY Castagné, C.
22 S3 p. S634
 artikel
1058 PIH53 EXAMINING OF PERINATAL CIRCUMSTANCES IN CHILDREN WITH COW’S MILK PROTEIN ALLERGY Lendvai-Emmert, D.
22 S3 p. S637
 artikel
1059 PIH15 EXTERNAL VALIDATION OF THE EX-ANTE BUDGET IMPACT ANALYSIS FOR PALIVIZUMAB de Oliveira, M.
22 S3 p. S630
 artikel
1060 PIH51 EXTRAPOLATION IN GERMAN BENEFIT ASSESSMENT: THE CHALLENGING REQUIREMENTS FOR PEDIATRIC PHARMACEUTICALS Ernst, N.
22 S3 p. S636-S637
 artikel
1061 PIH27 FACTORS THAT PREDISPOSE TO HOSPITALISM IN EARLY CHILDHOOD: A LITERATURE REVIEW Larenas-Stockle, F.A.
22 S3 p. S632
 artikel
1062 PIH33 FREQUENCY AND NATURE OF INPATIENT TREATMENT OF MULTIPLE OSTEOCHONDROMA (MO) IN GERMANY FROM 2005 TO 2016 Wahler, S.
22 S3 p. S633
 artikel
1063 PIH42 HEALTHCARE RESOURCE USE FOR THE MANAGEMENT OF POSTPARTUM HAEMORRHAGE IN FRANCE, ITALY, THE NETHERLANDS, AND THE UK Hollier-Hann, G.
22 S3 p. S635
 artikel
1064 PIH54 HEALTH RELATED QUALITY OF LIFE OF PRE-ADOLESCENT DEAF CHILDREN WITH COCHLEAR IMPLANTS: A CONCEPTUAL DISEASE MODEL Cooper, O.
22 S3 p. S637
 artikel
1065 PIH38 HYSTEROSCOPIC REMOVAL OF UTERINE FIBROIDS AND INFERTILITY TREATMENT: REIMBURSEMENT IN GERMANY Schleich, W.
22 S3 p. S634
 artikel
1066 PIH65 IMPACT ON CARERS OF PAEDIATRIC PATIENTS RECEIVING PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE Ballinger, R.
22 S3 p. S639
 artikel
1067 PIH14 INCREMENTAL COSTS OF PREMATURITY AND LOW BIRTHWEIGHT Kovacs, G.
22 S3 p. S630
 artikel
1068 PIH62 INVESTIGATING THE RESPONSIVENESS TO CHANGE OF THE HIV TREATMENT SATISFACTION QUESTIONNAIRE CHANGE VERSION (HIVTSQC) IN OVERCOMING CEILING EFFECTS IN THE HIV TREATMENT SATISFACTION QUESTIONNAIRE STATUS VERSION (HIVTSQS) Romaine, J.
22 S3 p. S638-S639
 artikel
1069 PIH26 JUVENILE IDIOPATHIC ARTHRITIS IS ASSOCIATED WITH CONSIDERABLE FINANCIAL BURDEN TO SOCIETY: RESULTS OF A DUTCH COST ANALYSIS van den Berg, I.
22 S3 p. S632
 artikel
1070 PIH59 KNOWLEDGE OF HUMAN PAPILLOMAVIRUSAMONG WOMEN LIVINGIN SOMOGY AND BARANYA COUNTIES, HUNGARY Vajda, R.
22 S3 p. S638
 artikel
1071 PIH6 METABOLICS SYNDROME AND COMPLICATIONS PREGNANT WITH PCOS Komlósi, K.
22 S3 p. S628-S629
 artikel
1072 PIH50 MODERN APPROACH TO CREATION OF DONOR BREAST MILK BANKS IN UKRAINE Lishchyshyna, O.
22 S3 p. S636
 artikel
1073 PIH60 PEDIATRIC PATIENT ENGAGEMENT: USING PATIENT INSIGHTS TO IMPROVE STUDY DESIGN Franchetti, K.
22 S3 p. S638
 artikel
1074 PIH56 PLACE OF COMPLEMENTARY MEDICINES AND OPPORTUNITIES IN THE MANAGEMENT OF GYNECOLOGICAL CANCER PATIENTS Tóthné Rádai, V.
22 S3 p. S637
 artikel
1075 PIH18 PREDICTED COST AND CAPACITY BENEFITS OF THE DIGITALIZED SECONDARY CARE PATH FOR WOMEN WITH ENDOMETRIOSIS @ VIRTUAL HOSPITAL 2.0 Väätäinen, S.
22 S3 p. S630-S631
 artikel
1076 PIH35 RATES OF DELIVERY WITH COMPLICATING CONDITIONS AND POSTPARTUM COMPLICATION RATES FOLLOWING DELIVERY SURGE AMONG U.S. MOTHERS Sainski-Nguyen, A.
22 S3 p. S633-S634
 artikel
1077 PIH1 RELATIONSHIP BETWEEN INFERTILITY RELATED DISTRESS AND PRE-TREATMENT MODERATE TO VIGOROUS PHYSICAL ACTIVITY IN FEMALE PATIENTS Prémusz, V.
22 S3 p. S628
 artikel
1078 PIH29 SELF- MEDICATION: ASSESSMENT OF PRACTICES AMONG PREGNANT WOMEN Swaroop, A.M.
22 S3 p. S632
 artikel
1079 PIH4 SUPPORTING THE CONTENT VALIDITY OF THE MENSTRUAL PICTOGRAM SUPER-ABSORBENT POLYMERS CONTAINING VERSION 3 (MP SAP-C V3) USING DATA FROM COGNITIVE INTERVIEWS (CIS) OF WOMEN WITH UTERINE FIBROIDS (UF) Haberland, C.
22 S3 p. S628
 artikel
1080 PIH44 SURGICAL TREATMENT OF PATIENTS NEWLY DIAGNOSED WITH UTERINE FIBROIDS: A CLAIMS-BASED DATA ANALYSIS McKain, L.
22 S3 p. S635
 artikel
1081 PIH34 THE ASSOCIATION BETWEEN ANTICHOLINERGIC MEDICINE AND COGNITION DECLINE IN OLDER ADULTS: A SYSTEMIC REVIEW AND META-ANALYSIS Yang, D.C.
22 S3 p. S633
 artikel
1082 PIH57 THE BLEEDING AND PELVIC DISCOMFORT SCALE: MEASURING PATIENT-REPORTED SYMPTOMS IN UTERINE FIBROIDS Li, J.
22 S3 p. S637-S638
 artikel
1083 PIH67 THE CHANGES OF COST FOR PREECLAMPSIA PREGNANCY AFTER THE ANGIOGENIC FACTORS (SFLT-1 AND PLGF) TESTS. PRELIMINARY DATA OF AN ECONOMIC MODEL BASED ON LOCAL RWD. Tanaka, E.
22 S3 p. S639
 artikel
1084 PIH16 THE COST-EFFECTIVENESS OF STRATEGIES PREVENTING LATE-ONSET INFECTION IN PRETERM INFANTS Grosso, A.
22 S3 p. S630
 artikel
1085 PIH66 THE ECONOMIC AND PATIENT BURDEN OF MILD-TO-MODERATE ATOPIC DERMATITIS IN PEDIATRIC PATIENTS IN SWEDEN Ortsäter, G.
22 S3 p. S639
 artikel
1086 PIH58 THE EFFECT OF LONG-LASTING INTAKE OF MG AND B12ON THE MOTHER AND THE INTRA-UTERINE DEVELOPMENT OF THE FOETUS AS WELL AS THE OUTCOME OF DELIVERY Karácsony, I.
22 S3 p. S638
 artikel
1087 PIH9 THE USE OF ECONOMIC EVALUATIONS IN PEDIATRIC ONCOLOGY: A NARRATIVE LITERATURE REVIEW Marshall, L.
22 S3 p. S629
 artikel
1088 PIH45 UPTAKE OF ANTENATAL CARE SERVICES AMONG HIV POSITIVE WOMEN ATTENDING AN URBAN HIV CLINIC IN UGANDA Hope, M.
22 S3 p. S635-S636
 artikel
1089 PIH5 USING ARTIFICIAL REPRODUCTIVE DATABASE TO ESTABLISH PREDICTED PROBABILISTIC MODEL OF A SUCCESS LIVE BIRTH AFTER IN VITRO FERTILIZATION Chang, C.J.
22 S3 p. S628
 artikel
1090 PIH61 VALIDATION OF THE STUDY MEDICATION SATISFACTION QUESTIONNAIRE (SMSQ). A MEASURE OF MEDICATION SATISFACTION DESIGNED FOR INDIVIDUALS TAKING PRE-EXPOSURE PROPHYLAXIS (PREP) MEDICATION FOR HIV Romaine, J.
22 S3 p. S638
 artikel
1091 PIH3 VARIATIONS IN DURATION OF MECHANICAL VENTILATION IN VERY LOW BIRTH WEIGHT INFANTS IN JAPAN Shinjo, D.
22 S3 p. S628
 artikel
1092 PIH12 VARIATIONS IN HEALTH INSURANCE AFFECT HEALTHCARE UTILIZATION IN CHILDREN WITH CROHNS DISEASE IN THE USA Quiros, A.
22 S3 p. S629
 artikel
1093 PIN45 A COST-UTILITY ANALYSIS OF SEASONAL QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINE IN TURKEY Amiche, A.
22 S3 p. S647
 artikel
1094 PIN133 A GEOSTATISTICAL ALGORITHM TO BETTER IDENTIFY CONTEXTUAL AND CLINICAL FACTORS ASSOCIATED TO HPV VACCINE COVERAGE IN FRANCE Majed, L.
22 S3 p. S660
 artikel
1095 PIN7 ANALYSIS OF THE EFFECTIVENESS OF ENHANCE ADHERENCE COUNSELLING (EAC) ON VIRALLY UNSUPPRESSED HIV PATIENTS IN ST CHARLES BORROMEO HOSPITAL, ONITSHA METROPOLIS, ANAMBRA STATE, NIGERIA. Okoro, K.
22 S3 p. S641
 artikel
1096 PIN129 ANALYSIS OF THE RELATIONSHIP BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) EVALUATION AND REIMBURSED PRICE OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) COMBINATION DRUGS IN EU-3 (FRANCE, GERMANY, UNITED KINGDOM [UK]) Roxlau, T.
22 S3 p. S659
 artikel
1097 PIN150 ANALYSIS OF TREATMENT SEQUENCES FROM THE FRENCH NATIONAL SNIIRAM DATABASE: CASE STUDY OF INCIDENT PEOPLE LIVING WITH HIV IN 2013 Laurent, M.
22 S3 p. S663
 artikel
1098 PIN61 ANALYSIS ON DIRECT MEDICAL EXPENSES OF PATIENTS WITH PULMONARY TUBERCULOSIS IN CHINA: BASED ON THE CASE OF 17,000 PATIENTS IN WUHAN Zhang, F.
22 S3 p. S649-S650
 artikel
1099 PIN115 ANALYZING SOCIO-ECONOMIC INEQUALITY IN CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA Wondimu, A.
22 S3 p. S658
 artikel
1100 PIN4 A NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL VERSUS NEURAMINIDASE INHIBITORS IN THE TREATMENT OF INFLUENZA VIRUS INFECTION IN OTHERWISE HEALTHY AND HIGH-RISK ADULTS Taieb, V.
22 S3 p. S640
 artikel
1101 PIN74 A NEW WAY TO INFORM DECISION-MAKER AND ENHANCE VACCINATION PROGRAMS IN COUNTRIES WITH LIMITED BUDGETS: THE CASE OF SERBIA Sauboin, C.
22 S3 p. S652
 artikel
1102 PIN97 ANTIMICROBIAL UTILIZATION AND INFECTION CAUSED BY GRAM-NEGATIVE BACTERIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES IN JAPAN: A MULTI-CENTRE CROSS-SECTIONAL STUDY Mimura, W.
22 S3 p. S655
 artikel
1103 PIN147 ANTIRETROVIRAL THERAPY AND LACTIC ACIDOSIS: RISK QUANTIFICATION USING DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM Viswam S, K.
22 S3 p. S662
 artikel
1104 PIN72 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF INFLUENZA VACCINATION IN THE AUSTRIAN POPULATION Walter, E.
22 S3 p. S651
 artikel
1105 PIN32 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF VACCINATING ADULTS AGAINST PNEUMOCOCCAL-DISEASES IN AUSTRIA Walter, E.
22 S3 p. S645
 artikel
1106 PIN34 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF VACCINATING CHILDREN AGAINST PNEUMOCOCCAL-DISEASES IN AUSTRIA Walter, E.
22 S3 p. S645
 artikel
1107 PIN58 ARE PUBLISHED HEALTH ECONOMIC MODELS FOR CHRONIC HEPATITIS B APPROPRIATELY CAPTURING THE BENEFITS OF HBSAG LOSS? Wigfield, P.
22 S3 p. S649
 artikel
1108 PIN107 ASSOCIATION BETWEEN NATURAL COLD REMEDIES AND ANTIBIOTIC THERAPY Kostev, K.
22 S3 p. S656
 artikel
1109 PIN127 BIRTH COHORT SCREENING FOR HEPATITIS C: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS Carty, P.
22 S3 p. S659
 artikel
1110 PIN128 BUDGET IMPACT ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA Djambazov, S.N.
22 S3 p. S659
 artikel
1111 PIN67 BUDGET IMPACT ANALYSIS OF THE IMPLEMENTATION OF A PRESURGICAL WARMING PROTOCOL TO EFFECTIVELY MANAGE SURGICAL PATIENT NORMOTHERMIA Schmerler, M.
22 S3 p. S650-S651
 artikel
1112 PIN76 BUDGET IMPACT OF CEFTAZIDIME AVIBACTAM (CAZ-AVI) FOR COMPLICATED INTRA-ABDOMINAL INFECTION, COMPLICATED URINARY TRACT INFECTION AND HOSPITAL-ACQUIRED PNEUMONIA IN SINGAPORE PARK, D.J.
22 S3 p. S652
 artikel
1113 PIN49 BURDEN OF S. AUREUS, E. COLI, K. PNEUMONIAE ASSOTIATED INFECTIONS IN RUSSIAN FEDERATION Kolbin, A.
22 S3 p. S648
 artikel
1114 PIN80 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF CARBAPENEM-RESISTANT PATHOGENS ASSOCIATED WITH HEALTHCARE-ASSOSIATED INFECTIONS: A BUDGET IMPACT ANALYSIS IN ARGENTINA Elgart, J.
22 S3 p. S653
 artikel
1115 PIN9 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Guerreiro, R.
22 S3 p. S641
 artikel
1116 PIN82 CHOICE OF INFLUENZA IMMUNIZATION PROVIDER AND IMPACT ON IMMUNIZATION COVERAGE IN ALBERTA, CANADA Kirwin, E.
22 S3 p. S653
 artikel
1117 PIN86 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH VARYING COVERAGE OF VARICELLA VACCINATION STRATEGIES IN SWITZERLAND Heininger, U.
22 S3 p. S654
 artikel
1118 PIN60 COMPARISON OF ANTI-HIV AND ANTI-HCV THERAPY COSTS IN THE CZECH REPUBLIC Stefancikova, I.
22 S3 p. S649
 artikel
1119 PIN46 CONTRASTING AVAILABLE THERAPY FOR PATIENTS WITH LIMITED OPTIONS DUE TO EXTREMELY DRUG-RESISTANCE BACTERIA WITH A NOVEL OPTION FOR COMPLICATED NOSOCOMIAL INFECTIONS Serrano Galan, C.E.
22 S3 p. S647
 artikel
1120 PIN28 COST EFFECTIVENESS ANALYSIS OF BACILLUS CALMETTE-GUÉRIN VACCINATION IN INDONESIA Machlaurin, A.
22 S3 p. S644
 artikel
1121 PIN130 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA Djambazov, S.N.
22 S3 p. S660
 artikel
1122 PIN66 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME-AVIBACTAM VERSUS COLISTIN-MEROPENEM IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE IN COLOMBIA Varon, F.A.
22 S3 p. S650
 artikel
1123 PIN63 COST-EFFECTIVENESS ANALYSIS OF POSACONAZOLE VERSUS VORICONAZOLE FOR THE PROPHYLAXIS OF INVASIVE FUNGAL DISEASE IN CHINA Tang, W.
22 S3 p. S650
 artikel
1124 PIN65 COST-EFFECTIVENESS ANALYSIS ON ELDERLY PNEUMOCOCCAL VACCINATION IN THE NETHERLANDS: CHALLENGING THE DUTCH HEALTH COUNCIL'S ADVICE Zeevat, F.
22 S3 p. S650
 artikel
1125 PIN16 COST-EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM + METRONIDAZOLE AS A FIRST-LINE TREATMENT IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS IN TAIWAN Chen, Y.C.
22 S3 p. S642-S643
 artikel
1126 PIN131 COST-EFFECTIVENESS OF CULTURE-BASED VERSUS EMPIRICAL ANTIBIOTIC TREATMENT FOR HOSPITALIZED ADULTS WITH COMMUNITY-ACQUIRED PNEUMONIA IN INDONESIA: A REAL-WORLD PATIENT-DATABASE STUDY Purba, A.K.R.
22 S3 p. S660
 artikel
1127 PIN33 COST-EFFECTIVENESS OF CURRENT PNEUMOCOCCAL VACCINES IN OLDER ADULTS IN EUROPEAN SETTINGS: A SYSTEMATIC LITERATURE REVIEW Bhavsar, A.B.
22 S3 p. S645
 artikel
1128 PIN40 COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA Ignatyeva, V.
22 S3 p. S646-S647
 artikel
1129 PIN44 COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM Zeevat, F.
22 S3 p. S647
 artikel
1130 PIN70 COST-EFFECTIVENESS OF SEASONAL VACCINATION WITH QUADRIVALENT INFLUENZA VACCINE IN PORTUGAL Almeida, J.
22 S3 p. S651
 artikel
1131 PIN64 COST OF HEPATITIS C VIRUS ERADICATION: ECONOMIC MODEL CONCEPT Szilberhorn, L.
22 S3 p. S650
 artikel
1132 PIN31 COST PER CYTOMEGALOVIRUS-ASSOCIATED DEATH AVERTED OF GANCICLOVIR AND VALGANCICLOVIR USE FOR PRE-EMPTIVE AND TREATMENT STRATEGIES IN ALLOGENEIC POSTTRANSPLANT RECIPIENTS Sangmala, P.
22 S3 p. S645
 artikel
1133 PIN105 DESCRIPTION OF PATIENTS HOSPITALIZED WITH MENINGOCOCCAL INFECTIONS IN FRANCE: AN ANALYSIS OF THE NATIONAL HEALTHCARE CLAIM(SNIIR-AM) DATABASE Weil-Olivier, C.
22 S3 p. S656
 artikel
1134 PIN109 DETERMINING THE BURDEN OF CARBAPENEM-RESISTANT GRAM-NEGATIVE INFECTIONS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA) Alfonso, J.L.
22 S3 p. S656-S657
 artikel
1135 PIN112 DISPARITIES AND SIMILARITIES IN THE INFLUENZA VACCINATION RECOMMENDATIONS ACROSS UNITED STATES AND EUROPE Jamdade, V.
22 S3 p. S657
 artikel
1136 PIN92 DO INTERNATIONAL MIGRANTS FACE HIGHER BACTERIAL DRUG RESISTANCE COMPARED TO NATIVES? A SYSTEMATIC REVIEW Cabieses, B.
22 S3 p. S654
 artikel
1137 PIN27 ECONOMIC AND QUALITY OF LIFE BURDEN OF PAEDIATRIC INFLUENZA IN AUSTRALIA Aghajanian, L.
22 S3 p. S644
 artikel
1138 PIN57 ECONOMIC EVALUATION OF AN ELECTRONIC HEALTH RECORD ALERT BY AGE IN PRIMARY CARE FOR THE DETECTION OF PATIENTS WITH CHRONIC HEPATITIS C García Herola, A.
22 S3 p. S649
 artikel
1139 PIN79 ECONOMIC EVALUATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS IN CHINESE HOSPITALS Wang, P.
22 S3 p. S653
 artikel
1140 PIN19 ECONOMIC EVALUATION OF THE FIRST PILOT OF PARTIAL DECENTRALIZATION OF HIV CARE AND TREATMENT FOR MEN WHO HAVE SEX WITH MEN IN GUATEMALA CITY FROM THE PATIENT'S PERSPECTIVE Alvis-Estrada, J.P.
22 S3 p. S643
 artikel
1141 PIN101 ECONOMIC IMPACT OF ICU-ACQUIRED MULTI-DRUG RESISTANT BACTERIAL INFECTIONS: EVIDENCE FROM SOUTHERN EUROPE Serra-Burriel, M.
22 S3 p. S655-S656
 artikel
1142 PIN152 ECONOMIC IMPACT OF SEQUELAE RELATED TO INVASIVE MENINGOCOCCAL DISEASE IN A FRENCH REAL-WORLD SETTING Fievez, S.
22 S3 p. S663
 artikel
1143 PIN51 ECONOMIC STUDY OF MEDICO-SURGICAL STRATEGIES IN PATIENTS WITH CHRONIC KNEE OR HIP PROSTHETIC JOINT INFECTION Serrier, H.
22 S3 p. S648
 artikel
1144 PIN2 EFFECTIVENESS AND SAFETY OF DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS INFECTED PATIENTS AFTER LIVER TRANSPLANTATION. RESULTS IN REAL CLINICAL PRACTICE. Margusino-Framiñán, L.
22 S3 p. S640
 artikel
1145 PIN77 EFFICACY MISAPPLICATION IN VACCINE MODELLING Sutton, K.
22 S3 p. S652
 artikel
1146 PIN96 EPIDEMIOLOGICAL AND ECONOMIC IMPACTS OF POTENTIAL HCV SCREENING STRATEGIES FOR THE NEXT 5 YEARS IN FRANCE Leleu, H.
22 S3 p. S654-S655
 artikel
1147 PIN26 ESTIMATING THE INVASIVE CANDIDIASIS COST-OF-CARE IN INTENSIVE CARE UNITS IN GREECE (HELICAS) Armaganidis, A.
22 S3 p. S644
 artikel
1148 PIN113 EU MARKET ACCESS PATHWAYS FOR VACCINES: DEFINITION OF COUNTRY ARCHETYPES USING MATHEMATICAL CLUSTERING Kapusniak, A.
22 S3 p. S657
 artikel
1149 PIN6 EVALUATION OF DIRECT-ACTING ANTIVIRALS RETREATMENT IN NON-SUSTAINED VIROLOGICAL RESPONDERS Margusino-Framiñán, L.
22 S3 p. S641
 artikel
1150 PIN1 EVALUATION OF THE DIFFERENT ADVERSE DRUG REACTIONS (ADR'S) AND THEIR GRADE AMONG HIV PATIENT'S NEWLY STARTED/SUBSTITUTED ON COMBINED TENOFOVIR/LAMIVUDINE/DOLUTEGRAVIR (TDF/3TC/DTG) IN THE TWO MAJOR HOSPITALS IN ONITSHA METROPOLIS, ANAMBRA STATE, NIGERIA. Okoro, K.
22 S3 p. S640
 artikel
1151 PIN56 EXCESS HEALTHCARE RESOURCE UTILISATION ASSOCIATED WITH PERTUSSIS INFECTION IN OLDER ADULTS Leong, R.N.
22 S3 p. S649
 artikel
1152 PIN20 EXPECTED COST-EFFECTIVENESS OF HIGH DOSE VERSUS ADJUVANTED STANDARD DOSE TRIVALENT INFLUENZA VACCINES IN ENGLAND AND WALES: ASSESSMENTS USING DIRECT AND INDIRECT COMPARATIVE EFFECTIVENESS DATA Skinner, L.
22 S3 p. S643
 artikel
1153 PIN25 EXPLORATORY ANALYSIS OF THE ECONOMICALLY JUSTIFIABLE PRICE OF AN RSV VACCINE FOR THE ELDERLY IN THE NETHERLANDS AND THE UNITED KINGDOM Zeevat, F.
22 S3 p. S643-S644
 artikel
1154 PIN47 FACING LIMITED ALTERNATIVES TO TREAT MULTI-DRUG RESISTANT BACTERIA IN THE FIELD OF NOSOCOMIAL PNEUMONIA Serrano Galan, C.E.
22 S3 p. S647-S648
 artikel
1155 PIN13 FIRST EMA-EUNETHTA PARALLEL CONSULTATION FOR VACCINES Laigle, V.
22 S3 p. S642
 artikel
1156 PIN35 GLOBAL ANNUAL COSTS OF PEOPLE LIVING WITH HIV IN FRANCE IN 2013 FROM A NATIONAL INSURANCE CLAIMS DATABASE (SNIIRAM) Genreau, M.
22 S3 p. S645-S646
 artikel
1157 PIN10 GROWTH FACTORS AND THEIR IMPACT ON HEALTHCARE UTILIZATION AND COST IN CACHECTIC HIV PATIENTS Buchenberger, J.D.
22 S3 p. S641
 artikel
1158 PIN37 HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN CHILDREN IN THREE EUROPEAN COUNTRIES Hu, T.
22 S3 p. S646
 artikel
1159 PIN110 HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN ADULTS 65 YEARS AND OLDER IN 5 EUROPEAN COUNTRIES Deb, A.
22 S3 p. S657
 artikel
1160 PIN132 HEALTH-ECONOMIC MODELLING OF INFECTIOUS DISEASE DIAGNOSTICS: CURRENT APPROACHES AND FUTURE OPPORTUNITIES Van der Pol, S.
22 S3 p. S660
 artikel
1161 PIN153 HEALTH OUTCOMES AND HEALTH SYSTEM COSTS ASSOCIATED WITH SEPSIS: A POPULATION-BASED, RETROSPECTIVE COHORT STUDY Farrah, K.
22 S3 p. S663
 artikel
1162 PIN14 HEALTH UTILITY ESTIMATES FOR CONGENITAL CYTOMEGALOVIRUS DISEASE: CONCEPTUAL DESIGN CONSIDERATIONS Cawson, M.
22 S3 p. S642
 artikel
1163 PIN94 HUMAN PAPILLOMAVIRUS (HPV) VACCINE COVERAGE RATES (VCR) IN FRANCE: A FRENCH CLAIMS DATA STUDY Dalon, F.
22 S3 p. S654
 artikel
1164 PIN142 IMPACT OF ADHERENCE ON VIRAL SUPPRESSION AND DETERMINANTS OF ADHERENCE IN PATIENTS WITH HIV Thakur, V.
22 S3 p. S662
 artikel
1165 PIN124 IMPACT OF CHICKENPOX VACCINATION IN COLOMBIA 2014-2017 Rey-Velasco, A.
22 S3 p. S658-S659
 artikel
1166 PIN99 INDIRECT COSTS ASSOCIATED WITH SKIN AND SOFT TISSUE INFECTIONS IN CHILDREN: A SYSTEMATIC LITERATURE REVIEW Lizano-Díez, I.
22 S3 p. S655
 artikel
1167 PIN156 INTRAVITREAL THERAPY WITH RANIBIZUMAB VS AFLIBERCEPT VS BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION: A WITHIN TRIAL COST-UTILITY ANALYSIS Flight, L.
22 S3 p. S664
 artikel
1168 PIN84 KNOWLEDGE, ATTITUDE AND PRACTICES ABOUT ZIKA VIRUS AMONG PHARMACY STUDENTS IN MAINLAND UNITED STATES (US) AND NON-MAINLAND US (PUERTO RICO AND WEST INDIES Patel, I.
22 S3 p. S653
 artikel
1169 PIN43 LIFECYCLE-MODEL-BASED ECONOMIC EVALUATION OF INFANT MENINGITIS B VACCINATION IN THE UK Sevilla, J.
22 S3 p. S647
 artikel
1170 PIN12 MARKET ACCESS PATHWAYS FOR VACCINES IN EU: THE NEED FOR MORE TRANSPARENT & COLLABORATIVE FRAMEWORK IN A CONTEXT OF EU28 TO DECREASE UNCERTAINTY AND ALLOW FASTER PATIENT ACCESS Kapuśniak, A.
22 S3 p. S641-S642
 artikel
1171 PIN143 MEASUREMENT OF HEALTH RELATED QUALITY OF LIFE IN TUBERCULOSIS PATIENTS USING SPECIFIC AND GENERIC INSTRUMENTS Endarti, D.
22 S3 p. S662
 artikel
1172 PIN135 MODELING HUMAN PAPILLOMAVIRUS TRANSMISSION FOR VACCINE EVALUATIONS: A PRELIMINARY AGENT-BASED MODEL Sultanov, M.
22 S3 p. S661
 artikel
1173 PIN136 MODELLING CD4 TRANSITIONS IN HIV PATIENTS: VALIDATING A MARKOV MODEL BASED APPROACH Parker, B.
22 S3 p. S661
 artikel
1174 PIN98 NATIONAL BURDEN OF SEPSIS IN INDONESIA: AN ANALYSIS BASED ON FOCAL INFECTIONS Purba, A.K.R.
22 S3 p. S655
 artikel
1175 PIN119 NOVEL PRICING OF NEW ANTIMICROBIALS – HOW CAN WE PRICE TO REFLECT THE VALUE TO SOCIETY AND THE MANUFACTURER? Martin, M.
22 S3 p. S658
 artikel
1176 PIN145 PATIENT PREFERENCES TOWARDS DRUG TREATMENT OF CHRONIC HEPATITIS B - A DISCRETE CHOICE EXPERIMENT IN GERMANY Hardtstock, F.
22 S3 p. S662
 artikel
1177 PIN151 PATIENTS TREATED FOR HEPATITIS C: AN OBSERVATIONAL STUDY WITH THE FRENCH ADMINISTRATIVE HEALTH CARE DATABASE (SNDS) Pol, S.
22 S3 p. S663
 artikel
1178 PIN85 POTENTIAL PUBLIC HEALTH IMPACT OF REACHING THE WHO/EU TARGET OF 75% INFLUENZA VACCINATION COVERAGE AMONG THE ELDERLY IN GERMANY Damm, O.
22 S3 p. S653-S654
 artikel
1179 PIN29 PUBLIC HEALTH AND ECONOMIC IMPACT OF VACCINATION OF SENIORS WITH A HIGH DOSE TRIVALENT INFLUENZA VACCINE IN BRAZILIAN PRIVATE HEALTH CARE SYSTEM Boiron, L.
22 S3 p. S644-S645
 artikel
1180 PIN71 PURSUING ELIMINATION OF HEPATITIS C IN EGYPT: AN ECONOMIC EVALUATION OF A COUNTRY-WIDE PROGRAM AND ITS ASSOCIATED COST EFFECTIVENESS Schwander, B.
22 S3 p. S651
 artikel
1181 PIN93 REAL WORLD DATA EXAMINING THE EFFECT OF DIRECT ACTING ANTIVIRALS AMONG PATIENTS DEFINED BY FIBROSIS STAGE AND VIRAL LOAD Kuranz, S.
22 S3 p. S654
 artikel
1182 PIN149 RETROSPECTIVE SURVEY FOR HEPATITIS B VIRUS REACTIVATION DURING IMMUNOSUPPRESSIVE THERAPIES FOR RHEUMATOID WITH ADMINISTRATIVE DATA Imai, S.
22 S3 p. S662-S663
 artikel
1183 PIN141 SOCIAL MEDIA AND VACCINE HESITANCY: FOCUS ON MMR Farrington, E.
22 S3 p. S661
 artikel
1184 PIN3 SOFOSBUVIR/VELPATASVIR VS GLECAPREVIR/PIBRENTASVIR IN GENOTYPE 3 HEPATITIS C VIRUS INFECTED PATIENTS Margusino-Framiñán, L.
22 S3 p. S640
 artikel
1185 PIN52 STUDIES REPORTING COSTS ASSOCIATED WITH INVASIVE MENINGOCOCCAL DISEASE IN EU-27: METHODOLOGY AND OUTCOMES de Courville, C.
22 S3 p. S648-S649
 artikel
1186 PIN106 SYSTEMATIC LITERATURE REVIEW OF HERPES ZOSTER INCIDENCE WORLDWIDE van Oorschot, D.
22 S3 p. S656
 artikel
1187 PIN125 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS: PRE-EXPOSURE PROPHYLAXIS (PREP) FOR THE PREVENTION OF HIV Marshall, L.
22 S3 p. S659
 artikel
1188 PIN108 THE BURDEN OF EBOLA VIRUS DISEASE (EVD) IN AFRICA: NEED FOR VACCINE (A TARGETED LITERATURE REVIEW) Arora, A.
22 S3 p. S656
 artikel
1189 PIN116 THE BURDEN OF INFLUENZA POSITIVE INPATIENTS IN TURKEY Bölek, H.
22 S3 p. S658
 artikel
1190 PIN68 THE COST-EFFECTIVENESS OF HEPATITIS C VIRUS SCREENING AND TREATMENT STRATEGIES AMONG RECENTLY ARRIVED MIGRANTS FOR THE NETHERLANDS Khayat M, Al
22 S3 p. S651
 artikel
1191 PIN117 THE COST OF INFLUENZA RELATED HOSPITALIZATIONS IN ELDERLY IN TURKEY Bölek, H.
22 S3 p. S658
 artikel
1192 PIN38 THE COST OF STIGMA ASSOCIATED WITH HIV: A COST-CONSEQUENCE ANALYSIS TO EVALUATE HIV TESTING AND PREVENTION INTERVENTIONS IN KSA Ali, B.
22 S3 p. S646
 artikel
1193 PIN21 THE ECONOMIC IMPACT OF TRICLOSAN-COATED SUTURES IN WOUND CLOSURE: A BUDGET IMPACT ANALYSIS FROM HOSPITAL PERSPECTIVE IN ITALY Piemontese, A.
22 S3 p. S643
 artikel
1194 PIN48 THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN OF DRUG-RESISTANT TUBERCULOSIS IN INDIA Agnarson, M.A.
22 S3 p. S648
 artikel
1195 PIN73 THE POTENTIAL COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INACTIVATED INFLUENZA VACCINE FOR THE PORTUGUESE ELDERLY POPULATION Tavares, D.
22 S3 p. S651-S652
 artikel
1196 PIN137 THE USE OF MULTI-YEAR AGE GROUPS IN VACCINATION MODELS BIAS THE RESULTS FOR VACCINATED INDIVIDUALS Kharitonova, E.
22 S3 p. S661
 artikel
1197 PIN155 THE USE OF PATIENT REPORTED OUTCOMES IN MEDICAL DEVICE Cheng, R.
22 S3 p. S663-S664
 artikel
1198 PIN15 THE VALUE OF ACHIEVING OPTIMAL ADHERENCE WITH LONG-ACTING DIRECTLY OBSERVED ANTIRETROVIRAL THERAPY (LA DOT ART) AMONGST PATIENTS LIVING WITH HIV-1 INFECTION: A MODELLING STUDY Ward, T.
22 S3 p. S642
 artikel
1199 PIN23 TREATING PATIENTS WITH DAAS ALLOWED TO SAVE 1 BILLION EUROS IN FRANCE - A BUDGET IMPACT MODEL FROM 2014 TO 2018 Leleu, H.
22 S3 p. S643
 artikel
1200 PIN114 UNDERSTANDING CHANGES IN FULL CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA BETWEEN 2000 AND 2016: OAXACA-BLINDER DECOMPOSITION ANALYSIS Wondimu, A.
22 S3 p. S658
 artikel
1201 PIN134 USING TIME-DEPENDENT PROPENSITY SCORE MATCHING TO ACCOUNT FOR PATIENT’S CHANGING CLINICAL STATUS LEADING UP TO THE THERAPEUTIC INTERVENTION: AN EXAMPLE USING REAL-WORLD DATA Chandak, A.
22 S3 p. S660-S661
 artikel
1202 PIN111 VACCINE REIMBURSEMENT TRENDS AND ASSOCIATED CHALLENGES IN EUROPE - A SYSTEMATIC LITERATURE REVIEW (SLR) Sharma, S.
22 S3 p. S657
 artikel
1203 PIN75 WHAT WE KNOW NOW: REVISITING THE COST-EFFECTIVENESS OF CHICKENPOX VACCINATION USING AN AGENT-BASED MODEL Rafferty, E.
22 S3 p. S652
 artikel
1204 PIN39 WHEN A PROBIOTIC-BASED SANITIZING METHOD MAY HALVE HEALTHCARE-ASSOCIATED INFECTIONS AND REDUCE ASSOCIATED COSTS Rognoni, C.
22 S3 p. S646
 artikel
1205 PIT14 COSTS AND HEALTHCARE UTILIZATION OF TRAUMA CASES WITH COMMINUTED GUSTILO-ANDERSON TYPE III FRACTURES Vanderkarr, M.
22 S3 p. S667
 artikel
1206 PIT8 ESTIMATION OF THE ECONOMIC BURDEN ASSOCIATED WITH 90-DAY COMPLICATIONS FOLLOWING INTERTROCHANTERIC HIP FRACTURE Adeyemi, A.
22 S3 p. S666
 artikel
1207 PIT5 EXPERIENCE OF 2 INSTITUTIONS WITH THE GERIATRIC FRACTURE PROGRAM IN COLOMBIA: LENGTH OF STAY, MORTALITY AND ESTIMATION OF COSTS Olarte, C.M.
22 S3 p. S665-S666
 artikel
1208 PIT17 HEALTH STATUS AND PSYCHOLOGICAL OUTCOME AFTER TRAUMA; A PROSPECTIVE LONGITUDINAL COHORT STUDY Kruithof, N.
22 S3 p. S668
 artikel
1209 PIT1 HEALTH STATUS AND RECOVERY PATTERNS ONE YEAR AFTER TRAUMA IN SEVERELY INJURED PATIENTS Havermans, R.
22 S3 p. S665
 artikel
1210 PIT9 IMPACT OF FALLS IN THE ELDERLY POPULATION FOR THE SPANISH NATIONAL HEALTH SYSTEM Busutil, R.
22 S3 p. S666-S667
 artikel
1211 PIT16 IMPROVING OPERATING ROOM EFFICIENCY IN SPINE SURGERIES: EVIDENCE FROM AN ITALIAN HOSPITAL Viti, R.
22 S3 p. S668
 artikel
1212 PIT15 INTRAMEDULLARY NAILING OF HUMERAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS Chitnis, A.S.
22 S3 p. S667
 artikel
1213 PIT6 MEASURING PROMS OF REHABILITATION WITH COMPUTER ADAPTIVE TESTING (CAT) AFTER AN OPERATIVE INTERVENTION OF AN EXTREMITY FRACTURE Havermans, R.
22 S3 p. S666
 artikel
1214 PIT4 PATIENT CHARACTERISTICS AND HEALTHCARE UTILIZATION FOLLOWING COMMINUTED GUSTILO-ANDERSON TYPE III FRACTURES Vanderkarr, M.
22 S3 p. S665
 artikel
1215 PIT2 PATTERNS OF OPIOID USE FOLLOWING FRACTURE BASED ON TIME BETWEEN PRESCRIPTION ORDER AND PATIENT FILL Brady, B.
22 S3 p. S665
 artikel
1216 PIT11 PREDICTION OF INTRA- AND EXTRAMURAL HEALTH CARE COSTS AND RETURN TO WORK AFTER TRAUMA: A PROSPECTIVE OBSERVATIONAL COHORT STUDY de Munter, L.
22 S3 p. S667
 artikel
1217 PIT3 PROGNOSTIC FACTORS FOR POOR RECOVERY AFTER TRAUMA: A PROSPECTIVE MULTICENTRE COHORT STUDY de Munter, L.
22 S3 p. S665
 artikel
1218 PIT7 RESOURCE UTILIZATION REQUIRED FOR THE USE OF PREMIXED NITROUS OXIDE IN OXYGEN INHALATION IN A LARGE PAEDIATRIC HOSPITAL SETTING Degrassat-Théas, A.
22 S3 p. S666
 artikel
1219 PIT10 THE INCREMENTAL COST OF TRAUMATIC BRAIN INJURY DURING THE FIRST YEAR AFTER A ROAD TRAFFIC ACCIDENT IN BELGIUM Van Deynse, H.
22 S3 p. S667
 artikel
1220 PMD45 A COMPANION APP TO SUPPORT PATIENTS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM A USABILITY STUDY Domańska, B.
22 S3 p. S677
 artikel
1221 PMD18 A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF C-REACTIVE PROTEIN POINT-OF-CARE TESTING TO GUIDE ANTIBIOTIC PRESCRIBING FOR RESPIRATORY TRACT INFECTIONS IN PRIMARY CARE SETTINGS IN IRELAND Fawsitt, C.G.
22 S3 p. S672
 artikel
1222 PMD60 AN INNOVATIVE REUSABLE ELECTRONIC INJECTION DEVICE FOR CERTOLIZUMAB PEGOL: RESULTS FROM A PILOT MARKET RESEARCH STUDY EXAMINING PATIENT PREFERENCE AND SATISFACTION Pouls, B.P.
22 S3 p. S679-S680
 artikel
1223 PMD47 BREAKAGE OF INTRAMEDULLARY NAILING IN TROCHANTERIC, INTERTROCHANTERIC AND SUBTROCHANTERIC FEMUR FRACTURES Chitnis, A.S.
22 S3 p. S677
 artikel
1224 PMD23 BUDGET IMPACT ANALYSIS OF A BIOSYNTHETIC MESH FOR ABDOMINAL WALL HERNIA REPAIR IN COMPLEX HERNIAS IN GREECE Vellopoulou, K.
22 S3 p. S673
 artikel
1225 PMD25 COMPARING ECONOMIC IMPACT OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN A SINGLE INSTITUTION IN THAILAND Lelamali, K.
22 S3 p. S674
 artikel
1226 PMD50 COMPARING THE ABILITY OF TWO INNOVATIVE OSTOMY BAGS TO PREVENT BALLOONING IN A REAL-LIFE SETTING Nørtoft, E.
22 S3 p. S678
 artikel
1227 PMD7 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A BELGIAN HEALTHCARE SYSTEM PERSPECTIVE Bosgra, O.J.
22 S3 p. S670
 artikel
1228 PMD6 COMPARING THE LONG-TERM COSTS ASSOCIATED WITH INTRAOCULAR LENS SELECTION AND ND:YAG LASER CAPSULOTOMY POST-CATARACT SURGERY: A COST-CONSEQUENCE ANALYSIS FROM A DUTCH HEALTHCARE SYSTEM PERSPECTIVE Bosgra, O.J.
22 S3 p. S670
 artikel
1229 PMD20 COST EFFECTIVENESS ANALYSIS OF IMPLANTABLE CARDIAC MONITORS TO DETECT ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE Edwards, S.J.
22 S3 p. S673
 artikel
1230 PMD15 COST EFFECTIVENESS ANALYSIS OF STANDARD AND PREMIUM INTRAOCULAR LENSES IMPLEMENTED IN THE TREATMENT OF CATARACT UNDER DIFFERENT INSURANCE SCHEMES IN EGYPT Zaky, H.
22 S3 p. S671-S672
 artikel
1231 PMD22 COST-EFFECTIVENESS ANALYSIS OF SUCROSE OCTASULFATE (URGOSTART) DRESSING IN THE TREATMENT OF DIABETIC FOOT AND VENOUS LEG ULCERS Mlcoch, T.
22 S3 p. S673
 artikel
1232 PMD14 COST-EFFECTIVENESS ANALYSIS OF THE USE OF MICROINVASIVE SURGERY WITH ISTENT® IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS IN THE MEXICAN PUBLIC HEALTH SYSTEM. Gay, J.G.
22 S3 p. S671
 artikel
1233 PMD59 COST-EFFECTIVENESS EVALUATION OF PHACOEMULSIFICATION PLATFORMS IN THE RUSSIAN FEDERATION Yagudina, R.
22 S3 p. S679
 artikel
1234 PMD13 COST-UTILITY ANALYSIS OF ISTENT INJECT IN MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA IN JAPAN Igarashi, A.
22 S3 p. S671
 artikel
1235 PMD5 ECONOMIC BENEFIT OF CENTRIFUGAL VERSUS MEMBRANE THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION EXPERIENCE IN VIETNAM Phan, T.T.H.
22 S3 p. S669-S670
 artikel
1236 PMD19 ECONOMIC EVALUATION OF CATARACT PHACOEMULSIFICATION IN THE RUSSIAN FEDERATION Yagudina, R.
22 S3 p. S672-S673
 artikel
1237 PMD24 ECONOMIC EVALUATION OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN TAIWAN Chiou, T.J.
22 S3 p. S673-S674
 artikel
1238 PMD21 ECONOMIC EVALUATION OF THE SFLT-1/PLGF RATIO TEST TO GUIDE THE MANAGEMENT OF CHINESE SUSPECTED PRE-ECLAMPSIA WOMEN Chen, Y.
22 S3 p. S673
 artikel
1239 PMD43 EFFICACY AND SAFETY OF MECHANICAL THROMBECTOMY IN PATIENTS WITH ISCHEMIC STROKE: AN UMBRELLA SYSTEMATIC REVIEW Dombrovskiy, V.
22 S3 p. S677
 artikel
1240 PMD1 EFFICACY AND SAFETY OF PACEMAKERS IN THE MANAGEMENT OF PATIENTS WITH BRADYCARDIA — SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS (RCTS) Verma, J.
22 S3 p. S669
 artikel
1241 PMD8 ESTIMATING THE POTENTIAL CASES OF BLINDNESS AND COSTS AVOIDED AND IN REALLOCATING HEALTHCARE RESOURCE UTILIZATION FROM TREATING POSTERIOR CAPSULAR OPACIFICATION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION O'Boyle, D.
22 S3 p. S670
 artikel
1242 PMD51 EVALUATING THE USE AND OUTCOMES OF DIGITALLY ASSISTED VITREO-RETINAL SURGERY: A SYSTEMATIC LITERATURE REVIEW Morris, L.
22 S3 p. S678
 artikel
1243 PMD37 EVOLUTION OF UNION EUROPEAN MEDICAL DEVICE REGULATION: PERSPECTIVE WITH THE CLINICAL EVALUATION OF DUAL MOBILITY ACETABULAR CUPS BY THE FRENCH NATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCY Bouschon, M.
22 S3 p. S675-S676
 artikel
1244 PMD34 FRENCH COVERAGE WITH EVIDENCE DEVELOPMENT (CED) SCHEME FOR INNOVATIVE MEDICAL DEVICES: AN OVERVIEW SINCE ITS REDESIGN IN 2015 Clément-Rio, N.
22 S3 p. S675
 artikel
1245 PMD16 HEALTH ECONOMIC VALUE OF BLOOD IN IVORY COAST: THE CASE OF MATERNAL BLEEDING Sekongo, Y.M.
22 S3 p. S672
 artikel
1246 PMD39 HOSPITAL REIMBURSEMENT PATHWAYS FOR NEW EXAMINATION AND TREATMENT METHODS IN GERMANY Worf, K.
22 S3 p. S676
 artikel
1247 PMD35 HOW HAVE HEALTH TECHNOLOGY ASSESSMENT BODIES INTERPRETED THE EARLY EVIDENCE ON FREESTYLE LIBRE IN TYPE 1 AND TYPE 2 DIABETES? Levrat Guillen, F.
22 S3 p. S675
 artikel
1248 PMD2 IMPLANTABLE CARDIAC MONITORS (BIOMONITOR 2-AF, CONFIRM RX INSERTABLE CARDIAC MONITOR AND REVEAL LINQ INSERTABLE CARDIAC MONITORING SYSTEM) TO DETECT ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE: A SYSTEMATIC REVIEW Wakefield, V.
22 S3 p. S669
 artikel
1249 PMD10 INSIGHTS INTO THE IMPACT OF POINT-OF-CARE TESTING: A SYSTEMATIC REVIEW OF HEALTH-ECONOMIC EVALUATIONS Lingervelder, D.
22 S3 p. S670-S671
 artikel
1250 PMD9 INTRODUCING BUDGET IMPACT ANALYSIS COMPARING REUSABLE TO SINGLE-USE BRONCHOSCOPES WITHIN A LARGE UK UNIVERSITY HOSPITAL Russell, R.
22 S3 p. S670
 artikel
1251 PMD11 MEASURING THE ECONOMIC IMPACT OF THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION STUDY IN XIAMEN, CHINA Hu, W.P.
22 S3 p. S671
 artikel
1252 PMD49 MECHANICAL COMPLICATIONS ASSOCIATED WITH INTRAMEDULLARY NAILING FOR TROCHANTERIC, INTERTROCHANTERIC AND SUBTROCHANTERIC FEMUR FRACTURES Chitnis, A.S.
22 S3 p. S678
 artikel
1253 PMD54 MEDICAL CAPITAL EQUIPMENT TENDER ANALYTICS: META ANALYSIS ON WIN/LOSS STUDIES van De Sande, J.
22 S3 p. S678-S679
 artikel
1254 PMD52 MEDICAL DEVICES AND SUSTAINABILITY: CLAIMS AND EVIDENCE IN NICE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME Sheldon, F.
22 S3 p. S678
 artikel
1255 PMD30 MEDICAL DEVICES MANAGED ENTRY AGREEMENTS IN FRANCE: A RETROSPECTIVE ANALYSIS (2018-2019) Zaccherini, T.
22 S3 p. S674-S675
 artikel
1256 PMD56 NETWORK META-ANALYSIS OF THE USE OF ISTENT® INJECT MICROINVASIVE SURGERY IN COMBINATION WITH PHACOEMUSIFICATION FOR GLAUCOMA AND CATARACT PATIENTS Valls, M.
22 S3 p. S679
 artikel
1257 PMD48 OPPORTUNITIES AND CHALLENGES FOR NOVEL MEDICAL DEVICES LAUNCHING IN EUROPE IN THE HOSPITAL SETTING Olid Gonzalez, A.
22 S3 p. S677-S678
 artikel
1258 PMD63 ORIGINAL VS BIOSIMILAR DRUGS PRICE DIFFERENCES IN EU COUNTRIES Psenkova, M.
22 S3 p. S680
 artikel
1259 PMD28 OUTCOMES-BASED AGREEMENTS IN MEDICAL DEVICES: A SUGGESTED METHOD TO DEPLOY THEM AND EVALUATE THEIR RISKS Schroer, D.
22 S3 p. S674
 artikel
1260 PMD61 PATIENT REPORTED OUTCOME MEASUREMENT: USING EQ-5D-3L PROFILES TO ASSESS QUALITY OF LIFE OF TOTAL KNEE REPLACEMENT PATIENTS Parkin, D.
22 S3 p. S680
 artikel
1261 PMD31 PERFORMANCE-BASED RISK SHARING AGREEMENTS: DO PAYERS CONSIDER MEDICINES AND MEDICAL DEVICES DIFFERENTLY? Parkinson, M.
22 S3 p. S675
 artikel
1262 PMD27 POST-COLONOSCOPIC INFECTION RATES: SYSTEMATIC LITERATURE REVIEW ASSESSING AN ATTRIBUTABLE RISK Larsen, S.
22 S3 p. S674
 artikel
1263 PMD44 PRICING AND REIMBURSEMENT, AND MARKET ACCESS OF THERAPEUTIC MATERIALS (MEDICAL DEVICES/DIAGNOSTICS/BIOMARKERS) IN SOUTH KOREA. Seo, M.
22 S3 p. S677
 artikel
1264 PMD3 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM BEARING SURFACE IN HIP REPLACEMENT 90-DAY EPISODE CLAIMS Patrick, C.
22 S3 p. S669
 artikel
1265 PMD17 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM HIP BEARING SURFACES WHEN A HIP FRACTURE IS PRESENT AT ADMISSION IN THE 90 DAY EPISODE OF CARE Patrick, C.
22 S3 p. S672
 artikel
1266 PMD4 SECONDARY CATARACT PROCEDURES DUE TO POSTERIOR CAPSULAR OPACIFICATION IN THE CZECH REPUBLIC: AN ANALYSIS OF HEALTH INSURANCE DATA Kutscherauer, P.
22 S3 p. S669
 artikel
1267 PMD32 STRUCTURE AND EVOLUTION OF THE FRENCH POSITIVE REIMBURSEMENT LIST FOR MEDICAL DEVICES De Joannis, P.E.
22 S3 p. S675
 artikel
1268 PMD40 SYSTEMATIC LITERATURE REVIEW ON THE USE OF ISTENT® INJECT FOR THE TREATMENT OF PATIENTS WITH GLAUCOMA AND CATARACT WITH IOP>21 MMHG Valls, M.
22 S3 p. S676
 artikel
1269 PMD62 THE ASSOCIATION BETWEEN STOMA RELATED COMPLICATIONS AND STOMA APPLIANCE PRESCREPTION SPEND Nørtoft, E.
22 S3 p. S680
 artikel
1270 PMD38 THE CLINICAL AND ECONOMIC ANALYSES OF VIDEO ASSISTED THORACOSCOPIC SURGERY FOR LOBECTOMY: EXPERIENCE FROM A TOP ACADEMIC MEDICAL CENTER IN CHINA Chen, C.
22 S3 p. S676
 artikel
1271 PMD42 THE DIRECT COSTS ASSOCIATED WITH POSTERIOR CAPSULE OPACIFICATION IN THE NETHERLANDS: A PAYER PERSPECTIVE Bosgra, O.J.
22 S3 p. S676-S677
 artikel
1272 PMD26 THE ECONOMIC EVALUATION OF THE SFLT-1/PIGF RATIO IN THE PREDICTION OF PRE-ECLAMPSIA Huang, Z.
22 S3 p. S674
 artikel
1273 PMD55 THE LEARNING CURVE AS A BARRIER IN THE CONDUCT OF RANDOMIZED CONTROLLED TRIALS WITH MEDICAL DEVICES - A LITERATURE REVIEW Borissov, B.
22 S3 p. S679
 artikel
1274 PMD57 TOTAL HOSPITAL COSTS AND READMISSION RATE OF PATIENT-SPECIFIC CUTTING GUIDE IN TOTAL KNEE ARTHROPLASTY (TKA) PATIENTS Thomas, S.
22 S3 p. S679
 artikel
1275 PMD12 UNDERSTANDING THE ECONOMIC IMPACT OF THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION STUDY IN PUNE, INDIA Mulay, A.
22 S3 p. S671
 artikel
1276 PMH35 A MODELLING APPROACH TO ESTIMATE THE PREVALENCE OF TREATMENT-RESISTANT SCHIZOPHRENIA IN THE UNITED STATES Mørup, M.
22 S3 p. S687
 artikel
1277 PMH67 ANALYSIS OF PSYCHOTROPIC MEDICATIONS PRESCRIPTIONS IN TURKEY Adam, K.
22 S3 p. S693
 artikel
1278 PMH1 ANIMAL ASSISTED THERAPY (AAT) IN DEPRESSION AND ANXIETY: A SYSTEMATIC REVIEW Eke, E.
22 S3 p. S681
 artikel
1279 PMH23 A RETROSPECTIVE CHART REVIEW STUDY TO QUANTIFY THE MONTHLY MEDICAL RESOURCE USE AND COSTS OF TREATING PATIENTS WITH TREATMENT RESISTANT DEPRESSION IN THE UNITED KINGDOM Denee, T.
22 S3 p. S684
 artikel
1280 PMH28 ASSESSING THE LIFE-CYCLE VALUE ADDED OF SECOND-GENERATION ANTIPSYCHOTICS IN SWEDEN AND THE UK: THE CASE OF RISPERIDONE Berdud, M.
22 S3 p. S685
 artikel
1281 PMH4 ASSESSMENT OF QUALITY OF LIFE AMONGST PATIENTS DEPRESCRIBED WITH BENZODIAZEPINES Monachan, J.
22 S3 p. S681
 artikel
1282 PMH60 ASSESSMENT OF THE INTERNAL CONSISTENCY AND CONCURRENT VALIDITY OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN AN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER POPULATION-BASED SAMPLE Unni, E.
22 S3 p. S691
 artikel
1283 PMH25 ASSOCIATION OF ADOLESCENT DEPRESSION WITH EARNINGS IN ADULTHOOD Philipson, A.
22 S3 p. S685
 artikel
1284 PMH51 BREXANOLONE INJECTION FOR THE TREATMENT OF POSTPARTUM DEPRESSION: MINIMAL IMPORTANT DIFFERENCE AND MEANINGFUL CHANGE Eldar-Lissai, A.
22 S3 p. S690
 artikel
1285 PMH2 BREXANOLONE INJECTION IN POSTPARTUM DEPRESSION: SUSTAINED REMISSION, SUSTAINED RESPONSE, AND NUMBER NEEDED TO TREAT Eldar-Lissai, A.
22 S3 p. S681
 artikel
1286 PMH15 BUDGET IMPACT ANALYSIS OF SCHIZOPHRENIA TREATMENT IN INDONESIA Puspandari, D.A.
22 S3 p. S683
 artikel
1287 PMH39 CHARACTERISTICS OF US ADULTS WITH SELF-REPORTED INSOMNIA BY INSOMNIA SYMPTOMS: 2018 NATIONAL SLEEP SURVEY Morlock, A.
22 S3 p. S687-S688
 artikel
1288 PMH58 COMPARATIVE ANALYSIS BETWEEN THE MICROSTRUCTURE NETWORK MANAGEMENT AND THE CONVENTIONAL MEDICAL OF PERSONS WITH ADDICTION IN FRANCE Cabout, E.
22 S3 p. S691
 artikel
1289 PMH37 COMPARING THE QUALITY OF SLEEP AMONGST BENZODIAZEPINE DEPRESCRIBED GROUP AND CONTINUING GROUP Monachan, J.
22 S3 p. S687
 artikel
1290 PMH65 COMPARISON OF CHARACTERISTICS AND MEDICATION-ASSISTED TREATMENT (MAT)-RELATED HEALTHCARE RESOURCE UTILIZATION AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MAT RECEIVED Perry, A.
22 S3 p. S692
 artikel
1291 PMH66 COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HCRU) AND EXPENDITURES AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MEDICATION-ASSISTED TREATMENT (MAT) RECEIVED Perry, A.
22 S3 p. S692-S693
 artikel
1292 PMH48 CONSTRUCTION AND VALIDATION OF A SCREENING MEASURE OF ADDICTION TO SOCIAL NETWORKS IN THE SPANISH GENERAL POPULATION Ovejero Bruna, M.
22 S3 p. S689
 artikel
1293 PMH31 COST-EFFECTIVENESS OF GUIDED INTERNET-DELIVERED COGNITIVE BEHAVIORAL THERAPY IN COMPARISON WITH CARE-AS-USUAL FOR PATIENTS WITH INSOMNIA IN GENERAL PRACTICE Baka, A.
22 S3 p. S686
 artikel
1294 PMH20 COST-EFFECTIVENESS OF INCREASING THE EFFICIENCY OF THE DETOXIFICATION PROCESS PRIOR TO INITIATION OF EXTENDED-RELEASE NALTREXONE FOR THE TREATMENT OF OPIOID USE DISORDER Murphy, S.
22 S3 p. S683-S684
 artikel
1295 PMH21 COST-EFFECTIVENESS OF THE PREDICT TEST: RESULTS AND LESSONS LEARNED FROM A EUROPEAN MULTINATIONAL DEPRESSION TRIAL Simon, J.
22 S3 p. S684
 artikel
1296 PMH30 COST-UTILITY ANALYSIS OF VORTIOXETINE FOR THE TREATMENT OF MAJOR DEPRESSION DISORDERS IN CHINA Liu, M.
22 S3 p. S686
 artikel
1297 PMH33 COST-UTILITY OF LURASIDONE VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH SCHIZOPHRENIA IN ITALY Bini, C.
22 S3 p. S686
 artikel
1298 PMH24 DEPENDENCE AS A MEASURE OF HEALTH BENEFIT IN THE ECONOMIC EVALUATION OF DEMENTIA INTERVENTIONS Hussain, H.
22 S3 p. S684-S685
 artikel
1299 PMH70 DIRECT HEALTHCARE COSTS FOR THE MANAGEMENT OF PATIENTS WITH OPIOID USE DISORDER TREATED WITH METHADONE AND BUPRENORPHINE/NALOXONE IN REAL-WORLD SETTING IN SPAIN. COSTEDOPIA STUDY Roncero, C.
22 S3 p. S693
 artikel
1300 PMH29 ESTIMATING A PREFERENCE-BASE INDEX FROM THE RECOVERING QUALITY OF LIFE MEASURE FOR ECONOMIC EVALUATION IN THE AREA OF MENTAL HEALTH: VALUATION OF REQOL-UI Keetharuth, A.
22 S3 p. S685-S686
 artikel
1301 PMH52 FACTORS ASSOCIATED WITH REGULAR NICOTINE SALT POD SYSTEM USE AMONG SMOKERS ABSTAINING FROM COMBUSTIBLE CIGARETTES Prakash, S.
22 S3 p. S690
 artikel
1302 PMH19 HEALTH CARE COSTS RELATED TO SCHIZOPHRENIA IN PATIENTS INITIATING ARIPIPRAZOLE LONG-ACTING INJECTABLE (LAI): RESULTS FROM THE DOMINO STUDY Marcellusi, A.
22 S3 p. S683
 artikel
1303 PMH38 IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH HYPONATREMIA IN PSYCHIATRIC PATIENTS: A CASE CONTROL STUDY Powle, H.
22 S3 p. S687
 artikel
1304 PMH53 IMPACT OF COGNITIVE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN CHINESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE PROACT STUDY Wang, G.
22 S3 p. S690
 artikel
1305 PMH57 IMPACT ON QUALITY OF LIFE AND PRODUCTIVITY FOR CAREGIVERS OF ADULTS WITH DEPRESSION Balkaran, B.
22 S3 p. S691
 artikel
1306 PMH68 IMPLEMENTING AND INTERPRETING A PROPOSED NEW MEASURE FOR HEDIS® 2020: PHARMACOTHERAPY FOR OPIOID USE DISORDER (OUD) Perry, A.
22 S3 p. S693
 artikel
1307 PMH62 IMPROVEMENT IN FUNCTIONING, DEPRESSIVE AND COGNITIVE SYMPTOMS AFTER TREATMENT OF MAJOR DEPRESSION WITH VORTIOXETINE. INTERIM RESULTS FROM THE "REAL-LIFE EFFECTIVENESS OF VORTIOXETINE (RELIEVE)” STUDY Llorca, P.M.
22 S3 p. S692
 artikel
1308 PMH44 INCREASED USE OF AUGMENTATION THERAPIES ILLUSTRATES COMPLEX MANAGEMENT OF TREATMENT RESISTANT DEPRESSION. PRELIMINARY RESULTS FROM A REAL-WORD EVIDENCE REGISTRY IN EUROPE, THE 54135419DEP4001 STUDY Morrens, J.
22 S3 p. S688
 artikel
1309 PMH54 IS THE OXCAP-MH CAPABILITY MEASURE A FEASIBLE AND PSYCHOMETRICALLY VALID TOOL FOR THE ROUTINE EVALUATION OF MENTAL HEALTH SERVICES? Simon, J.
22 S3 p. S690
 artikel
1310 PMH7 LEVERAGING INNOVATIVE DIGITAL TECHNOLOGY: A NOVEL APPROACH TO SERVICE OPTIMISATION Kailey, R.S.
22 S3 p. S682
 artikel
1311 PMH16 LONG-TERM COST-EFFECTIVENESS OF ESKETAMINE FOR THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION Touchette, D.
22 S3 p. S683
 artikel
1312 PMH6 MEASURING THE LEVEL OF TRANSPARENCY WITH REGARD TO HOW SUBSTANCE DEPENDENCY IS TREATED IN THE PUBLIC HEALTH SYSTEMS OF SOME EUROPEAN AND NEIGHBOURING COUNTRIES Daneasa, D.
22 S3 p. S681-S682
 artikel
1313 PMH26 MODEL DEVELOPMENT FOR ASSESSING COST-EFFECTIVENESS AND PREPARE REIMBURSEMENT DOSSIER OF RTMS IN PATIENT POPULATION WITH TREATMENT-RESISTANT DEPRESSION IN HUNGARY Richárd, B.
22 S3 p. S685
 artikel
1314 PMH61 NEUROLEPTIC THERAPY COMPLIANCE DIFFERS AMONG PATIENTS TREATED BY DIFFERENT PSYCHIATRISTS Kostev, K.
22 S3 p. S691-S692
 artikel
1315 PMH5 PATIENTS MAY BE CONCERNED WITH THE CONSEQUENCES OF THEIR ANSWERS WHEN REPORTING ON SYMPTOMS OF DEPRESSION Sadler, M.
22 S3 p. S681
 artikel
1316 PMH49 PERSONALIZED HEALTHCARE EPISODE IDENTIFICATION IN SCHIZOPHRENIA SPECTRUM DISORDER USING HEALTHCARE CONSUMPTION TRAJECTORIES Konings, S.
22 S3 p. S689
 artikel
1317 PMH64 PHARMACOTHERAPY COST AND PRESCRIBING PRACTICE FOR PSYCHOTIC DISORDERS IN BULGARIA Tachkov, K.
22 S3 p. S692
 artikel
1318 PMH22 PREVALENCE OF DECISION ANALYTICAL MODELLING IN ECONOMIC EVALUATIONS OF MENTAL HEALTH INTERVENTIONS Murphy, A.
22 S3 p. S684
 artikel
1319 PMH18 PREVENTING MENTAL HEALTH CONDITIONS IN CHILDREN AND YOUNG ADULTS: A REVIEW OF THE COSTS OF COMPLEX INTERVENTIONS Thorn, J.
22 S3 p. S683
 artikel
1320 PMH8 PSYCHOLOGICAL ASPECTS OF GENETIC COUNSELING IN RARE GENETIC CNS DISORDERS - SHOULD REGULATORS BE MORE INVOLVED? Jarosławski, S.
22 S3 p. S682
 artikel
1321 PMH69 RISING DEPENDENCE ON ANTI-DEPRESSANTS AMONG ADULTS IN US: A STUDY BASED ON NHANES FROM 2005 TO 2016 Mazumder, D.
22 S3 p. S693
 artikel
1322 PMH36 ST. JOHN'S WORT THERAPY IS ASSOCIATED WITH A REDUCED INCIDENCE OF DEMENTIA IN PATIENTS TREATED IN GENERAL PRACTICES Kostev, K.
22 S3 p. S687
 artikel
1323 PMH27 SUCCESSFULLY TREATED PATIENTS WITH VORTIOXETINE VERSUS VENLAFAXINE: A SIMPLIFIED COST-EFFECTIVENESS ANALYSIS IN ASIAN PATIENTS WITH MAJOR DEPRESSIVE DISORDER Wang, G.
22 S3 p. S685
 artikel
1324 PMH13 SYSTEMATIC REVIEW OF UTILITY VALUES USED IN THE PHARMACOECONOMIC EVALUATIONS FOR SCHIZOPHRENIA: IMPLICATIONS ON COST-EFFECTIVENESS RESULTS Zhou, J.
22 S3 p. S682
 artikel
1325 PMH42 TARGETED LITERATURE REVIEW (TLR) OF THE ECONOMIC BURDEN OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) McGovern, A.
22 S3 p. S688
 artikel
1326 PMH14 THE BURDEN OF TREATMENT-RESISTANT DEPRESSION: A TARGETED LITERATURE REVIEW Khanduri, P.
22 S3 p. S682-S683
 artikel
1327 PMH12 THE COST OF RELAPSES MANAGEMENT IN PATIENTS SUFFERING FROM SCHIZOPHRENIA IN ITALY AND SPAIN: COMPARISON BETWEEN LURASIDONE AND QUETIAPINE XR Restelli, U.
22 S3 p. S682
 artikel
1328 PMH32 THE ECONOMIC BURDEN OF ALCOHOL CONSUMPTION IN THE CZECH REPUBLIC Chadimova, K.
22 S3 p. S686
 artikel
1329 PMH34 THE ECONOMIC BURDEN OF SCHIZOPHRENIA: A REAL-WORLD DATA ANALYSIS IN ITALY Gazzillo, S.
22 S3 p. S687
 artikel
1330 PMH47 THE IMPACT OF A DIGITAL SLEEP-IMPROVEMENT PROGRAM ON HEALTH CARE COSTS Sampson, C.
22 S3 p. S689
 artikel
1331 PMH56 THE IMPACT OF PHYSICAL AND MENTAL STRESS ON THE PRODUCTIVITY LOSS IN JAPANESE WORKPLACE Shoji, A.
22 S3 p. S690-S691
 artikel
1332 PMH50 THE LONGITUDINAL VALIDITY OF THE CHU9D - EVIDENCE FROM A MENTAL HEALTH TRIAL Wolf, R.
22 S3 p. S689
 artikel
1333 PMH41 THE REAL WORLD USE OF ORAL ANTIPSYCHOTICS IN SPAIN-STILL A NEED FOR NEW TREATMENTS? Parramon Ponz, M.
22 S3 p. S688
 artikel
1334 PMH46 THE USE OF PHARMACOEPIDEMIOLOGICAL DATA IN PREDICTING THE EXPENDITURES OF A PSYCHIATRIC HOSPITAL Velum, I.
22 S3 p. S688-S689
 artikel
1335 PMH63 USE OF ARTIFICIAL INTELLIGENCE METHODS TO BETTER DEFINE TREATMENT LINES IN SCHIZOPHRENIA Touzeni, S.
22 S3 p. S692
 artikel
1336 PMH59 VALIDATION OF A SCREENING INSTRUMENT OF ADDICTION TO FAST FOOD IN SPANISH GENERAL POPULATION Ovejero Bruna, M.
22 S3 p. S691
 artikel
1337 PMS3 A COMPARATIVE ANALYSIS OF THE QUALITY OF LIFE OF PATIENTS TREATED WITH MINIMAL INVASIVE ANTERIOR HIP REPLACEMENT SURGERY AND NON-SURGICAL PATIENTS Ruzsics, T.
22 S3 p. S694
 artikel
1338 PMS66 A COMPARISON OF STATISTICAL METHODS USED IN TRIAL-BASED ECONOMIC EVALUATIONS; DOES IT MATTER WHICH METHOD IS USED? Mutubuki, E.
22 S3 p. S705
 artikel
1339 PMS22 ANNUAL COST OF PATIENTS UNDERGOING A TOTAL KNEE REPLACEMENT IN FRANCE Fayad, M.
22 S3 p. S697
 artikel
1340 PMS11 A RETROSPECTIVE COHORT ANALYSIS OF THE BURDEN OF TOTAL KNEE ARTHROPLASTY IN JAPAN LoPresti, M.
22 S3 p. S695
 artikel
1341 PMS64 ASSESSING THE QUALITY OF BIOLOGIC SWITCH DECISIONS IN PSORIATIC ARTHRITIS: VALIDATION OF PASQAL - AN OUTCOMES MEASUREMENT TOOL Laires, P.
22 S3 p. S705
 artikel
1342 PMS49 ASSOCIATION OF FINANCIAL ACCESS TO HEALTHCARE WITH PRODUCTIVITY LOSS AND ASSOCIATEDPATIENTS’ OUT OF POCKET COSTS AMONG PATIENTS WITH RHEUMATOID DISEASES Xiong, X.
22 S3 p. S702
 artikel
1343 PMS36 BUDGET IMPACT ANALYSIS OF TRIPLE THERAPY AFTER FAILURE OF METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN FRANCE Scarica, R.
22 S3 p. S700
 artikel
1344 PMS75 BURDEN OF DISEASE AND UNMET NEEDS OF KNEE OSTEOARTHRITIS IN COLOMBIA Castellanos, C.
22 S3 p. S707
 artikel
1345 PMS78 CANADIAN REAL-WORLD EVIDENCE ON EPIDEMIOLOGY, OUTCOMES AND ECONOMICS OF MODERATE-TO-SEVERE OSTEOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW Larkin-Kaiser, K.
22 S3 p. S707
 artikel
1346 PMS52 CLINICAL GUIDELINE DEVELOPMENT FOR THE MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN PRIMARY CARE Verdonck, C.
22 S3 p. S703
 artikel
1347 PMS10 COMPARATIVE ANALYSIS OF HIP PROSTHESIS BY REVISION METHODS FOR LATERAL AND DIRECT ANTERIOR APPROACH Pakai, A.
22 S3 p. S695
 artikel
1348 PMS20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-EXPERIENCED PATIENTS FROM THE PORTUGUESE PERSPECTIVE Laires, P.A.
22 S3 p. S697
 artikel
1349 PMS31 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-NAIVE PATIENTS FROM THE PORTUGUESE PERSPECTIVE Laires, P.
22 S3 p. S699
 artikel
1350 PMS38 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN COMPARISON WITH ANAKINRA IN SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS (SJIA) TREATMENT IN TURKEY Erdogan-Ciftci, E.
22 S3 p. S700
 artikel
1351 PMS33 COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SC IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) TREATMENT IN TURKEY Erdogan-Ciftci, E.
22 S3 p. S699-S700
 artikel
1352 PMS32 COST MINIMIZATION ANALYSIS OF ZENTIUS FOR THE TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCY IN TURKEY Çalışkan, Z.
22 S3 p. S699
 artikel
1353 PMS19 COST OF ILLNESS OF OSTEOPOROSIS IN ITALY Nardone, C.
22 S3 p. S696-S697
 artikel
1354 PMS56 CURRENT PATTERNS OF CARE IN THE ASSESSMENT AND TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) Bapat, B.
22 S3 p. S703-S704
 artikel
1355 PMS48 270-DAYMORTALITY AND ITS PREDICTORS IN MEN WITH CONTRALATERAL HIP FRACTURE AFTER FEMORAL NECK FRACTURE Juhász, K.
22 S3 p. S702
 artikel
1356 PMS40 270-DAYMORTALITY AND ITS PREDICTORS IN WOMEN WITH CONTRALATERAL HIP FRACTURE AFTER FEMORAL NECK FRACTURE Juhász, K.
22 S3 p. S701
 artikel
1357 PMS73 DEPRESCRIBING OF ANALGESICS AND REPLACEMENT WITH PHYSIOTHERAPY IN THE DEPARTMENT OF ORTHOPEDICS FOR KNEE OSTEOARTHRITIS PATIENTS Abuzear, I.
22 S3 p. S706-S707
 artikel
1358 PMS43 DUCHENNE MUSCULAR DYSTROPHY PREVALENCE IN FIVE EUROPEAN COUNTRIES: A NOVEL INCIDENCE-BASED MODELING APPROACH USING SYSTEM DYNAMICS Giegerich, E.
22 S3 p. S701
 artikel
1359 PMS63 ECONOMIC ANALYSIS OF WOUND CLOSURE METHODS IN KNEE ARTHROPLASTY FROM 4 EUROPEAN COUNTRIES Jamous, N.
22 S3 p. S704-S705
 artikel
1360 PMS69 EFFECT OF HIP FLEXION CONTRACTURE ON TERMINAL STANCE OF GAIT AMONG INACTIVE UNIVERSITY STUDENTS Tóth, B.
22 S3 p. S706
 artikel
1361 PMS16 EFFECTS OF HYDROXYCHLOROQUINE ON THROMBOSIS FACTORS AND INFLAMMATORY CYTOKINES IN PATIENTS WITH ELDERLY RHEUMATOID ARTHRITIS Liu, D.
22 S3 p. S696
 artikel
1362 PMS7 EFFICACY EXAMINATION OF PILATES TRAINING AMONG HEALTHY WOMEN ON THE CHANGE OF TRUNK STATE, POSTURE, LUMBAR MOTOR CONTROL ABILITY AND BALANCE Horváth, K.
22 S3 p. S695
 artikel
1363 PMS1 EFFICACY OF EXERCISE THERAPY AMONG PRESCHOOL CHILDREN WITH DOWN SYNDROME Kraliczky, O.
22 S3 p. S694
 artikel
1364 PMS4 EFFICACY OF RENAL FUNCTION IN PATIENTS WITH EARLY DIABETIC NEPHROPATHY COMPLICATED WITH HYPERURICEMIA. Zhang, J.W.
22 S3 p. S694
 artikel
1365 PMS50 EPIDEMIOLGY AND ROUTINE CARE TREATMENT PATTERNS OF PATIENTS WITH HIP/KNEE OSTEOARTHRITIS AND CHRONIC LOWER BACK PAIN IN GERMANY Ohlmeier, C.
22 S3 p. S702
 artikel
1366 PMS35 EVIDENCE MAP OF ECONOMIC EVALUATIONS IN RHEUMATOID ARTHRITIS Martin, A.
22 S3 p. S700
 artikel
1367 PMS2 EXAMINATION OF A SPORT-SPECIFIC DYNAMIC CORE STABILITY PROGRAMME AMONG FEMALE ACROBATIC ROCK AND ROLL DANCERS Halász, D.
22 S3 p. S694
 artikel
1368 PMS67 EXPERIENCE AND PREFERENCE-BASED EQ-5D-3L VALUE SET DERIVED FROM LONGITUDINAL DATA: RESULTS FROM THE INTERNATIONAL COSTS AND UTILITIES OF OSTEOPOROTIC FRACTURES STUDY (ICUROS) Svedbom, A.
22 S3 p. S705-S706
 artikel
1369 PMS13 EXPERIMENTAL STUDY OF TOPICAL TREATMENT OF RHEUMATOID ARTHRITIS WITH TNF-Α ANTAGONIST Qiu, H.
22 S3 p. S696
 artikel
1370 PMS14 FLARE QUESTIONNAIRE FOR RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND RECURRENCE IDENTIFICATION IN CLINICAL RESEARCH Liu, H.
22 S3 p. S696
 artikel
1371 PMS54 FRACTURE LIAISON SERVICES Rabe, A.P.
22 S3 p. S703
 artikel
1372 PMS44 FRACTURES OF THE RADIUS IN WOMEN AGED 50 YEARS AND OVER: A STUDY OF ELECTRONIC MEDICAL RECORDS Petri, J.
22 S3 p. S701
 artikel
1373 PMS28 HEALTHCARE SERVICE UTILISATION BY PATIENTS WITH CHRONIC LOW BACK PAIN - RESULTS FROM A GLOBAL 8,990 PATIENT SURVEY: CITIZENS' RESEARCH Morlion, B.
22 S3 p. S698
 artikel
1374 PMS24 HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ELBOW AND FOREARM IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Sebestyén, A.
22 S3 p. S698
 artikel
1375 PMS29 HEALTH STATE UTILITY VALUES FOR JUVENILE IDIOPATHIC ARTHRITIS: A SYSTEMATIC REVIEW Grazziotin Lago, L.
22 S3 p. S699
 artikel
1376 PMS58 HEALTH TECHNOLOGY ASSESSMENT (HTA) OF EQUISTASI FOR THE TREATMENT OF PATIENTS WITH PARKINSONIAN POST-DYSKINESIA FALLS. Rossi, D.
22 S3 p. S704
 artikel
1377 PMS26 IMPACT OF CHRONIC LOW BACK PAIN ON EMPLOYMENT AND PRODUCTIVITY - RESULTS FROM A GLOBAL 8,990 PATIENT SURVEY: CITIZENS' RESEARCH Roomes, D.
22 S3 p. S698
 artikel
1378 PMS57 IS DEFLAZACORT A COST-EFFECTIVE TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY? Quach, D.
22 S3 p. S704
 artikel
1379 PMS23 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ANKLE AND FOOT IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Endrei, D.
22 S3 p. S697
 artikel
1380 PMS27 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE HIP AND THIGH IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Boncz, I.
22 S3 p. S698
 artikel
1381 PMS25 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE KNEE AND LOWER LEG IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Boncz, I.
22 S3 p. S698
 artikel
1382 PMS39 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE SHOULDER AND UPPER ARM IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Gazsó, T.
22 S3 p. S700-S701
 artikel
1383 PMS34 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE WRIST AND HAND IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA Sebestyén, A.
22 S3 p. S700
 artikel
1384 PMS12 PATIENTS PRESCRIBED WITH OPIOID TREATMENT IN PRIMARY CARE PRACTICES: A POPULATION-BASED STUDY IN ITALY Peduto, I.
22 S3 p. S695-S696
 artikel
1385 PMS68 PREDICTORS OF AGREEMENT BETWEEN PATIENT AND CLINICIAN GLOBAL ASSESSMENTS OF RHEUMATOID ARTHRITIS SEVERITY Foley, C.
22 S3 p. S706
 artikel
1386 PMS21 PRELIMINARY RESULTS OF A COST-UTILITY ANALYSIS OF A FRACTURE LIAISON SERVICE BASED ON HEALTH SERVICES INDICATORS Senay, A.
22 S3 p. S697
 artikel
1387 PMS42 PREVALENCE, PAIN INTENSITY AND DISABILITY OF LOW BACK PAIN AMONG INDIAN POPULATION. A CROSS SECTIONAL STUDY Asrar, M.M.
22 S3 p. S701
 artikel
1388 PMS41 PROJECTION OF THE PREVALENCE OF RHEUMATIC DISEASES IN PORTUGAL THROUGH THE FIRST HALF OF THE 21ST CENTURY Laires, P.
22 S3 p. S701
 artikel
1389 PMS70 PSYCHOLOGICAL SYMPTOMS AND TOTAL KNEE REPLACEMENT. Escobar, A.
22 S3 p. S706
 artikel
1390 PMS6 QUALITY OF LIFE OF PATIENTS UNDERWENT IMPLANTATION OF KNEE ENDOPROSTHESIS Busa, M.
22 S3 p. S694-S695
 artikel
1391 PMS8 RATE OF FRACTURES LEADING TO HOSPITALISATION AND HEALTHCARE BURDEN IN UNTREATED OSTEOPOROSIS ELDERLY PATIENTS IN GERMANY: AN INGEF HEALTHCARE INSURANCE DATABASE ANALYSIS Böcker, W.
22 S3 p. S695
 artikel
1392 PMS59 REAL-WORLD EFFECTIVENESS OF PHYSIOTHERAPY INTERVENTIONS FOR MUSCULOSKELETAL DISORDERS IN NIGERIA Mbada, C.
22 S3 p. S704
 artikel
1393 PMS15 REAL-WORLD EFFECTIVENESS OF SECUKINUMAB FOR PSORIATIC ARTHRITIS PATIENTS: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN Chung, C.Y.
22 S3 p. S696
 artikel
1394 PMS30 SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE TURKISH PAYER PERSPECTIVE Seyhun, O.
22 S3 p. S699
 artikel
1395 PMS47 SIZING THE PATIENT POTENTIAL FOR DISEASE MODIFYING OSTEOARTHRITIS THERAPIES IN USA AND EU MARKETS Talbot-Watt, N.
22 S3 p. S702
 artikel
1396 PMS74 TAPERING BIOLOGIC? AN INSIGHT AND PERSPECTIVE OF RHEUMATOID ARTHRITIS PATIENTS Suz Jack, C.
22 S3 p. S707
 artikel
1397 PMS71 THE BURDEN OF CONTROLLED AND UNCONTROLLED GOUT: AN ANALYSIS OF PATIENT-REPORTED OUTCOMES IN THE EUROPEAN UNION FIVE (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM) Abhishek, A.
22 S3 p. S706
 artikel
1398 PMS5 THE EFFECT OF DANCE THERAPY ON DEVELOPMENT OF MOVEMENT IN CHILDREN WITH DOWN SYNDROME Mészáros, D.
22 S3 p. S694
 artikel
1399 PMS18 THE EXAMINATION AND DEVELOPMENT OF TRUNK STABILITY IN HIGH SCHOOL STUDENTS Pálvölgyi, A.
22 S3 p. S696
 artikel
1400 PMS53 THE MOST COMMON REASONS FOR A MEDICAL VISIT AMONG PEOPLE PERFORMING CONDITIONING GYM WEIGHT TRAINING Király, B.
22 S3 p. S703
 artikel
1401 PMS51 TRAJECTORIES OF FOLLOW-UP COMPLIANCE AND THEIR PREDICTORS IN A FRACTURE LIAISON SERVICE Senay, A.
22 S3 p. S702-S703
 artikel
1402 PMS55 TREATMENT PATTERNS AMONG MS PATIENTS NEWLY INITIATING DISEASE-MODIFYING THERAPY Kantor, D.
22 S3 p. S703
 artikel
1403 PMS65 USE OF REGISTRY DATA AS A SOURCE OF REAL WORLD EVIDENCE IN BRIDGING DISCONNECTED NETWORKS OF FIRST AND SECOND LINES OF THERAPIES IN RHEUMATOID ARTHRITIS Bujkiewicz, S.
22 S3 p. S705
 artikel
1404 PMS76 WHAT LOW BACK PAIN PATIENTS REALLY CARE ABOUT: REAL WORLD EVIDENCE ON PATIENT REPORTED HEALTH OUTCOMES IN AUSTRALIA. Markus, K.J.
22 S3 p. S707
 artikel
1405 PMU137 A BIBLIOMETRIC ANALYSIS OF SOUTH AFRICAN HEALTH-RELATED QUALITY OF LIFE STUDIES RELEVANT TO ECONOMIC EVALUATIONS Marsh, S.E.
22 S3 p. S732
 artikel
1406 PMU105 ACCEPTANCE OF EVIDENCE TRANSFER FROM ADULTS TO CHILDREN IN THE CONTEXT OF BENEFIT ASSESSMENT IN GERMANY, FRANCE, AND UK Weihing, J.
22 S3 p. S726
 artikel
1407 PMU140 A COMPREHENSIVE CATALOGUE OF EQ-5D SCORES IN CHRONIC DISEASE: RESULTS OF A SYSTEMATIC REVIEW Van Wilder, L.
22 S3 p. S733
 artikel
1408 PMU103 A CRITICAL REVIEW FRAMEWORK FOR THE ASSESSMENT OF EUNETHTA METHODOLOGICAL GUIDELINES TO INFORM FUTURE JOINT CLINICAL ASSESSMENTS Miikkulainen, K.
22 S3 p. S726
 artikel
1409 PMU112 ADHERENCE: NUDGING INNOVATION OF OUTCOMES-BASED CONTRACTS TO REWARD BEHAVIOR Eslami, N.
22 S3 p. S727
 artikel
1410 PMU43 A MORE ACCURATE MEASURE OF AFFORDABILITY OF ALCOHOL FOR THE RUSSIAN FEDERATION Gil, A.
22 S3 p. S715
 artikel
1411 PMU59 ANALYSIS OF THE EVOLUTION IN THE ACCESS TO MEDICINES IN ITALY IN THE LAST 5 YEARS (2014-2018) Prada, M.
22 S3 p. S718
 artikel
1412 PMU52 ANALYSIS OF THE REIMBURSEMENT DECISIONS MADE BY THE INTERMINISTERIAL PRICE COMMISSION FOR MEDICINES IN SPAIN Sánchez-Martín, J.
22 S3 p. S717
 artikel
1413 PMU12 AN OVERVIEW OF SYSTEMATIC REVIEWS OF ECONOMIC EVALUATIONS OF PHARMACY-BASED PUBLIC HEALTH INTERVENTIONS: ADDRESSING METHODOLOGICAL CHALLENGES Costa, S.
22 S3 p. S710
 artikel
1414 PMU78 APPLICATION OF MACHINE LEARNING TECHNIQUES IN EARLY DISEASE DETECTION: A REVIEW Goyal, A.
22 S3 p. S721
 artikel
1415 PMU97 A REVIEW OF CONTRIBUTIONS MADE BY PATIENT ADVOCACY GROUPS IN THE ASSESSMENT OF DRUGS BY THE FRENCH HAUTE AUTORITE DE SANTE Belkhous, S.
22 S3 p. S725
 artikel
1416 PMU86 A REVIEW OF TOP COUNTRIES CONTRIBUTING TO POSTERS PRESENTED AT ISPOR EUROPE 2018 Cagnan, L.
22 S3 p. S723
 artikel
1417 PMU117 A SCOPING REVIEW OF STATISTICAL RECOMMENDATIONS FOR TRIAL-BASED ECONOMICS EVALUATIONS: WHERE ARE WE NOW? El Alili, M.
22 S3 p. S728-S729
 artikel
1418 PMU153 ASSESSING THE FUTURE, EVALUATION OF THE INITIAL HTA ASSESSMENTS OF ATMPS IN THE NORDICS Wikström, A.
22 S3 p. S736
 artikel
1419 PMU142 ASSESSING THE HUMAN AND ECONOMIC BURDEN OF SHORT STATURE: A SYSTEMATIC LITERATURE REVIEW Lundkvist, J.
22 S3 p. S733
 artikel
1420 PMU93 ASSESSING THE OUTCOMES FOR ORPHAN STATUS OR ACCELERATED ASSESSMENT EMA APPROVED MEDICINES: A COMPARISON OF HEALTH TECHNOLOGY ASSESSMENT IN DENMARK, FINLAND, NORWAY AND SWEDEN Falla, E.
22 S3 p. S724
 artikel
1421 PMU62 ASSESSING WHETHER PRODUCTS NEED TO BE COST-SAVING IN ORDER TO GAIN ACCELERATED ACCESS COLLABORATIVE RAPID UPTAKE STATUS IN NHS ENGLAND Naylor, C.
22 S3 p. S718-S719
 artikel
1422 PMU5 ASSESSMENT OF ADVERSE DRUG REACTIONS IN PATIENTS WITH HEPATIC DISEASES AT THE DEPARTMENT OF GASTROENTEROLOGY: A PROSPECTIVE OBSERVATIONAL STUDY Nair, S.
22 S3 p. S708
 artikel
1423 PMU1 A SYSTEMATIC LITERATURE REVIEW OF THE EFFICACY AND SAFETY OF MICROINCISION VITRECTOMY SURGERY TOOLS IN VITREORETINAL DISEASES Gauthier, G.
22 S3 p. S708
 artikel
1424 PMU100 A SYSTEMATIC REVIEW OF PREVIOUSLY PUBLISHED OR APPRAISED HEALTH ECONOMIC ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS Hashim, M.
22 S3 p. S725
 artikel
1425 PMU30 A SYSTEMATIC REVIEW OF PREVIOUSLY PUSBLISHED OR APPRAISED HEALTH ECONOMIC MODELS ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS Vincken, T.
22 S3 p. S713
 artikel
1426 PMU124 ATTENDING PHYSICIAN MODELS OF CARE AND PATIENT OUTCOMES Johnson, T.J.
22 S3 p. S730
 artikel
1427 PMU72 ATTRIBUTES OF DISSATISFACTION OF HEALTH INSURANCE COVERAGE IN PATIENTS VISITED PUBLIC AND PRIVATE DENTAL HEALTHCARE CENTERS Vahidibenehkohal, J.
22 S3 p. S720
 artikel
1428 PMU54 A 10-YEAR REVIEW (2009-2018) OF MARKET ACCESS OF PHARMACEUTICALS IN THE EU5 AND US Mycka, J.
22 S3 p. S717-S718
 artikel
1429 PMU51 BARRIERS AGAINST PROGRAMS FOR THE PREVENTION OF IODINE DEFICIENCY DISORDERS IN EUROPE: A DELPHI STUDY Schaffner, M.
22 S3 p. S717
 artikel
1430 PMU22 BROADER ECONOMIC BURDEN OF SMOKING ATTRIBUTABLE DISEASES IN GREECE Antonopoulou, V.
22 S3 p. S711
 artikel
1431 PMU27 BUDGET IMPACT ANALYSIS OF IMPLEMENTING THE CLOSED-SYSTEM TRANSFER DEVICE QIMONO® DURING CHEMOTHERAPY ADMINISTRATION IN A FRENCH HOSPITAL Cabout, E.
22 S3 p. S712
 artikel
1432 PMU28 CAVEATS IN COST-EFFECTIVENESS ANALYSIS OF REMOTE PATIENT MONITORING: IMPACT OF END-OF-LIFE ADJUSTMENT OF QALYS ON DECISION MAKING METRICS Wirth, T.
22 S3 p. S712-S713
 artikel
1433 PMU39 CERVICAL CANCER PREVENTION THROUGH HUMAN PAPILLOMAVIRUS (HPV) VACCINATION: A CASE STUDY IN ETHIOPIA Lenahan, K.
22 S3 p. S715
 artikel
1434 PMU34 COMPARATIVE ANALYSIS OF DISABILITY ADJUSTED LIFE YEARS FROM ADVERSE EFFECTS OF MEDICAL TREATMENT IN UKRAINE AND OTHER COUNTRIES Dobrova, A.
22 S3 p. S714
 artikel
1435 PMU10 CONSIDERATIONS FOR THE TRANSLATION AND LINGUISTIC VALIDATION OF CLINICAL OUTCOME ASSESSMENTS (COAS) IN VARIANTS OF SPANISH FOR THE UNITED STATES Simpson-Finch, H.
22 S3 p. S709
 artikel
1436 PMU75 CONSUMER VALUE OF ANTIDIABETIC, ANTINEOPLASTIC, AND RESPIRATORY DRUGS Ganz, M.L.
22 S3 p. S721
 artikel
1437 PMU13 COST-EFFECTIVENESS ANALYSIS OF PCT-GUIDED ANTIBIOTIC STEWARDSHIP FOR HOSPITALIZED PATIENTS WITH SEPSIS OR LOWER RESPIRATORY TRACT INFECTIONS IN A US HOSPITAL Voermans, A.
22 S3 p. S710
 artikel
1438 PMU23 COST OF ILLNESS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS DISEASE. COEPSO STUDY Llamas-Velasco, M.D.M.
22 S3 p. S712
 artikel
1439 PMU17 COSTS ASSOCIATED WITH THE MANAGEMENT OF CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA IN ADULT PATIENTS UNDERGOING INVASIVE PROCEDURES IN SPAIN Gil, A.
22 S3 p. S711
 artikel
1440 PMU38 COSTS-EFFECTIVITY, HEALTH ECONOMIC EVALUATION, SYSTEMATIC REVIEW AND METANALYSIS OF BARIATRIC SURGERY IN REDUCING OBESITY RELATED DISEASES, MORTALITY, DEPRESSION AND CANCER Turri, J.A.
22 S3 p. S714-S715
 artikel
1441 PMU32 COSTS OF HEALTHCARE ANTICIPATED IN PEOPLE AFTER METHANOL INTOXICATION Doubek, J.
22 S3 p. S713-S714
 artikel
1442 PMU21 COST-UTILITY ANALYSES OF INTERVENTIONS FOR INFORMAL CAREGIVERS: A SYSTEMATIC AND CRITICAL REVIEW Guets, W.
22 S3 p. S711
 artikel
1443 PMU121 CRITICAL REVIEW OF VALIDATION STUDIES OF ARTIFICIAL INTELLIGENCE TECHNOLOGIES APPLIED IN MEDICINE DURING THE LAST FIVE YEARS Rebollo, P.
22 S3 p. S729
 artikel
1444 PMU120 CRITICAL REVIEW OF VALIDATION STUDIES OF NATURAL LANGUAGE PROCESSING TECHNIQUES APPLIED TO INFORMATION FROM ELECTRONIC MEDICAL RECORDS DURING THE LAST 5 YEARS Rebollo, P.
22 S3 p. S729
 artikel
1445 PMU91 CURRENT TREND OF UTILITY VALUES IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISAL GUIDANCE Azuma, M.
22 S3 p. S724
 artikel
1446 PMU148 CUTANEOUS LYMPHOMAS IN GERMANY: LANDSCAPING ANALYSIS OF GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA Doess, A.
22 S3 p. S735
 artikel
1447 PMU94 DATA GENERATED BY THE FRENCH COMPASSIONATE USE PROGRAM: HOW CAN THEY CONTRIBUTE TO THE HEALTH TECHNOLOGY ASSESSMENT? Mazin, N.
22 S3 p. S724
 artikel
1448 PMU80 DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN Andrade, R.
22 S3 p. S722
 artikel
1449 PMU141 DEVELOPMENT OF EQ-5D-5L BOLT-ONS FOR COGNITION AND VISION Sampson, C.
22 S3 p. S733
 artikel
1450 PMU102 DIFFERENCES IN HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS BETWEEN EUROPEAN JURISDICTIONS: THE ROLE OF PRACTICE VARIATIONS Vreman, R.
22 S3 p. S725-S726
 artikel
1451 PMU149 DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CANCER PATIENTS: DID THEY INCREASE IN RECENT YEARS? Ghiani, M.
22 S3 p. S735
 artikel
1452 PMU144 DISEASE STATE ADAPTATION AND ESTIMATES OF QUALITY-OF-LIFE: A SYSTEMATIC LITERATURE REVIEW Shaikh, A.
22 S3 p. S734
 artikel
1453 PMU123 DO SYSTEMATIC REVIEWS SYSTEMATICALLY ASSESS RISK OF BIAS IN REAL-WORLD EVIDENCE STUDIES? Kazmierska, P.
22 S3 p. S730
 artikel
1454 PMU84 DRUG DECISION-MAKING PATHWAYS IN ENGLAND: CURRENT PROCESSES AND THE POTENTIAL IMPACT OF NICE CHANGES Lilley, H.
22 S3 p. S722
 artikel
1455 PMU31 EARLY COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS MONITORING OF LUNG-AERATION WITH ELECTRICAL IMPEDANCE TOMOGRAPHY IN PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME Voermans, A.
22 S3 p. S713
 artikel
1456 PMU151 ECONOMIC BURDEN OF BIOSIMILAR DELIVERY IN FRANCE: REAL WORLD ANALYSIS FROM THE PERMANENT SAMPLE OF NATIONAL HEALTH INSURANCE BENEFICIARIES, BETWEEN 2007 TO 2017 Parmentier, R.
22 S3 p. S735-S736
 artikel
1457 PMU29 ECONOMIC EVALUATION FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURES INFECTIONS (ABSSSI) FROM THE NATIONAL PAYER PERSPECTIVE: INTRODUCTION OF A NEW TREATMENT INTO THE PATIENT JOURNEY. SIMULATION IN 3 EUROPEAN COUNTRIES Mennini, F.S.
22 S3 p. S713
 artikel
1458 PMU24 ECONOMIC EVALUATION OF BIOCELLULOSE WOUND DRESSINGS FOR THE MANAGEMENT OF CHRONIC LEG ULCERS IN CANADA Patenaude, J.
22 S3 p. S712
 artikel
1459 PMU15 ECONOMIC IMPACT OF PREVENAR 13 VACCINATION AGAINST PNEUMOCOCCAL PNEUMONIA HOSPITALIZATIONS IN DANES 65+ WITH A CHRONIC DISEASE - A MODELLED ANALYSIS Poulsen, P.B.
22 S3 p. S710
 artikel
1460 PMU71 EFFECTIVE IMPLEMENTATION OF BIOSIMILAR MEDICINE AT PATENT EXPIRATION TO ACHIEVE OPTIMAL FINANCIAL GAIN: BEST PRACTICE MODEL WITH ADALIMUMAB AS CASE Trolle, S.
22 S3 p. S720
 artikel
1461 PMU115 EMAPS: A BENCHMARKING STUDY OF 9 DIGITAL HEALTH MARKETS ACROSS EUROPE Rose, J.
22 S3 p. S728
 artikel
1462 PMU33 EPIDEMIOLOGY OF PROLIFERATIVE DIABETIC RETINOPATHY (PDR): EVIDENCE FROM A LITERATURE REVIEW Singh, I.
22 S3 p. S714
 artikel
1463 PMU138 EXPLORATIVE SCOPING REVIEW AND BIBLIOMETRIC ANALYSIS OF BIG DATA APPLICATIONS FOR MEDICATION ADHERENCE Pirri, S.
22 S3 p. S732-S733
 artikel
1464 PMU70 FACTORS INFLUENCING THE SELECTION OF PRODUCTS FOR THE ACCELERATED ACCESS COLLABORATIVE'S RAPID UPTAKE PATHWAY Mellor, L.
22 S3 p. S720
 artikel
1465 PMU44 FIFTY SHADES OF... INNOVATIVENESS IN ITALY Casilli, G.
22 S3 p. S715-S716
 artikel
1466 PMU74 FIRST 27 MONTHS OF CONDITIONAL REIMBURSEMENT IN FINLAND Hahl, J.
22 S3 p. S721
 artikel
1467 PMU63 FRENCH HEALTH TECHNOLOGY ASSESSMENT OF DRUGS APPROVED UNDER EXCEPTIONAL CIRCUMSTANCES Qiu, T.
22 S3 p. S719
 artikel
1468 PMU9 HIGH DRUG PRICES AND THE ADEQUACY OF RETURN ON PUBLIC INVESTMENT INTO DRUG RESEARCH AND DEVELOPMENT BY THE U.S. NATIONAL INSTITUTES OF HEALTH (NIH). Jarosławski, S.
22 S3 p. S709
 artikel
1469 PMU109 HOW DO NICE EVIDENCE REVIEW GROUPS AND APPRAISAL COMMITTEES PERCEIVE FRACTIONAL POLYNOMIAL METHODOLOGY IN TECHNOLOGY APPRAISALS? Leahy, T.
22 S3 p. S727
 artikel
1470 PMU55 HURDLES TO REGULATORY AND ACCESS (PRICING AND REIMBURSEMENT) OF 3D-PRINTED TUMOR ASSAYS FOR PERSONALIZED MEDICINE IN ONCOLOGY Jaalouk, S.
22 S3 p. S718
 artikel
1471 PMU61 IDENTIFYING DISEASE AREAS WHERE DISRUPTIVE INNOVATION IS LIKELY TO HAVE A SIGNIFICANT IMPACT ON HEALTHCARE SYSTEMS AND BUDGETS. THE IMPORTANCE OF TRACKING PAYER BEHAVIOURS Roldan Gomendio, A.
22 S3 p. S718
 artikel
1472 PMU127 ILLNESS-RELATED STIGMA: CONCEPTUAL AND MEASUREMENT CONSIDERATIONS FOR PATIENT-CENTERED ASSESSMENT IN INTERVENTIONAL CONTEXTS Brohan, E.
22 S3 p. S730
 artikel
1473 PMU60 INCENTIVE STRUCTURES OF ADDITIONAL PAYMENTS FOR NEW TECHNOLOGIES IN INPATIENT CARE: DOES IT WORK? Henschke, C.
22 S3 p. S718
 artikel
1474 PMU107 INSIGHTS INTO REIMBURSEMENT RATES AND TIMELINES FOR ORPHAN DRUGS IN IRELAND Marsh, S.E.
22 S3 p. S726
 artikel
1475 PMU150 ISHLT REGISTRY DATA AND COUNTRY REGISTRIES: COMPARISON OF REPORTED COUNTRY LUNG TRANSPLANT ACTIVITIES IN NORTH AMERICA AND EUROPEAN COUNTRIES IN 2016 Hofstetter, E.
22 S3 p. S735
 artikel
1476 PMU8 IS PREFERENCE OF ELICITATION TECHNIQUE BASED ON THE DISEASE AREA BEING STUDIED? Agnihotri, N.
22 S3 p. S709
 artikel
1477 PMU113 IS THERE AN ASSOCIATION BETWEEN ERG AND NICE REIMBURSEMENT RECOMMENDATIONS? Farinella, M.
22 S3 p. S727-S728
 artikel
1478 PMU95 IS THERE REGIONAL VARIATION IN WORSE AND SLOWER COST/QALY HTA OUTCOMES FOR COMBINATION PRODUCTS INVOLVING TWO VS. ONE MANUFACTURER? Turkstra, E.
22 S3 p. S724-S725
 artikel
1479 PMU85 LESSONS FOR BREAKING NEW GROUND WITH FIRST-IN-CLASS THERAPIES Kolotourou, K.
22 S3 p. S723
 artikel
1480 PMU108 LEVERAGING ELECTRONIC HEALTH RECORDS TO MEET THE REAL-WORLD EVIDENCE NEEDS OF HTA: A UK PERSPECTIVE Leahy, T.
22 S3 p. S726-S727
 artikel
1481 PMU11 MAIN WEAKNESSES AND PROBLEMATICS OF CYBERSECURITY IN MEDICAL DEVICES Blavatskyi, I.
22 S3 p. S709
 artikel
1482 PMU73 MONETIZATION OF ADDITIONAL BENEFIT OF ORPHAN DRUGS IN GERMAN ARBITRATION BOARD DECISIONS Ladicke, N.
22 S3 p. S720
 artikel
1483 PMU128 MY DAUGHTER LOVES THE NEW PENS!: QUANTIFYING THE PATIENT EXPERIENCE WITH MACHINE READING AND APPLIED SEMANTIC COMPUTING Bichteler, A.
22 S3 p. S730
 artikel
1484 PMU104 NAVIGATING DIVERGENCE: ACCOMMODATING THE MULTITUDE OF NEW PAYER BODIES IN EMERGING MARKETS Macaulay, R.
22 S3 p. S726
 artikel
1485 PMU49 NEGOTIATION OUTCOMES IN ITALY: WHAT’S THE IMPACT OF ORPHAN DRUG DESIGNATION? Enrici, A.
22 S3 p. S716-S717
 artikel
1486 PMU40 NEWLY DIAGNOSED DEPRESSION AND DEPRESSION SEVERITY AMONG WOMEN WITH INCIDENT BREAST CANCER Chopra, I.
22 S3 p. S715
 artikel
1487 PMU37 NEWLY DIAGNOSED NONALCOHOLIC FATTY LIVER DISEASE AFTER BARIATRIC SURGERY: A STUDY OF ELECTRONIC MEDICAL RECORD DATA Buysse, B.
22 S3 p. S714
 artikel
1488 PMU116 NICE MEDICAL TECHNOLOGIES GUIDANCE: IMPACT BEYOND THE UK Millar, L.
22 S3 p. S728
 artikel
1489 PMU14 NON-MEDICAL SWITCHING AT THE HOSPITAL: A SYSTEMATIC REVIEW ON THERAPEUTIC CLASSES AND PATHOLOGIES THAT ARE APPROPRIATE TO ACHIEVE SAVINGS Krstic, M.
22 S3 p. S710
 artikel
1490 PMU77 OPIOID USE PATTERNS AND HEALTHCARE USE AMONG INDIVIDUALS WITH COMORBID CHRONIC NON-CANCER PAIN AND OBSTRUCTIVE SLEEP APNEA Gandhi, A.B.
22 S3 p. S721
 artikel
1491 PMU110 OPTIMIZING EARLY ACCESS THROUGH ITALY'S PHARMACEUTICAL INNOVATION SYSTEM: KEY SUCCESS FACTORS FOR ATTAINING INNOVATIVE AND CONDITIONALLY INNOVATIVE STATUS Sligh, S.
22 S3 p. S727
 artikel
1492 PMU47 ORPHAN DRUG DESIGNATION: NO IMPACT ON P&R PROCESS TIMING IN ITALY Enrici, A.
22 S3 p. S716
 artikel
1493 PMU143 PATIENT CENTRICITY IN PATIENT PREFERENCE STUDIES: INTERVIEWS WITH PATIENTS van Overbeeke, E.
22 S3 p. S734
 artikel
1494 PMU134 PATIENT CENTRICITY? PATIENT NOISE IN SOCIAL MEDIA AND SUPPORT PROGRAMS IN THE GERMAN HEALTHCARE ENVIRONMENT Freiberg, M.
22 S3 p. S732
 artikel
1495 PMU83 PATIENT-FOCUSED OUTCOMES IN THE AMNOG-PROCESS - STATUS QUO AND QUO VADIS Wilmes, R.
22 S3 p. S722
 artikel
1496 PMU135 PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH CHRONIC OCULAR SURFACE PAIN : A LITERATURE REVIEW Sharma, G.
22 S3 p. S732
 artikel
1497 PMU67 PERFORMACE-BASED SCHEMES IN ITALY: IMPACT OF THEIR APPLICATION IN THE LAST 5 YEARS (2013-2017) Prada, M.
22 S3 p. S719-S720
 artikel
1498 PMU129 PERFORMANCE OF A COMPREHENSION QUESTION IN DISCRETE-CHOICE EXPERIMENT SURVEYS (DCE) Mansfield, C.
22 S3 p. S730-S731
 artikel
1499 PMU46 POSITIVE IMPACT OF INNOVATIVE STATUS IN P&R PROCESS TIMING IN ITALY Enrici, A.
22 S3 p. S716
 artikel
1500 PMU45 PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY Casilli, G.
22 S3 p. S716
 artikel
1501 PMU65 PRICE ANALYSIS OF NEW MEDICINAL PRODUCTS REIMBURSED IN ITALY AND GERMANY Casilli, G.
22 S3 p. S719
 artikel
1502 PMU48 P&R PROCESS IN ITALY: A FOCUS ON NEGOTIATION OUTCOMES OF INNOVATIVE DRUGS Enrici, A.
22 S3 p. S716
 artikel
1503 PMU136 PSYCHOMETRIC PROPERTIES OF MALE SEXUAL HEALTH QUESTIONNAIRE (MSHQ), IN HIV AND HCV PATIENTS Tran Lu y, M.
22 S3 p. S732
 artikel
1504 PMU132 PUBLICATION PATTERNS IN PATIENT-REPORTED OUTCOMES IN ORIGINAL RESEARCH ARTICLES ABOUT DIABETES AND INFLAMMATORY BOWEL DISEASE Richmond, G.
22 S3 p. S731
 artikel
1505 PMU147 PUBLICATION PATTERNS OF HEALTH ECONOMIC OUTCOME DATA OVER 2 DECADES: AN INCREASE IN PEER-REVIEWED HEOR PUBLICATIONS ACROSS INFLAMMATORY DISEASES van den Broek, R.
22 S3 p. S734-S735
 artikel
1506 PMU7 QUALITY OF LIFE IN CHILDREN WHO HAVE UNDERGONE ALLO-HSCT FOR MALIGNANT/NON-MALIGNANT HAEMATOLOGICAL DISEASE (QUEST) Irwin, J.
22 S3 p. S709
 artikel
1507 PMU35 QUANTIFYING THE LOST MARKET SIZE OPPORTUNITY OF A TNF-INHIBITOR DUE TO DELAY IN TIME FROM PRIMARY TO SECONDARY INDICATION APPROVAL Thiel, E.
22 S3 p. S714
 artikel
1508 PMU19 RARE DISEASES AND THE COST FOR SOCIAL SECURITY SYSTEM: ESTIMATING THE SOCIO-ECONOMIC BURDEN IN ITALY Nardone, C.
22 S3 p. S711
 artikel
1509 PMU130 REPRESENTATIVENESS OF THE NATIONAL HEALTH AND WELLNESS SURVEY IN EUROPE: CURRENT EPIDEMIOLOGY ACROSS MULTIPLE DISEASES Jaffe, D.H.
22 S3 p. S731
 artikel
1510 PMU87 REVIEW OF ORPHAN TREATMENTS ASSESSED BY NICE AND THE SMC IN THE UK. Nelson, L.
22 S3 p. S723
 artikel
1511 PMU90 REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) Tardu, J.
22 S3 p. S723
 artikel
1512 PMU99 REVIEW OF RECENT NICE TECHNOLOGY APPRAISALS USING SIMULATED TREATMENT COMPARISONS Besford, M.
22 S3 p. S725
 artikel
1513 PMU3 RISK FACTORS FOR ADVERSE DRUG REACTIONS IN PATIENTS UNDERGOING GENERAL SURGERY: A PROSPECTIVE OBSERVATIONAL STUDY Vinoj, J.
22 S3 p. S708
 artikel
1514 PMU16 SOCIETAL DISEASE SEVERITY PREFERENCES WHEN VALUING AND PRIORITIZING HEALTHCARE INTERVENTIONS. Molnar, D.
22 S3 p. S710-S711
 artikel
1515 PMU114 SPECIALISED HEALTH TECHNOLOGY ASSESSMENT PROCESSES FOR VERY RARE DISEASES: PAST, PRESENT AND FUTURE Akehurst, R.L.
22 S3 p. S728
 artikel
1516 PMU152 SWITCHING AMONG BIOLOGIC THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY Santos, P.M.
22 S3 p. S736
 artikel
1517 PMU145 SYSTEMATIC REVIEW OF PAEDIATRIC ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: DONOR AVAILABILITY, QUALITY OF LIFE AND ECONOMIC IMPLICATIONS Irwin, J.
22 S3 p. S734
 artikel
1518 PMU6 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF 5% LIDOCAINE-MEDICATED PLASTER VS. PREGABALIN Ryder, S.
22 S3 p. S708
 artikel
1519 PMU41 THE ASSOCIATION BETWEEN MULTIMORBIDITY AND PERCEIVED WORKING CONDITIONS IN EUROPE Laires, P.
22 S3 p. S715
 artikel
1520 PMU92 THE DANISH MEDICINE COUNCIL'S PROCESS OF ASSESSING NEW HOSPITAL MEDICINES: AN ANALYSIS OF DECISIONS 2017-2019 Nousios, P.
22 S3 p. S724
 artikel
1521 PMU53 THE INCENTIVE FINANCIAL FRAMEWORK REGARDING FRENCH HOSPITAL PRESCRIPTION OF BIOSIMILAR MEDICINES WHEN DELIVERED IN RETAIL PHARMACY: IMPACT ANALYSIS OF ARTICLE 51 EXPERIMENTATION FOR 2018 Bajard, P.
22 S3 p. S717
 artikel
1522 PMU68 THE ROLE OF OUTCOMES-BASED MODELS FOR THE REIMBURSEMENT OF MEDICINES IN THE UK NATIONAL HEALTH SERVICE Armendariz, Y.
22 S3 p. S720
 artikel
1523 PMU66 TIMEFRAME FOR DRUG MARKETING AUTHORIZATION IN EUROPE Costa-Samarra, J.
22 S3 p. S719
 artikel
1524 PMU133 TRANSLATION AND CULTURAL ADAPTATION OF 15D QUALITY OF LIFE QUESTIONNAIRE FROM ENGLISH TO ROMANIAN LANGUAGE Subtirelu, M.S.
22 S3 p. S731
 artikel
1525 PMU79 TWO YEARS OF A HOSPITAL-WIDE FULLY INTEGRATED BIOSIMILARS UTILIZATION MANAGEMENT SYSTEM: AN EFFICIENCY ANALYSIS Feio, J.
22 S3 p. S721-S722
 artikel
1526 PMU50 UNFOLD THE MYSTERY OF PRICE NEGOTIATION IN CHINA: HOW REIMBURSEMENT PAYMENT STANDARD WAS FORMULATED Song, N.
22 S3 p. S717
 artikel
1527 PMU64 UNLOCKING ACCESS FOR TRANSFORMATIONAL CAR-T CELL AND GENE THERAPIES. ARE BIOSIMILARS THE KEY? Ivanova, H.
22 S3 p. S719
 artikel
1528 PMU122 UPDATING DISABILITY WEIGHTS FOR MEASUREMENT OF HEALTHY LIFE EXPECTANCY AND DISABILITY-ADJUSTED LIFE YEAR IN KOREA Ock, M.
22 S3 p. S729-S730
 artikel
1529 PMU118 USE OF COMPUTER-ASSISTED METHODS TO REALIZE THE CONCEPT OF A LIVING SYSTEMATIC REVIEW VIA AN ONLINE PLATFORM Hearnden, J.
22 S3 p. S729
 artikel
1530 PMU111 USE OF EXTERNAL COMPARATORS IN HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS Patel, D.
22 S3 p. S727
 artikel
1531 PMU25 USING MULTIPLE CRITERIA DECISION ANALYSIS (MCDA) TO CREATE A PRIORITY LIST OF CHRONIC NON-COMMUNICABLE DISEASES (NCDS) TO GUIDE HEALTH RESEARCH SPENDING Babashahi, S.
22 S3 p. S712
 artikel
1532 PMU98 UTILITY OF EARLY ACCESS TO MEDICINES SCHEME DATA FOR NICE DECISION-MAKING Brett, A.
22 S3 p. S725
 artikel
1533 PMU146 VALIDATION AND REPRESENTATIVENESS OF THE SPANISH BIG-PAC DATABASE: INTEGRATED COMPUTERIZED MEDICAL RECORDS FOR RESEARCH INTO EPIDEMIOLOGY, MEDICINES AND HEALTH RESOURCE USE (REAL WORD EVIDENCE) Sicras-Mainar, A.
22 S3 p. S734
 artikel
1534 PMU131 VALIDITY OF THE POLISH VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE POLISH GENERAL POPULATION Golicki, D.
22 S3 p. S731
 artikel
1535 PMU139 VALIDITY OF THE SLOVENIAN VERSION OF THE CARERQOL-7D QUESTIONNAIRE AMONG INFORMAL CAREGIVERS IN THE SLOVENIAN GENERAL POPULATION Prevolnik Rupel, V.
22 S3 p. S733
 artikel
1536 PMU82 VARYING WILLINGNESS-TO-PAY BASED ON DISEASE BURDEN: IMPACT ON HEALTH TECHNOLOGY ASSESSMENT OUTCOMES OF SPECIALIST DRUGS IN THE NETHERLANDS Schurer, M.
22 S3 p. S722
 artikel
1537 PMU119 WHAT ARE THE KEY CHALLENGES ENCOUNTERED IN THE DESIGN, CONDUCT AND ASSESSMENT OF PRAGMATIC TRIALS AND HOW ARE THEY ADDRESSED? Steenhuis, C.
22 S3 p. S729
 artikel
1538 PMU4 WHAT IS A GOOD OR BAD NUMBER NEED TO TREAT (NNT) VALUE? A LITERATURE REVIEW Azimpour, K.
22 S3 p. S708
 artikel
1539 PMU88 WHAT IS THE ROLE OF THE COMPANY EVIDENCE SUBMISSION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) MULTIPLE TECHNOLOGY APPRAISALS? Pearson, I.
22 S3 p. S723
 artikel
1540 PND83 ACCESS TO INTRAVENOUS TISSUE-LIKE PLASMINOGEN ACTIVATOR (IV TPA) THERAPY AND MECHANICAL THROMBECTOMY (MT) FOR PATIENTS WITH ACUTE ISCHEMIC STROKE IN HUNGARY Zemplényi, A.
22 S3 p. S752
 artikel
1541 PND39 A COST-EFFECTIVENESS ANALYSIS OF PREGABALIN VS. DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN CHINA Xie, X.
22 S3 p. S744
 artikel
1542 PND82 A DELPHI PANEL ON TREATMENT OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE NETHERLANDS Peters, M.L.
22 S3 p. S752
 artikel
1543 PND58 AN ECONOMIC EVALUATION ATTACHED TO A SINGLE-CENTRE, PARALLEL GROUP, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF AN THREE DAY INTENSIVE SOCIAL COGNITIVE TREATMENT (CAN DO TREATMENT) IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS AND LOW DISABILITY van Mastrigt, G.A.
22 S3 p. S747
 artikel
1544 PND126 ANTI-DEMENTIA DRUGS: CHANGING PRESCRIBING PATTERNS WITH THE INTRODUCTION OF GENERIC DRUGS Truter, I.
22 S3 p. S761
 artikel
1545 PND121 ANTIPSYCHOTICS UTILIZATION AND DIRECT MEDICAL COSTS ASSOCIATED WITH SCHIZOPHRENIA IN CHINESE PATIENTS Fan, C.S.
22 S3 p. S760
 artikel
1546 PND10 ANTI-TNF-α INHIBITORS IN PREVENTING ALZHEIMER'S DISEASE (AD): A RETROSPECTIVE REVIEW USING BOTH EMR AND CLAIMS DATA Stacey, J.
22 S3 p. S738-S739
 artikel
1547 PND101 AN UPDATE OF A SYSTEMATIC REVIEW: ATTRIBUTE BASED STATED PREFERENCE STUDIES IN MULTIPLE SCLEROSIS PATIENTS Adlard, N.E.
22 S3 p. S756
 artikel
1548 PND91 APPLICATION OF BIG DATA IN RARE DISEASE MANAGEMENT: TREATMENT COST OF THERAPEUTIC PLASMA EXCHANGE VERSUS IMMUNOGLOBULINS IN AN INPATIENT SETTING Dierick, K.
22 S3 p. S754
 artikel
1549 PND90 APPLICATION OF BIG DATA IN RARE DISEASE MANAGEMENT: TREATMENT COST OF THERAPEUTIC PLASMA EXCHANGE VERSUS IMMUNOGLOBULINS IN AN OUTPATIENT SETTING Dierick, K.
22 S3 p. S754
 artikel
1550 PND124 A REAL-WORLD DATA STUDY TO ANALYSE THE PHARMACOLOGICAL TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN SPAIN Ramos-Quiroga, J.A.
22 S3 p. S760
 artikel
1551 PND16 A SEMI-STANDARDIZED SYMPTOM MENU TO FACILITATE GOAL ATTAINMENT SCALING IN DEMENTIA DRUG TRIALS: COMPARISON WITH TRADITIONAL APPROACHES Stanley, J.
22 S3 p. S739
 artikel
1552 PND66 ASSESSING THE POTENTIALLY INAPPROPRIATE USE OF ACETYLCHOLINESTERASE INHIBITORS IN ELDERLY PATIENTS WITH PARKINSON DISEASE USING KOREA NATIONAL HEALTH INSURANCE CLAIMS DATA Baik, D.
22 S3 p. S749
 artikel
1553 PND68 ASSOCIATION BETWEEN HEPATITIS C VIRUS INFECTION AND PARKINSON'S DISEASE IN PATIENTS FOLLOWED BY GENERAL PRACTITIONERS IN GERMANY Zingel, R.
22 S3 p. S749
 artikel
1554 PND63 ASSOCIATION BETWEEN TYPE OF SURGERY AND DEVELOPMENT OF PARKINSON'S DISEASE: A NESTED CASE-CONTROL STUDY USING A US INSURANCE CLAIMS DATABASE Igarashi, A.
22 S3 p. S748
 artikel
1555 PND8 A SYSTEMATIC LITERATURE REVIEW OF EFFICACY AND SAFETY OF DISEASE MODIFYING THERAPIES (DMTS) IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS Thakur, D.
22 S3 p. S738
 artikel
1556 PND129 BAD WEATHER CAUSES MIGRAINE? ASSOCIATION BETWEEN METEOROLOGICAL VARIABLES, HEADACHES AND MIGRAINE USING GERMAN CLAIMS DATA Ghiani, M.
22 S3 p. S761
 artikel
1557 PND56 BUDGET IMPACT ANALYSIS OF INCLUSION IN THE PUBLIC FINANCING OCRELIZUMAB THERAPY FOR PRIMARY-PROGREDIENT AND HIGHLY ACTIVE REMITTING FORMS OF MULTIPLE SCELEROSIS IN THE RUSSIAN FEDERATION Holownia-Voloskova, M.
22 S3 p. S747
 artikel
1558 PND59 BUDGET IMPACT ANALYSIS OF THE NATIONAL CLINICAL GUIDELINE FOR APPROPRIATE PRESCRIBING OF PSYCHOTROPIC MEDICATION IN PEOPLE WITH DEMENTIA Kelly, R.
22 S3 p. S747
 artikel
1559 PND27 BUDGET IMPACT MODEL (BIM) FOR THE EQUISTASI® DEVICE D'ambrosio, F.
22 S3 p. S741
 artikel
1560 PND43 BUDGET IMPACT OF THE INTRODUCTION OF ALEMTUZUMAB IN NORWAY; A REAL WORLD EVIDENCE ANALYSIS USING DATA FROM THE NORWEGIAN PATIENT REGISTRY, THE NORWEGIAN PRESCRIPTION DATABASE, AND IMS SALES DATA Ristun, C.
22 S3 p. S744
 artikel
1561 PND102 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES Lipton, R.B.
22 S3 p. S756
 artikel
1562 PND103 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON WORK PRODUCTIVITY IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES Lipton, R.B.
22 S3 p. S756
 artikel
1563 PND48 BURDEN OF MULTIPLE SCLEROSIS IN GERMANY — A MATCHED COHORT STUDY USING A LARGE CLAIMS DATABASE König, C.
22 S3 p. S745
 artikel
1564 PND4 CHARACTERISTICS OF MIGRAINE PATIENTS IN PORTUGUESE HEADACHE SPECIALIST CENTERS Silva, C.
22 S3 p. S737
 artikel
1565 PND47 CLADRIBINE TABLET, AS A DOMINANT COMPARATOR TO NATALIZUMAB IN HIGH-DISEASE ACTIVITY RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN THE CONTEXT OF A DEVELOPING COUNTRY Ayati, N.
22 S3 p. S745
 artikel
1566 PND132 CLAIMS DATABASE ANALYSIS OF HEADACHE AND MIGRAINE IN SPAIN 2011-2016: PATIENT PROFILE, HEALTHCARE MANAGEMENT AND DIRECT MEDICAL COSTS Darba, J.
22 S3 p. S762
 artikel
1567 PND35 CLINICAL AND ECONOMIC BURDEN OF MIGRAINE IN SPAIN, FRANCE, AND THE UNITED KINGDOM: RESULTS OF A POOLED ANALYSIS Benhaddi, H.
22 S3 p. S743
 artikel
1568 PND14 CLINICALLY RELEVANT REDUCTION OF MIGRAINE SYMPTOMS BY FREMANEZUMAB IN PATIENTS WHO FAILED TO VALPROIC ACID TREATMENT Caesar, M.
22 S3 p. S739
 artikel
1569 PND6 CLINICALLY RELEVANT REDUCTION OF MIGRAINE SYMPTOMS BY FREMANEZUMAB IN PATIENTS WITH UP TO ONE PREVENTIVE MIGRAINE PROPHYLAXIS TREATMENT IN THE PAST Caesar, M.
22 S3 p. S738
 artikel
1570 PND96 COMPARISON OF PROPENSITY SCORE METHODS A CASE STUDY OF DIRECT ORAL ANTICOAGULANTS Ciminata, G.
22 S3 p. S755
 artikel
1571 PND32 COST-EFECTIVENESS AND BUDGET IMPACT OF VAGUS NERVE STIMULATION WITH ASPIRE SR MODEL 106 COMPARED TO ANTI-EPILEPTIC DRUGS IN A SUBGROUP OF PATIENTS WITH DRUG RESISTANT EPILEPSY IN PUBLIC SETTING IN TURKEY Chirita-Parker, O.
22 S3 p. S742
 artikel
1572 PND24 COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY Mantovani, L.G.
22 S3 p. S740-S741
 artikel
1573 PND31 COST-EFFECTIVENESS ANALYSIS OF 5% LIDOCAINE PLASTER COMPARED TO PREGABALIN IN PATIENTS WITH POSTHERPETIC NEURALGIA IN CHINA Zhu, H.
22 S3 p. S742
 artikel
1574 PND54 COST-OF-ILLNESS TRAJECTORIES AMONG NEWLY DIAGNOSED MS PATIENTS TREATED WITH INTERFERONS, GLATIRAMER ACETATE, OR NATALIZUMAB: HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COSTS IN SWEDEN Karampampa, K.
22 S3 p. S746
 artikel
1575 PND69 COSTS OF MULTIPLE SCLEROSIS IN DENMARK: INFORMAL CAREGIVER'S PERSPECTIVE Komkova, A.
22 S3 p. S749
 artikel
1576 PND86 COST-UTILITY ANALYSIS OF DELTA-9-TETRAHIDROCANNABINOL AND CANNABIDIOL OROMUCOSAL SPRAY Oppe, M.
22 S3 p. S753
 artikel
1577 PND111 DESIGN OF THE INDIVIDUALISED MEMORY DEPENDENT QUALITY OF LIFE (MEMORYDQOL) AND THE MEMORY TREATMENT SATISFACTION QUESTIONNAIRE (MEMORYTSQ) FOR PEOPLE WITH DEMENTIA USING EXISTING DQOL AND TSQ TEMPLATES AND ITEM LIBRARIES Gibbons, A.
22 S3 p. S758
 artikel
1578 PND113 DESIGN OF THE INDIVIDUALISED PARKINSON'S DEPENDENT QUALITY OF LIFE (PARKINSON'SDQOL) AND THE PARKINSONS TREATMENT SATISFACTION QUESTIONNAIRE (PARKINSON'STSQ) USING TEMPLATES AND ITEM LIBRARIES FROM EXISTING DQOL AND TSQ MEASURES FOR OTHER CONDITIONS Gibbons, A.
22 S3 p. S758-S759
 artikel
1579 PND104 DIAGNOSIS AND TREATMENT PATTERNS ON BRAZILIAN PATIENTS: RESULTS FROM THE MY MIGRAINE VOICE SURVEY Huerta, C.
22 S3 p. S757
 artikel
1580 PND61 DIRECT AND INDIRECT COSTS OF MIGRAINE IN HEADACHE SPECIALIST CENTERS IN PORTUGAL Silva, C.
22 S3 p. S748
 artikel
1581 PND50 ECONOMIC BURDEN OF ALZHEIMER'S DISEASE DEMENTIA IN JAPAN Ikeda, S.
22 S3 p. S745
 artikel
1582 PND26 ECONOMIC BURDEN OF HUNTINGTON'S DISEASE IN EUROPE Kaur, G.
22 S3 p. S741
 artikel
1583 PND34 ECONOMIC BURDEN OF PARKINSON'S DISEASE (PD) IN U.S.: A TARGETED LITERATURE REVIEW Ashri, S.
22 S3 p. S742-S743
 artikel
1584 PND53 ECONOMIC EVALUATION OF CLADRIBINE TABLETS IN RELAPSING MULTIPLE SCLEROSIS (RMS) PATIENTS WITH HIGH DISEASE ACTIVITY (HDA) IN LEBANON Metni, M.
22 S3 p. S746
 artikel
1585 PND55 ECONOMIC EVALUATION OF ENDOSCOPIC THIRD VENTRICULOSTOMY COMPARED TO SHUNTING IN PEDIATRIC PATIENTS WITH HYDROCEPHALUS IN UZBEKISTAN Djalalov, S.
22 S3 p. S746
 artikel
1586 PND85 EFFICACY AND SAFETY OF ABOBOTULINUMTOXINA IN ADULTS WITH UPPER LIMB SPASTICITY AFTER STROKE: A SYSTEMATIC REVIEW Klabukova, D.
22 S3 p. S753
 artikel
1587 PND7 EFFICACY OF VIRTUAL REALITY GLASSES AMONG PATIENTS WITH STROKE Okner, L.
22 S3 p. S738
 artikel
1588 PND71 EPIDEMIOLOGY OF ATTENTION DEFICIT HYPERACTIVITY DISORDERS IN SPAIN BASED ON REAL-WORLD DATA Ramos-Quiroga, J.A.
22 S3 p. S750
 artikel
1589 PND64 EPIDEMIOLOGY OF CHRONIC MIGRAINE: A REAL-WORLD STUDY IN PRIMARY CARE IN ITALY Nica, M.
22 S3 p. S748
 artikel
1590 PND72 EVOLUTION OF THE CONSUMPTION OF ANTIEPILETEC DRUGS IN MOROCCO FROM 2004 TO 2016 Niyonkuru, E.
22 S3 p. S750
 artikel
1591 PND97 FACTORS INFLUENCING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS USING EXPAND TRIAL DATA Vadapalle, S.
22 S3 p. S755
 artikel
1592 PND73 FACTORS INFLUENCING INTENTION TO ENGAGE IN PREVENTIVE BEHAVIORS FOR ALZHEIMER'S DISEASE: A PROTECTION MOTIVATION THEORY APPROACH Sansgiry, S.S.
22 S3 p. S750
 artikel
1593 PND65 FILLING THE GAP IN MS; UNIQUE IDENTIFICATION OF PREVALANCE & TREATMENT OF SPMS PATIENTS IN THE NETHERLANDS Koenders, J.
22 S3 p. S749
 artikel
1594 PND22 GENDER DIFFERENCES AND SOCIO-ECONOMIC IMPACT OF MIGRAINE IN ITALY Rognoni, C.
22 S3 p. S740
 artikel
1595 PND23 HEALTHCARE EXPENDITURES ASSOCIATED WITH ADHERENCE TO ANTIDEPRESSANT MEDICATION MANAGEMENT MEASURES DURING ACUTE AND CONTINUATION PHASES OF DEPRESSION TREATMENT AMONG OLDER ADULTS WITH DEMENTIA AND MAJOR DEPRESSIVE DISORDER Bhattacharjee, S.
22 S3 p. S740
 artikel
1596 PND60 HEALTH CARE RESOURCE UTILIZATION AND DIRECT MEDICAL COSTS AMONG PATIENTS WITH INCIDENT MIGRAINE INITIATING TREATMENT - A COHORT STUDY USING THE CLINICAL PRACTICE RESEARCH DATALINK Yelland, E.
22 S3 p. S747-S748
 artikel
1597 PND105 HEALTHCARE RESOURCE UTILIZATION OF MIGRAINE IN BRAZIL: RESULTS FROM THE MY MIGRAINE VOICE SURVEY Huerta, C.
22 S3 p. S757
 artikel
1598 PND122 HEALTHCARE RESOURCE UTILIZATIONS AND COSTS AMONG PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS - A COMPARISON OF PATIENTS WITH AND WITHOUT UPPER LIMB FUNCTION IMPAIRMENT Hardtstock, F.
22 S3 p. S760
 artikel
1599 PND80 HEALTHCARE UTILISATION AND PERCEIVED HEALTH NEEDS OF MULTIPLE SCLEROSIS PATIENTS IN GREECE: EVIDENCE FROM A QUALITATIVE STUDY Karampli, E.
22 S3 p. S752
 artikel
1600 PND20 HEALTH TECHNOLOGY ASSESSMENTS OF DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING- REMITTING MULTIPLE SCLEROSIS CHALLENGES IN NICE TECHNOLOGY APPRAISALS Lamb, A.
22 S3 p. S739-S740
 artikel
1601 PND79 HOW DIFFERENT ARE MIGRAINE PATIENTS TREATED BY GENERAL PRACTITIONERS VERSUS THOSE TREATED BY NEUROLOGISTS? Silva, C.
22 S3 p. S751-S752
 artikel
1602 PND131 HOW WELL ARE MULTIPLE SCLEROSIS PATIENTS INFORMED ABOUT THEIR DISEASE AND THEIR TREATMENT: AN ANALYSIS OF DATA COLLECTED BY A NOVEL MOBILE APPLICATION (MS GEMEINSAM) Wilke, T.
22 S3 p. S761
 artikel
1603 PND134 HTA AND ACCESS FOR ORPHAN DRUGS: IDENTIFICATION OF 4 CRITICAL DIFFERENCES BETWEEN UK AND US PATHWAYS Green, N.
22 S3 p. S762
 artikel
1604 PND67 IDENTIFICATION AND CHARACTERIZATION OF HIGH DISEASE ACTIVITY RELAPSING REMITTING MULTIPLE SCLEROSIS ADULT PATIENTS BASED ON THE SNIIRAM DATABASE Van Hille, B.
22 S3 p. S749
 artikel
1605 PND11 IMPACT OF A COMMUNITY PHARMACY-BASED INFORMATION PROTOCOL ON MULTIPLE SCLEROSIS PATIENTS' ADHERENCE TO THEIR ORAL TREATMENT WITH DIMETHYL FUMARATE: TECPHIE, A RANDOMIZED STUDY VS USUAL PRACTICE (INTERIM RESULTS) Michiels, Y.
22 S3 p. S739
 artikel
1606 PND133 IMPACT OF CLINICAL COMPLICATIONS ON ECONOMIC BURDEN IN NEWLY DIAGNOSED PARKINSON POPULATION USING A US CLAIM DATABASE Bozzi, S.
22 S3 p. S762
 artikel
1607 PND3 IMPACT OF SOCIAL NETWORK INTERVENTIONS ON SCHIZOPHRENIA OUTCOMES Dasari, M.
22 S3 p. S737
 artikel
1608 PND77 IMPACT OF THE INTERHOSPITAL TRANSFER TIME ON THE CLINICAL OUTCOMES OF ACUTE STROKE PATIENTS TREATED WITH MECHANICAL THROMBECTOMY Boltyenkov, A.
22 S3 p. S751
 artikel
1609 PND2 INDIRECT COMPARISON OF THE EFFICACY OF FREMANEZUMAB VERSUS ERENUMAB IN EPISODIC MIGRAINE PATIENTS WHO HAD FAILED 2-4 PRIOR MIGRAINE PREVENTIVE TREATMENTS Patterson-Lomba, O.
22 S3 p. S737
 artikel
1610 PND57 INFORMAL CARE COST IN NEUROLOGIC DISORDERS WITH THE CONTINGENT VALUATION METHOD Dalaudiere, J.
22 S3 p. S747
 artikel
1611 PND81 LANDSCAPE ASSESSMENT AND KEY HTA CONSIDERATIONS IN ALZHEIMER'S DISEASE Takyar, S.
22 S3 p. S752
 artikel
1612 PND106 LIVING WITH MIGRAINE: SUPPORT NEEDED AND HEALTHCARE EXPENDITURE ON BRAZILIAN PATIENTS FROM THE MY MIGRAINE VOICE SURVEY Huerta, C.
22 S3 p. S757
 artikel
1613 PND78 MULTIPLE SCLEROSIS IN PUERTO RICO: AN ANALYSIS OF DEMOGRAPHICS AND TREATMENT MODALITIES BY GEOGRAPHICAL REGION Odom, J.
22 S3 p. S751
 artikel
1614 PND70 NARCOLEPSY TREATMENT IN SWEDEN: REGISTER BASED STUDY Komkova, A.
22 S3 p. S749-S750
 artikel
1615 PND89 NEGATIVE HTA RECOMMENDATIONS FOR MEDICINES IN NEUROLOGY THERAPEUTIC AREAS – FOURFOLD HIGHER ODDS IN POLAND COMPARED WITH THE UNITED KINGDOM Lach, K.
22 S3 p. S753-S754
 artikel
1616 PND107 NEUROLOGIST AND PATIENT PREFERENCES IN MULTIPLE SCLEROSIS: UK AND US QUALITATIVE RESEARCH FINDINGS Tencer, T.
22 S3 p. S757
 artikel
1617 PND45 OCRELIZUMAB IS A COST-EFFECTIVE OPTION FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS, IN IRAN Ayati, N.
22 S3 p. S744-S745
 artikel
1618 PND49 OUT-OF-POCKET EXPENSES IN MIGRAINE IN PORTUGAL Silva, C.
22 S3 p. S745
 artikel
1619 PND5 OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES: GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE Dabbous, M.
22 S3 p. S737-S738
 artikel
1620 PND109 PATIENT PREFERENCE FOR DOSING REGIMEN AND PERCEPTION OF DOSING FLEXIBILITY WITH FREMANEZUMAB FOR CHRONIC OR EPISODIC MIGRAINE: RESULTS FROM A WEB-BASED, PATIENT SURVEY FOLLOWING COMPLETION OF A 1-YEAR EXTENSION STUDY Cowan, R.P.
22 S3 p. S758
 artikel
1621 PND115 PATIENT REALITIES IN MIGRAINE. LITERATURE REVIEW ENHANCED BY SOCIAL MEDIA Freiberg, M.
22 S3 p. S759
 artikel
1622 PND117 PATIENTS' PERSPECTIVES OF LIVING WITH MULTIPLE SCLEROSIS IN GREECE: AN INTERPRETIVE PHENOMENOLOGICAL ANALYSIS Koulierakis, G.
22 S3 p. S759
 artikel
1623 PND118 PATIENTS WITH CHRONIC PAIN DISORDERS: PREFERENCE OF EPRO SCREEN DISPLAY AND FEATURES Ly, J.
22 S3 p. S759-S760
 artikel
1624 PND98 PATTERNS AND PREDICTION FOR COGNITIVE DECLINE IN ALZHEIMER'S PATIENTS AS ASSESSED BY THE MINI-MENTAL STATUS EXAM IN AN AMBULATORY ELECTRONIC MEDICAL RECORD Ransom, J.
22 S3 p. S755
 artikel
1625 PND52 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY Gitlin, M.
22 S3 p. S746
 artikel
1626 PND40 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN Gitlin, M.
22 S3 p. S744
 artikel
1627 PND94 PERFORMANCE OF PREDICTIVE ALGORITHMS VS DATA QUALITY: A COMPARATIVE STUDY IN ALZHEIMER'S DISEASE Pafitis, S.
22 S3 p. S754-S755
 artikel
1628 PND125 PREGABALIN PRESCRIBING IN PRIVATE HEALTHCARE SETTINGS IN SOUTH AFRICA WITH SPECIFIC FOCUS ON DOSAGES Truter, I.
22 S3 p. S760-S761
 artikel
1629 PND74 PREVALENCE OF PROGRESSIVE SUPRANUCLEAR PALSY (PSP) IN EUROPE, JAPAN AND THE USA Scowcroft, A.
22 S3 p. S750
 artikel
1630 PND95 PRODUCTIVITY LOSS COST IN MIGRAINE USING TWO DIFFERENT QUESTIONNAIRES: FINDINGS FROM THE BECOME STUDY FOR PORTUGAL Silva, C.
22 S3 p. S755
 artikel
1631 PND51 PRODUCTIVITY LOSS IN NHS HOSPITALS DUE TO DIFFICULT-TO-TREAT MIGRAINE Laires, P.
22 S3 p. S745-S746
 artikel
1632 PND21 PROJECT HERCULES: A NEW PARADIGM FOR PATIENT-CENTRED COLLABORATION IN HTA Crossley, E.
22 S3 p. S740
 artikel
1633 PND116 QUALITATIVE CONCEPT ELICITATION INTERVIEWS TO UNDERSTAND THE PATIENT EXPERIENCE OF GLUCOCEREBROSIDASE-PARKINSON'S DISEASE (GBA-PD) Bonner, N.
22 S3 p. S759
 artikel
1634 PND99 QUALITY OF LIFE FOR PATIENTS WITH MIGRAINE IN THE UNITED KINGDOM, FRANCE, AND SPAIN: RESULTS OF A POOLED ANALYSIS Benhaddi, H.
22 S3 p. S755-S756
 artikel
1635 PND108 QUALITY OF LIFE OF PATIENTS AFTER ISCHAEMIC STROKE TREATED IN A PROVINCIAL HOSPITAL IN POLAND Jarosławski, S.
22 S3 p. S757-S758
 artikel
1636 PND114 REAL WORLD PATIENT SURVEY ON HOW MIGRAINE AFFECTS EGYPTIAN SOCIAL AND WORK LIFE Kotb, Y.
22 S3 p. S759
 artikel
1637 PND84 RECENT HEALTH TECHNOLOGY ASSESSMENT SCENARIO ACROSS THE EU-5 - A FOCUS ON MULTIPLE SCLEROSIS Ghosh, S.
22 S3 p. S753
 artikel
1638 PND100 REFINEMENT OF THE TREATMENT PREFERENCE QUESTIONNAIRE IN ADULTS WITH PARKINSON'S DISEASE AND OFF-EPISODES Ervin, C.
22 S3 p. S756
 artikel
1639 PND1 RELAPSE-RELATED OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH FIRST-LINE DISEASE-MODIFYING THERAPIES Cohan, S.
22 S3 p. S737
 artikel
1640 PND17 SELECTING APPROPRIATE OUTCOME MEASURES FOR ALS CLINICAL TRIALS Arjunji, R.
22 S3 p. S739
 artikel
1641 PND110 SYMPTOM SEVERITY IN MULTIPLE SCLEROSIS FROM THE PATIENT'S PERSPECTIVE: REVISITING THE PSYCHOMETRIC PROPERTIES OF THE SYMPTOMSCREEN QUESTIONNAIRE (PERCEPTIONS-MS STUDY) Meca-Lallana, J.
22 S3 p. S758
 artikel
1642 PND25 SYSTEMATIC LITERATURE REVIEW OF ECONOMIC BURDEN ASSOCIATED WITH MULTIPLE SCLEROSIS Joshi, P.
22 S3 p. S741
 artikel
1643 PND87 SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUES (HSUVS) IN MULTIPLE SCLEROSIS Badgujar, L.
22 S3 p. S753
 artikel
1644 PND33 THE CLINICAL AND ECONOMIC BURDEN OF OBSTRUCTIVE SLEEP APNEA IN ADULTS: A COST-OF-ILLNESS ANALYSIS Armeni, P.
22 S3 p. S742
 artikel
1645 PND29 THE COST OF ACHIEVING NEDA WHILE USING TWO ALTERNATIVE FORMULATIONS OF INTERFERON BETA-1A FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN PORTUGAL: LET'S LOOK AT EVIDENCE Silverio, N.
22 S3 p. S741-S742
 artikel
1646 PND28 THE ECONOMIC BURDEN OF MULTIPLE SCLEROSIS DEVELOPMENT OVER TIME: AN ANALYSIS FROM THE MULTIPLE SCLEROSIS CENTERS PERSPECTIVE Cozzolino, P.
22 S3 p. S741
 artikel
1647 PND42 THE PRODUCTIVITY IMPACT OF EXCEEDING THE LEGAL TIME FOR PRICING AND REIMBURSEMENT DECISION OF ERENUMAB IN THE TREATMENT OF MIGRAINE IN PORTUGAL Laires, P.
22 S3 p. S744
 artikel
1648 PND30 THE SOCIETAL IMPACT OF ERENUMAB IN PROPHYLACTIC TREATMENT OF PATIENTS WITH MIGRAINE IN GERMANY: A MACROECONOMIC OPEN-COHORT APPROACH Seddik, A.
22 S3 p. S742
 artikel
1649 PND92 TREATMENT PATTERNS AND CHARACTERIZATION OF MIGRAINE PATIENTS FOLLOWED IN HEADACHE SPECIALIZED CENTERS OF PORTUGAL Laires, P.
22 S3 p. S754
 artikel
1650 PND130 TREATMENT PATTERNS, HEALTH RESOURCES CONSUMPTION AND COSTS OF PATIENTS WITH MIGRAINE IN AN ITALIAN REAL-WORLD SETTING Perrone, V.
22 S3 p. S761
 artikel
1651 PND119 TRIPTAN PRESCRIBING IN A SOUTH AFRICAN PATIENT POPULATION: HOW GENERIC SUBSTITUTION IMPACTS ON THE AFFORDABILITY OF ANTIMIGRAINE PREPARATIONS Truter, I.
22 S3 p. S760
 artikel
1652 PND9 UPDATED META-ANALYSIS OF THE EFFICACY OF ADJUVANT TREATMENT TO LEVODOPA IN PARKINSON'S DISEASE Batson, S.
22 S3 p. S738
 artikel
1653 PND76 USING ICD-10 TO DETERMINE THE ROLE OF METABOLIC SYNDROMES IN THE RISK OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS IN THE ELDERLY POPULATION Li, M.
22 S3 p. S751
 artikel
1654 PND75 VALIDATION OF AN ALGORITHM IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS USING THE FRENCH NATIONWIDE CLAIMS DATABASE Bosco-Levy, P.
22 S3 p. S750-S751
 artikel
1655 PND62 WEATHER CONDITIONS AS PREDICTORS OF SEVERE MIGRAINES: A CASE-CROSSOVER STUDY USING LINKED WEATHER AND CLAIMS DATA Thiel, E.
22 S3 p. S748
 artikel
1656 PND93 WHAT GOOD ARE DIGITAL TECHNOLOGIES IN ALZHEIMER'S DISEASE RESEARCH? - A SYSTEMATIC LITERATURE REVIEW Vinals, L.
22 S3 p. S754
 artikel
1657 PND38 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO ERENUMAB AS PREVENTIVE TREATMENT IN EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS Smolen, L.
22 S3 p. S743
 artikel
1658 PND36 10-YEAR COST-EFFECTIVENESS ANALYSES OF FREMANEZUMAB COMPARED TO NO TREATMENT AS A PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS Smolen, L.
22 S3 p. S743
 artikel
1659 PND37 10-YEAR COST-EFFECTIVENESS ANALYSES OF RESPONSE-BASED USE OF FREMANEZUMAB AS PREVENTIVE TREATMENT IN CHRONIC AND EPISODIC MIGRAINE FOR PATIENTS WITH INADEQUATE RESPONSE TO PRIOR PREVENTIVE TREATMENTS Smolen, L.
22 S3 p. S743
 artikel
1660 PNS76 A BAYESIAN PARAMETRIC APPROACH TO HANDLE MISSING LONGITUDINAL OUTCOME DATA IN TRIAL-BASED HEALTH ECONOMIC EVALUATIONS Gabrio, A.
22 S3 p. S775
 artikel
1661 PNS258 ABBREVIATED HTA PATHWAYS, EXPEDITING PATIENT ACCESS TO NOVEL TREATMENTS? Campbell, J.
22 S3 p. S805-S806
 artikel
1662 PNS91 ACCESS AND UTILIZATION OF MATERNAL HEALTHCARE IN A RURAL DISTRICT IN THE FOREST BELT OF GHANA Agyei Baffour, P.
22 S3 p. S777
 artikel
1663 PNS155 ACCESS OF BULGARIAN PATIENTS TO BIOSIMILAR MEDICINES Tamer, J.
22 S3 p. S787
 artikel
1664 PNS382 ACCURACY OF PRO DATA SIGNIFICANTLY IMPROVES WITH SUBJECT TRAINING IN MIGRAINE CLINICAL TRIALS Conrad, E.
22 S3 p. S829
 artikel
1665 PNS36 A CONCEPTUAL PAPER ON THE USE OF PATIENT SUPPORT PROGRAMS IN PROVIDING BETTER ACCESS TO MEDICAL CARE IN EGYPT Anan, I.
22 S3 p. S768-S769
 artikel
1666 PNS45 ADDING NOISE TO MARKOV COHORT MODELS Iskandar, R.
22 S3 p. S770
 artikel
1667 PNS28 ADVANCING VALUE ASSESSMENTS: HOW CAN A PARADIGM OF VALUE MEASUREMENT BEYOND QALY BE ENHANCED TO HOLISTICALLY CAPTURE WHAT TRULY MATTERS TO PATIENTS AND PAYERS? Willems, D.
22 S3 p. S767
 artikel
1668 PNS268 AGGREGATING MULTIPLE ENDPOINTS/PERFORMANCE INDICATORS TO CALCULATE A UNIDIMENSIONAL MEASUREMENT OF VALUE IN A COMPOSITE INDEX Mühlbacher, A.
22 S3 p. S807-S808
 artikel
1669 PNS212 AIFA'S NEW INNOVATIVENESS DESIGNATION: DRIVERS FOR AWARD AND COMPARISON TO FRENCH HTA ASSESSMENTS Murphy, E.
22 S3 p. S796-S797
 artikel
1670 PNS206 AIM FOR THE STARS, REACH THE MOON? A SIMPLE STRATEGY TO IMPROVE ADDITIONAL BENEFIT OUCTOMES IN GERMANY? Macaulay, R.
22 S3 p. S795
 artikel
1671 PNS113 ALLOCATING VACCINATIONS COSTS IN GREECE: POLICY IMPLICATIONS Stefanidou, Z.
22 S3 p. S780
 artikel
1672 PNS272 AMNOG BENEFIT ASSESSMENT IN GERMANY AND ITS IMPACT ON PRICE NEGOTIATIONS Claes, A.K.
22 S3 p. S808
 artikel
1673 PNS416 A MODEL-BASED STANDARDISATION APPROACH TO INCREASE GENERALISABILITY OF CLAIMS DATA ANALYSES: THE EXAMPLE OF GERMAN CLAIMS DATA Ghiani, M.
22 S3 p. S836
 artikel
1674 PNS83 A MONTE CARLO VALIDATION OF A META-MODELLING APPROACH FOR SYNTHETIZING CASE-CONTROL STUDIES Zur, R.M.
22 S3 p. S776
 artikel
1675 PNS341 ANALYSIS OF EDUCATION AND TRAINING OPPORTUNITIES IN HE/PE/HTA IN CEE CONSORTIUM COUNTRIES Zaliska, O.
22 S3 p. S822
 artikel
1676 PNS409 ANALYSIS OF EPIDEMIOLOGY AND PHARMACOUTILIZATION ON PATIENTS AFFECTED BY OPHTHALMIC DISEASES WITH INDICATIONS FOR INTRAVITREAL TREATMENTS IN A NORTHERN ITALIAN REGION Degli Esposti, L.
22 S3 p. S835
 artikel
1677 PNS58 ANALYSIS OF FINANCIAL STATUS AND DETERMINANTS WITH ALTMAN'S Z-SCORE MODEL: A PANEL DATA INVESTIGATION FROM TRADITIONAL CHINESE MEDICINE LISTED COMPANIES IN CHINA Yang, F.
22 S3 p. S772
 artikel
1678 PNS350 ANALYSIS OF HEALTH CARE WORKERS' MIGRATION: THE MOTIVATIONS OF HUNGARIAN PHISIOTHERAPISTS FOR WORKING ABROAD Vizsy, M.
22 S3 p. S823
 artikel
1679 PNS200 ANALYSIS OF HOSPITAL USE OF SURGERY WARDS TO OPTIMIZE HOSPITAL INFRASTRUCTURE PLANNING Vajasdi, H.
22 S3 p. S794
 artikel
1680 PNS221 ANALYSIS OF HTA DOSSIERS SUBMISSION AND RECOMMENDATION REPORTS FOR DRUG PROCUREMENT AND REIMBURSMENT IN UKRAINE Oleshchuk, O.
22 S3 p. S798
 artikel
1681 PNS130 ANALYSIS OF LENGTH OF STAY AND COST OF INPATIENT MEDICAL CARE IN RUSSIAN DRG MODEL IN 2018 Zuev, A.V.
22 S3 p. S783-S784
 artikel
1682 PNS188 ANALYSIS OF MARKET ACCESS AGREEMENTS IN TURKEY Kockaya, G.
22 S3 p. S793
 artikel
1683 PNS282 ANALYSIS OF METHODOLOGICAL LIMITATIONS RAISED BY THE FRENCH HEALTH TECHNOLOGY ASSESSMENT ON PUBLISHED EFFICIENCY OPINIONS FROM FEBRUARY 2014 TO MAY 2019 Boussahoua, M.
22 S3 p. S810-S811
 artikel
1684 PNS320 ANALYSIS OF MINIMAL IMPORTANT CHANGE THROUGH ITEM RESPONSE THEORY METHODS Bjorner, J.
22 S3 p. S818
 artikel
1685 PNS291 ANALYSIS OF RECALLS OF MEDICAL DEVICES FROM 2009 TO 2018 BY RISK CLASS AND DEVICE CATEGORY BASED ON ITALIAN DATA Ciani, O.
22 S3 p. S812
 artikel
1686 PNS288 ANALYSIS OF RECENT TRENDS IN E-HEALTH SOLUTIONS DEVELOPED BY PHARMACEUTICAL AND BIOTECH COMPANIES Barchańska, M.
22 S3 p. S812
 artikel
1687 PNS280 AN ASSESSMENT OF THE LIKELIHOOD OF RECEIVING A POSITIVE RECOMMENDATION THROUGH NICE'S STA PROCESS WITHOUT A PATIENT ACCESS SCHEME OF COMMERCIAL ACCESS AGREEMENT Greenhill, W.
22 S3 p. S810
 artikel
1688 PNS264 AN ASSESSMENT OF THE RECOMMENDATIONS MADE BY NICE'S MEDICAL TECHNOLOGIES EVALUATION PROGRAMME, AND WHETHER THE RECOMMENDATIONS SUPPORT MTEP'S STATED AIMS. Forsyth, C.
22 S3 p. S807
 artikel
1689 PNS47 AN ECONOMIC EVALUATION OF THE HOSPITAL RESOURCING IMPLICATIONS FOR THE TREATMENT OF ADVERSE EVENTS Hughes, R.
22 S3 p. S770
 artikel
1690 PNS324 A NOVEL APPROACH OF USING GRAPHICAL REPRESENTATION OF EQ-5D-3L DIMENSIONS, LEVELS, AND HEALTH STATES FOR ILLITERATE RESPONDENTS IN VALUATION STUDIES - AN EXAMPLE FROM MOROCCO Al Sayah, F.
22 S3 p. S819
 artikel
1691 PNS41 A PRAGMATIC METHOD FOR COSTING IMPLEMENTATION STRATEGIES USING THE TIME-DRIVEN ACITVITY-BASED COSTING Cidav, Z.
22 S3 p. S769
 artikel
1692 PNS98 A QUALITATIVE EXPLORATION OF KNOWLEDGE, ATTITUDE AND PRACTICES OF PHYSICIANS ABOUT PHARMACOVIGIILANCE ACTIVITIES IN TERTIARY CARE HOSPITALS OF LAHORE, PAKISTAN Hussain, R.
22 S3 p. S778-S779
 artikel
1693 PNS135 ARE THE SALES FORECAST FOR MEDICAL DEVICES ACCURATE? A RETROSPECTIVE ANALYSIS IN FRANCE (2018-2019) De Joannis, P.E.
22 S3 p. S784
 artikel
1694 PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS Balijepalli, C.
22 S3 p. S810
 artikel
1695 PNS4 A REVIEW OF PERFOS IN FDA AND EMA LABELLING CLAIMS (2009-2019) Zupan, Z.
22 S3 p. S763
 artikel
1696 PNS372 A SIMULATION STUDY COMPARING THE PERFORMANCE OF DISCRETE CHOICE EXPERIMENT AND SWING WEIGHTING FOR ELICITATION OF PREFERENCES Zur, R.M.
22 S3 p. S827
 artikel
1697 PNS192 ASSESSING FACTORS ASSOCIATED WITH CATASTROPHIC HEALTH CARE PAYMENTS IN A WEST AFRICAN COUNTRY, CÔTE D'IVOIRE Attia-Konan, A.R.
22 S3 p. S793
 artikel
1698 PNS17 ASSESSING TECHNOLOGIES THAT ARE EFFECTIVE BUT NOT COST-EFFECTIVE AT ZERO PRICE: AN ALTERNATIVE FRAMEWORK Gouveia, M.
22 S3 p. S765
 artikel
1699 PNS279 ASSESSING THE LIKELIHOOD OF RECEIVING A POSITIVE RECOMMENDATION THROUGH NICE'S STA PROCESS IN LINE WITH THE INDICATED PATIENT POPULATION Greenhill, W.
22 S3 p. S810
 artikel
1700 PNS270 ASSESSING THE PUBLIC HEALTH BENEFIT OF A MEDICINE: AN ANALYSIS OF THE CRITERIA APPRAISED BY THE FRENCH HTA BODY SINCE THE PUBLICATION OF ITS UPDATED MISSION STATEMENT OF SEPTEMBER 2018 Vetillard, C.
22 S3 p. S808
 artikel
1701 PNS235 ASSESSMENT OF DIGITAL HEALTH TECHNOLOGIES - COMPARISON OF EVIDENCE FRAMEWORKS OF NICE AND HAS Kloc, K.
22 S3 p. S801
 artikel
1702 PNS411 ASSESSMENT OF THE ACTIVITY OF PHARMACISTS IN ENSURING THE SAFE USE OF MEDICINES IN UKRAINE Mishchenko, O.
22 S3 p. S835
 artikel
1703 PNS52 ASSESSMENT OF THE IMPACT OF THE LEVEL OF ASMR ON THE DRUG'S PRICE AND ITS NEGOTIATION TIME WITH THE HEALTH AUTHORITIES IN TREATMENTS THAT BENEFITED FROM THE FRENCH EARLY ACCESS PROGRAM Gaillard, L.
22 S3 p. S771
 artikel
1704 PNS101 ASSOCIATION BETWEEN RISK FACTORS AND SAFE DRUG DISPOSAL IN COMMUNITY: A CROSS SECTIONAL STUDY Challa, R.
22 S3 p. S779
 artikel
1705 PNS100 A STUDY OF KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING ADMINISTRATION OF PAEDIATRIC DOSAGE FORMS Chacko, S.
22 S3 p. S779
 artikel
1706 PNS117 A STUDY ON THE FACTORS AFFECTING CHINESE CITIZENS' WILLINGNESS TO PURCHASE TAX-DEDUCTIBLE PRIVATE HEALTH INSURANCE Wo, T.
22 S3 p. S781
 artikel
1707 PNS313 A SYSTEMATIC REVIEW OF PATIENT EXPERIENCE DATA CAPTURED IN CLINICAL TRIALS Kongsø, J.H.
22 S3 p. S816-S817
 artikel
1708 PNS32 AUTOMATIC ABSTRACT SCREENING USING MACHINE LEARNING TECHNIQUES: ARE WE THERE YET AND HOW CAN WE MOVE FORWARD? Rivolo, S.
22 S3 p. S768
 artikel
1709 PNS242 BALANCING GLOBAL HTA REQUIREMENTS FOR LITERATURE REVIEWS ACROSS EUROPE, NORTH AMERICA, AND ASIA Ostawal, A.
22 S3 p. S802
 artikel
1710 PNS377 BARRIERS AND ENABLERS TO PATIENT ENGAGEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS: AN IRISH PERSPECTIVE Hayes, K.
22 S3 p. S828-S829
 artikel
1711 PNS177 BARRIERS TO PUBLIC PRIVATE PARTNERSHIPS IMPLEMENTATION IN HEALTHCARE SECTOR IN KINGDOM OF SAUDI ARABIA Al-Hanawi, M.
22 S3 p. S791
 artikel
1712 PNS199 BARRIERS TO THE USE OF HEALTH SERVICES AMONG THE ELDERLY POPULATION OF A RURAL REGIONAL UNITY IN GREECE: A CROSS-SECTIONAL STUDY Kolotourou, M.
22 S3 p. S794
 artikel
1713 PNS115 BARRIERS TO TRANSPARENCY IMPROVEMENT OF HOSPITALS PERFORMANCE: A QUALITATIVE STUDY IN IRAN Bouzarjomehri, H.
22 S3 p. S780-S781
 artikel
1714 PNS303 BAYESIAN ESTIMATION OF THE TRANSITION PROBABILITY MATRIX IN MARKOV MODELLING WITH INFORMATIVE PRIOR: AN EXAMPLE FROM THE ANALYSIS OF THE TREATMENT OF PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH CARIPRAZINE Vokó, Z.
22 S3 p. S814-S815
 artikel
1715 PNS339 BAYESIAN NETWORK META-ANALYSES WHERE INFORMATIVE PRIORS WERE USED FOR THE BETWEEN-STUDY HETEROGENEITY; A PRAGMATIC REVIEW Gebregergish, S.B.
22 S3 p. S821-S822
 artikel
1716 PNS295 BEST WORST SCALING: FOR GOOD OR FOR BAD BUT NOT FOR BOTH Soekhai, V.
22 S3 p. S813
 artikel
1717 PNS133 BEYOND INTERNATIONAL PRICING INDEX MODEL IN THE UNITED STATES - IMPACT TO GLOBAL PRICING STRATEGIES & ACCESS TO INNOVATIVE MEDICINES Svitil, P.
22 S3 p. S784
 artikel
1718 PNS380 BREAST CANCER PATIENT PERSPECTIVES ON IMPORTANT SYMPTOM INFORMATION Peechatka, A.
22 S3 p. S829
 artikel
1719 PNS57 BUDGET IMPACT ANALYSIS OF A WEARABLE REMOTE CONTINUOUS MONITORING DEVICE TO FACILITATE EARLY DISCHARGE OF BARIATRIC SURGERY PATIENTS IMMEDIATELY AFTER POSTOPERATIVE OBSERVATION IN THE RECOVERY WARD Peters, G.
22 S3 p. S772
 artikel
1720 PNS292 BUDGET IMPACT OF SOFTWARE SUPPORTING SAFE, EFFECTIVE AND EFFICIENT WORKING OF NHS ACUTE CARE PROVIDERS: ACTUAL BUDGET IMPACT FOR IMPLEMENTATION SITE AND LOST OPPORTUNITY SAVING AND PROJECTED BUDGET IMPACT POTENTIAL FOR OTHER SITES Kapoor, M.
22 S3 p. S812-S813
 artikel
1721 PNS406 BURDEN OF POST-TRANSPLANT OUTCOMES AFTER LIVER TRANSPLANTATION IN SOUTH KOREA: KOREAN ORGAN TRANSPLANTATION REGISTRY (KOTRY) ANALYSIS STUDY Kim, J.
22 S3 p. S834
 artikel
1722 PNS345 BUSINESS MODEL INNOVATION OF INTERNET HOSPITALS IN CHINA: A SYSTEMATIC REVIEW LAI, Y.F.
22 S3 p. S822
 artikel
1723 PNS190 BUSINESS MODELS SUPPORTING THE INTEGRATION OF POINT-OF-CARE TESTING AT THE GENERAL PRACTICE: A COMPARISON OF ENGLAND AND THE NETHERLANDS Lingervelder, D.
22 S3 p. S793
 artikel
1724 PNS250 CADTH PARALLEL SCIENTIFIC ADVICE PROGRAMS WITH NICE AND HEALTH CANADA Boss, J.
22 S3 p. S804
 artikel
1725 PNS230 CALL FOR EFFECTIVE GUIDANCE: ASSESSMENT OF PHARMACOTHERAPEUTIC GUIDELINES IMPLEMENTATION Amorim, M.
22 S3 p. S800
 artikel
1726 PNS207 CANCER-RELATED HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES BY EUROPEAN HTA AGENCIES: A COMPARATIVE ANALYSIS OF G-BA, HAS AND NICE Schaefer, R.
22 S3 p. S795-S796
 artikel
1727 PNS346 CAN META-ANALYSES HELP IN SYNTHESIZING DATA ACROSS HEALTH ECONOMIC STUDIES? Kazmierska, P.
22 S3 p. S822
 artikel
1728 PNS18 CAN REFLECTIVE MCDA CONTRIBUTE TO ACHIEVING EMA'S STRATEGIC OBJECTIVES FOR REGULATORY SCIENCE TO 2025? WHEN THE BOTTOM UP APPROACH CAN BE THE WAY TO GO: INSIGHTS FROM SPANISH EXPERIENCE Gil, A.
22 S3 p. S765-S766
 artikel
1729 PNS60 CAN WE APPLY NICE COST-EFFECTIVENESS TO FRENCH EFFICIENCY OPTIONS: A COMPARISON OF SEVEN NICE AND HAS BASECASE COST-EFFECTIVENESS SCENARIOS Paris, A.
22 S3 p. S772
 artikel
1730 PNS89 CATEGORIZATION AND ASSOCIATION ANALYSIS OF RISK FACTORS FOR SAFE DRUG DISPOSAL Challa, R.
22 S3 p. S777
 artikel
1731 PNS77 CHALLENGES OF STUDIES ON ECONOMIC EVALUATION IN CHILD HEALTH IN CHINA-BASED ON A REVIEW OF PUBLISHED LITERATURE Xi, X.
22 S3 p. S775
 artikel
1732 PNS156 CHANGES IN LEADING CAUSES OF DEATHS AND THE NUMBER OF HOSPITAL BEDS IN HUNGARY BETWEEN 2002 AND 2017 Ágoston, I.
22 S3 p. S787
 artikel
1733 PNS170 CHEAP OR TIMELY DRUG? PRACTICAL IMPACT OF EXTERNAL REFERENCE PRICING POLICY IN THE EUROPEAN UNION Laxton, J.
22 S3 p. S790
 artikel
1734 PNS297 CLINICAL AND KEY OPINION LEADERS VALIDATION IN HEALTH ECONOMICS MODEL AND COMPARATIVE EFFECTIVENESS: A GUIDE FOR NON-EXPERT AUDIENCE Azimpour, K.
22 S3 p. S813
 artikel
1735 PNS374 CLINICAL BURDEN AND HEALTH-RELATED QUALITY OF LIFE IN CAREGIVERS OF CANCER PATIENTS: RESULTS FROM LINKING ELECTRONIC HEALTH RECORDS TO PATIENT-REPORTED OUTCOMES Huynh, S.
22 S3 p. S828
 artikel
1736 PNS237 CLINICAL OUTCOME ASSESSMENTS AS A CONDITION IN HTA RECOMMENDATIONS: THE CANADIAN PERSPECTIVE Gubbels, L.
22 S3 p. S801
 artikel
1737 PNS229 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE ADDED MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE THROUGH EARLY ACCESS PROGRAM VS THE OTHERS Benazet, F.
22 S3 p. S800
 artikel
1738 PNS236 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE IN EARLY ACCESS PROGRAM VS THE OTHERS IN FRANCE Benazet, F.
22 S3 p. S801
 artikel
1739 PNS116 COMPARATIVE PRICING POLICY ANALYSIS BETWEEN DENMARK AND FRANCE. Rodrigues, J.
22 S3 p. S781
 artikel
1740 PNS3 COMPARISON OF FIVE METHODS FOR DOWNLOADING CONFERENCE ABSTRACTS: A CASE STUDY Cooper, C.
22 S3 p. S763
 artikel
1741 PNS176 COMPARISON OF HOSPITAL BED NUMBERS IN EUROPEAN OECD COUNTRIES WITH BISMARCK- AND BEVERIDGE HEALTH CARE MODELS Elmer, D.
22 S3 p. S791
 artikel
1742 PNS414 COMPARISON OF THREE LARGE REAL-WORLD DATABASES FROM THREE DIFFERENT COUNTRIES AND IMPLICATIONS FOR THEIR USE FOR RETROSPECTIVE STUDIES Wang, X.
22 S3 p. S835-S836
 artikel
1743 PNS150 CONDITIONAL MARKETING AUTHORISATION FOR NOVEL TREATMENTS: A LANDSCAPE ASSESSMENT OF EXPEDITED PATHWAYS OUTSIDE US AND EU Berdunov, V.
22 S3 p. S786
 artikel
1744 PNS80 COST-EFFECTIVENESS ANALYSES OF PERSONALISATION/HOME CARE FOR OLDER PEOPLE COMPARED TO NURSING HOME CARE: A SYSTEMATIC REVIEW Fatoye, C.
22 S3 p. S776
 artikel
1745 PNS74 COST-EFFECTIVENESS AND RETURN-ON-INVESTMENT OF THE DYNAMIC WORK INTERVENTION Ben, Â.
22 S3 p. S774-S775
 artikel
1746 PNS15 COVARIATE ADJUSTMENT IN INDIRECT TREATMENT COMPARISON (ITC): HOW TO BLEND THE USEFUL WITH THE AGREEABLE Dolph, M.
22 S3 p. S765
 artikel
1747 PNS274 CRITICALLY APPRAISING SYSTEMATIC REVIEWS OF ECONOMIC EVALUATIONS: WHAT, WHY AND HOW? AN EXPLORATORY STUDY USING AN IRISH NATIONAL CLINICAL GUIDELINE Carty, P.
22 S3 p. S809
 artikel
1748 PNS225 CURRENT STATUS OF OUTCOMES-BASED AGREEMENTS IN SELECTED EUROPEAN COUNTRIES AND CANADA Tomassy, J.
22 S3 p. S799
 artikel
1749 PNS410 DATA FROM EXPANDED ACCESS PROGRAMS: TREATMENT FIRST, COLLECTION SECOND. AN OVERVIEW OF FDA AND EMA REGULATORY APPROVALS. Polak, T.
22 S3 p. S835
 artikel
1750 PNS332 DEALING WITH MISSING DATA IN TRIAL-BASED ECONOMIC EVALUATIONS: A METHODOLOGICAL SCOPING REVIEW Guevara Morel, A.
22 S3 p. S820
 artikel
1751 PNS10 DEFINING CONFOUNDING BY INDICATION: RESOLVING THE GAP BETWEEN AN EPIDEMIOLOGIST AND ECONOMETRICIAN Varga, A.
22 S3 p. S764
 artikel
1752 PNS84 DEMOGRAPHIC FORECASTING WITH UNCERTAINTY OF POPULATION PROJECTION IN CYPRUS: A BAYESIAN PROBABILISTIC POPULATION PROJECTION STUDY Giannakou, K.
22 S3 p. S776
 artikel
1753 PNS405 DERIVING DATA FOR COST-EFFECTIVENESS MODELS FROM THE FRENCH SNDS DATABASE: A FEASIBILITY ASSESSMENT Meng, J.
22 S3 p. S834
 artikel
1754 PNS79 DETERMINING THE BASELINE STRATEGY IN A COST-EFFECTIVENESS ANALYSIS WITH TREATMENT SEQUENCES Viola, M.
22 S3 p. S775-S776
 artikel
1755 PNS358 DEVELOPMENT AND OPTIMIZATION OF NATIONWIDE INTEROPERABLE CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) IN KOREA Yang, W.
22 S3 p. S824-S825
 artikel
1756 PNS118 DEVELOPMENT AND POTENTIALS OF HEALTH TECHNOLOGY ASSESSMENT SYSTEM IN KAZAKHSTAN. Kostyuk, A.
22 S3 p. S781
 artikel
1757 PNS394 DEVELOPMENT OF A MULTIPLICATIVE MULTI-ATTRIBUTE AND SINGLE-ATTRIBUTE UTILITY FUNCTION FOR THE HUI3 IN JAPAN Noto, S.
22 S3 p. S832
 artikel
1758 PNS349 DEVELOPMENT OF PLAIN ENGLISH SUMMARIES OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REPORTS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IRELAND Gorry, C.
22 S3 p. S823
 artikel
1759 PNS399 DEVELOPMENT OF POPULATION TARIFFS FOR THE CARER-QOL-7D INSTRUMENT FOR HUNGARY, POLAND AND SLOVENIA: A DISCRETE CHOICE EXPERIMENT STUDY TO MEASURE THE BURDEN OF INFORMAL CAREGIVING Baji, P.
22 S3 p. S833
 artikel
1760 PNS338 DEVELOPMENT, VALIDATION AND ASSESSMENT OF RELIABILITY OF DDQ-KAP 16 QUESTIONNAIRE Swarna, M.
22 S3 p. S821
 artikel
1761 PNS413 DEVELOPMENT, VALIDATION AND CONCORDANCE OF CLINICAL CODE SETS USED IN REAL-WORLD DATABASE STUDIES Artignan, A.
22 S3 p. S835
 artikel
1762 PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE Dintsios, C.M.
22 S3 p. S807
 artikel
1763 PNS61 DOES A STANDARD WILLINGNESS-TO-PAY THRESHOLD EXIST IN GREECE? Tzanetakos, C.
22 S3 p. S772-S773
 artikel
1764 PNS276 DOES FDA BREAKTHROUGH DESIGNATION AFFECT HTA RECOMMENDATIONS IN TERMS OF TIMING AND OUTCOME? Cai, J.
22 S3 p. S809
 artikel
1765 PNS64 DOES IT WORTH TO INVEST ON INTRAOPERATIVE HYPOTHERMIA PREVENTION? - HYBRID EVIDENCES FROM META-ANALYSES AND COST-BENEFIT ANALYSIS Xu, H.
22 S3 p. S773
 artikel
1766 PNS248 DOES THE EVALUATION OF THE FRENCH TRANSPARENCY COMMITTEE (TC) ON DRUG EFFECTIVENESS HAVE AN IMPACT ON THE HEALTH-ECONOMIC EVALUATION CONDUCTED BY THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP)? Caillon, M.
22 S3 p. S803
 artikel
1767 PNS327 DO FLEXIBLE SURVIVAL MODELS PROVIDE BETTER EXTRAPOLATIONS THAN STANDARD SURVIVAL MODELS? A SIMULATION STUDY Kearns, B.C.
22 S3 p. S819
 artikel
1768 PNS252 DO MARKET WITHDRAWALS IMPACT PATIENT ACCESS TO TREATMENT IN GERMANY? Pownell, A.
22 S3 p. S804
 artikel
1769 PNS281 DO SPANISH TPRS AFFECT THE NATIONAL PRICING AND REIMBURSEMENT OF DRUGS? Macaulay, R.
22 S3 p. S810
 artikel
1770 PNS131 DO THE EVOLVING MARKET ACCESS POLICY DYNAMICS AND INCREASING IMPORTANCE OF CLINICAL AND HEALTH ECONOMIC EVIDENCE REPRESENT THE NEXT BIG OPPORTUNITY FOR PHARMA TO DEMONSTRATE VALUE IN CHINA? Wang, A.
22 S3 p. S784
 artikel
1771 PNS262 EARLY DIALOGUE WITH NICE AND EUNETHTA: A UK PERSPECTIVE IN A POLITICALLY UNCERTAIN ERA Heyes, A.
22 S3 p. S806
 artikel
1772 PNS11 EARLY HEALTH ECONOMIC MODELLING AS A TOOL TO GUIDE STRATEGIC CLINICAL DEVELOPMENT AND IN-LICENSING DECISIONS Buchanan, V.
22 S3 p. S764
 artikel
1773 PNS321 EASINESS AND RELIABILITY IN ESTIMATING PATIENT-LEVEL SURVIVAL DATA FROM KAPLAN-MEIER CURVES Kosaner Kließ, M.
22 S3 p. S818
 artikel
1774 PNS50 ECONOMIC IMPACT OF THE DEVELOPMENT OF OUTPATIENT SURGERY IN FRANCE Touahmia, S.E.
22 S3 p. S770
 artikel
1775 PNS233 ECONOMIC MODEL AND METHODOLOGIES EMPLOYED IN RECENT NICE SINGLE TECHNOLOGY APPRAISAL SUBMISSIONS Dasari, M.
22 S3 p. S800-S801
 artikel
1776 PNS390 EMA/FDA PARALLEL QUALIFICATION PROCEDURE FOR THE DEVELOPMENT OF NOVEL PATIENT REPORTED OUTCOME INSTRUMENTS:PROCESS AND IMPACT Vladimirova, A.
22 S3 p. S831
 artikel
1777 PNS246 EMA & G-BA - A COMPARISON OF TIME LIMITATIONS OF EUROPEAN MARKETING AUTHORIZATIONS AND GERMAN ADDED BENEFIT ASSESSMENTS FOR NEW PHARMACEUTICALS. Schulze, K.
22 S3 p. S803
 artikel
1778 PNS362 EQ-5D-5L DATA FOR BULGARIAN POPULATION Encheva-Malinova, M.
22 S3 p. S825
 artikel
1779 PNS376 EQUIVALENCE OF ONLINE METHODS TO ASSESS CONTENT VALIDITY Rodriguez, A.M.
22 S3 p. S828
 artikel
1780 PNS94 ESTIMATING MISSING BASELINE SERUM CREATININE FOR ACUTE KIDNEY INJURY DIAGNOSIS IN HOSPITALISED PATIENTS Azevedo, A.
22 S3 p. S778
 artikel
1781 PNS160 ESTIMATING THE MARKET VALUE OF PERSONAL HEALTH RECORDS: THE CASE OF INDIVIDUAL DATA OWNERSHIP Schneider, J.
22 S3 p. S788
 artikel
1782 PNS329 ESTIMATION OF A DUTCH TARIFF FOR THE ADULT SOCIAL CARE OUTCOMES TOOLKIT FOUR-LEVEL SELF-COMPLETION TOOL (ASCOT-SCT4) Van Leeuwen, K.M.
22 S3 p. S819-S820
 artikel
1783 PNS371 EVALUATING QUALITY OF PRIMARY HEALTH CARE (PHC) SERVICES FROM THE PATIENTS' PERSPECTIVE IN GREECE Konstantakopoulou, O.
22 S3 p. S827
 artikel
1784 PNS72 EVALUATION OF MEDICAL TECHNOLOGIES WITH UNCERTAIN BENEFITS Phelps, C.
22 S3 p. S774
 artikel
1785 PNS56 EVALUATION OF THE IMPACT OF ALTERNATIVE DRUG PRICING STRATEGIES USED ON THE BUDGET IMPACT AND COST-EFFECTIVENESS FOR PRODUCTS WITH MULTIPLE INDICATIONS Smyrnaios, C.
22 S3 p. S771-S772
 artikel
1786 PNS289 EVALUATION OF THE SAFETY AND EFFICACY OF AI FOR DETECTION OF CHRONIC NON-COMMUNICABLE DISEASES IN REMOTE AREAS Vorobiev, A.
22 S3 p. S812
 artikel
1787 PNS25 EVALUATION OF THE SCIENTIFIC ACTIVITY OF MEDICAL UNIVERSITIES AND RESEARCH CENTERS TO CREATE THE NATIONAL STRATEGY OF THE MEDICAL SCIENCE DEVELOPMENT Koikov, V.
22 S3 p. S767
 artikel
1788 PNS290 EVIDENCE-BASED VALUE FRAMEWORK FOR THE EVALUATION OF CLINICAL PHARMACY SERVICES Gyimesi, N.
22 S3 p. S812
 artikel
1789 PNS285 EVOLVING MHEALTH REIMBURSEMENT LANDSCAPES: WHERE SHOULD COMPANIES LOOK TO? Rounds, M.
22 S3 p. S811
 artikel
1790 PNS2 EXISTENCE OF NOTORIETY BIAS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE AND ITS IMPACT ON SIGNAL STRENGTH Ravindra Reddy, N.
22 S3 p. S763
 artikel
1791 PNS241 EXPERIENCE AND IMPACT OF NICE SCIENTIFIC ADVICE: 10 YEARS ON Gwladys, N.
22 S3 p. S802
 artikel
1792 PNS196 EXPERIENCES WITH SUPPLEMENTARY HEALTH INSURANCE POLICIES IN HUNGARY AND OTHER EUROPEAN COUNTRIES Komáromy, M.
22 S3 p. S793-S794
 artikel
1793 PNS333 EXTRAPOLATING SURVIVAL BY ASSUMING PROPORTIONAL HAZARDS BETWEEN GENERAL POPULATION MORTALITY AND DISEASE SPECIFIC MORTALITY van Oostrum, I.
22 S3 p. S820
 artikel
1794 PNS54 FACIAL DRUG PRICES REGULATION BETWEEN 2011 AND 2018 IN FRANCE Dorizon, D.
22 S3 p. S771
 artikel
1795 PNS106 FACTORS AFFECTING THE HEALTHCARE PROVIDERS KNOWLEDGE OF PROJECT MANAGEMENT Alomi, Y.A.
22 S3 p. S779
 artikel
1796 PNS251 FACTORS ASSOCIATED WITH THE OUTCOMES OF RAPID REVIEWS SUBMITTED TO THE NCPE Varley, A.
22 S3 p. S804
 artikel
1797 PNS12 FACTORS TO BE CONSIDERED TO ENSURE ACCEPTABILITY OF HISTORICALLY CONTROLLED STUDIES BY HTA BODIES Rémuzat, C.
22 S3 p. S764-S765
 artikel
1798 PNS317 FAILURE OR EFFECT: ATTRIBUTE FRAMING IN A DISCRETE CHOICE EXPERIMENT Smith, I.P.
22 S3 p. S817
 artikel
1799 PNS375 FEASIBILITY OF AN ONLINE-ONLY METHOD OF GENERATING SUBJECT USABILITY AND COGNITIVE UNDERSTANDING DATA FOR ELECTRONICALLY ADMINISTERED QUESTIONNAIRES: AN EXAMPLE USING THE TREATMENT SATISFACTIONS QUESTIONNAIRE FOR MEDICATION (TSQM) Rodriguez, A.M.
22 S3 p. S828
 artikel
1800 PNS293 FITTING AN AIC-BASED AVERAGING SURVIVAL MODEL TO TIME-TO-EVENT DATA – A CASE STUDY USING PUBLISHED OVERALL SURVIVAL DATA Meng, J.
22 S3 p. S813
 artikel
1801 PNS124 FRAMEWORK CONCEPTS FOR FINANCIAL RISK SHARING IN NOVEL POTENTIALLY CURATIVE MODALITIES Farrington, J.
22 S3 p. S782
 artikel
1802 PNS325 GAME THEORY IN THE HEALTHCARE LITERATURE:A SYSTEMATIC REVIEW FOCUSING ON NEGOTIATIONS Wolfrum, F.
22 S3 p. S819
 artikel
1803 PNS171 GEOGRAPHICAL INEQUALITIES OF GENERAL PRACTITIONER CARE IN HUNGARY BETWEEN 2009-2016 Petrics, Á.
22 S3 p. S790
 artikel
1804 PNS97 GEOGRAPHIC DIFFERENCES IN IRISH HEALTH STATUS Jabakhanji, S.
22 S3 p. S778
 artikel
1805 PNS62 HEALTH ECONOMIC VALUE OF BLOOD IN GHANA: THE CASE OF MATERNAL BLEEDING Owusu-Ofori, S.P.O.
22 S3 p. S773
 artikel
1806 PNS158 HEALTH ECONOMIC VALUE OF BLOOD IN SUB-SAHARAN AFRICA: THE CASE OF MATERNAL BLEEDING Owusu-Ofori, S.P.O.
22 S3 p. S788
 artikel
1807 PNS223 HEALTH-RELATED QUALITY OF LIFE DATA AVAILABILITY IN DRUG APPRAISALS IN FRANCE: WHERE DO WE STAND TODAY? Gwladys, N.
22 S3 p. S799
 artikel
1808 PNS384 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASURED BY PROMIS PREFERENCE SCORE (PROPR) IN THE GENERAL POPULATION OF THE UNITED KINGDOM, FRANCE, AND GERMANY Klapproth, C.
22 S3 p. S830
 artikel
1809 PNS383 HEALTH-RELATED QUALITY OF LIFE IN ROMANIA: CROSS-SECTIONAL STUDIES USING EQ-5D-3L AND EQ-5D-5L Paveliu, M.S.
22 S3 p. S829-S830
 artikel
1810 PNS29 HEALTH RESEARCH AND BIG DATA IN UKRAINE: PERSPECTIVES AND CONCERNS Ratushna, K.
22 S3 p. S767-S768
 artikel
1811 PNS249 HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENTS IN EUROPE AND NORTH AMERICA SYSTEMATIC REVIEW Roth, J.
22 S3 p. S803-S804
 artikel
1812 PNS217 HOW CENTRAL LIMIT THEOREM RELATES TO THE SELECTION OF DISTRIBUTIONS FOR PROBABILISTIC SENSITIVITY ANALYSIS Hale, O.
22 S3 p. S797-S798
 artikel
1813 PNS179 HOW DOES EXTERNAL REFERENCE PRICING FOR MEDICARE PART B DRUGS COMPARE TO OTHER COST METRICS AVAILABLE IN THE UNITED STATES? Levy, J.
22 S3 p. S791
 artikel
1814 PNS355 HOW INVOLVED SHOULD PAYERS BE IN THE DEVELOPMENTS OF TARGET PRODUCT PROFILE (TPP), PRODUCT DEVELOPMENT PLAN (PDP) AND DESIGN OF CLINICAL TRIALS (DOCT) Fatoye, C.
22 S3 p. S824
 artikel
1815 PNS408 HOW IS THE ENGLISH NHS PRESCRIPTION DRUGS BUDGET SPENT Buckle, J.
22 S3 p. S834-S835
 artikel
1816 PNS144 HOW THE RESULTS OF THE AMNOG EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY HAVE DEVELOPED OVER TIME Reindl, S.
22 S3 p. S785
 artikel
1817 PNS82 HOW TO DEAL WITH CONTRADICTORY COST-EFFECTIVENESS OF THERAPEUTICALLY SIMILAR MEDICINES? Tolkushin, A.
22 S3 p. S776
 artikel
1818 PNS300 HOW TO INTERPRET AND ACCOUNT FOR OVER/UNDER-DISPERSION WHEN MODELLING INCIDENCE RATES WITH POISSON MODELS Alsop, J.
22 S3 p. S814
 artikel
1819 PNS357 HOW TO RESOLVE ISSUES EXPERIENCED BY PAYERS FOR THEIR INVOLVEMENT AT PRE-LAUNCH STAGE Fatoye, C.
22 S3 p. S824
 artikel
1820 PNS232 HTA RESHAPING: REDEFINING THE HEALTH TECHNOLOGY EVALUATION FRAMEWORK IN PORTUGAL Rodrigues, B.
22 S3 p. S800
 artikel
1821 PNS273 ICER: SIMILARITIES AND DIFFERENCES BETWEEN UK (ENGLAND) AND USA COST-EFFECTIVENESS WATCHDOGS Brough, A.
22 S3 p. S808-S809
 artikel
1822 PNS373 IDENTIFICATION AND RECOMMENDATIONS OF READABILITY TESTS FOR THE EVALUATION OF CLINICAL OUTCOME ASSESSMENTS Gauthier, M.
22 S3 p. S828
 artikel
1823 PNS8 IDENTIFYING MECHANISMS IN PARTICIPANT RECRUITMENT IN THE DANSIH EQ-5D-5L VALUATION STUDY Jensen, V.
22 S3 p. S764
 artikel
1824 PNS215 IMPACT OF CONDITIONAL MARKETING AUTHORISATION AND ACCELERATED ASSESSMENT ON HEALTH TECHNOLOGY ASSESSMENT (HTA) OUTCOMES Hall, D.
22 S3 p. S797
 artikel
1825 PNS209 IMPACT OF GENERICS AND BIOSIMILARS ON BRANDED DRUG LISTING DECISIONS IN SINGAPORE S, L.I.M.
22 S3 p. S796
 artikel
1826 PNS87 IMPACT OF SELF SUSTAINABLE SYSTEM FOR SAFE DRUG DISPOSAL: A FOLLOW UP STUDY Swarna, M.
22 S3 p. S777
 artikel
1827 PNS191 IMPLEMENTATION OF A NEW MODEL OF THE NURSING CARE MANAGEMENT IN THE REPUBLIC OF KAZAKHSTAN: POLICY BRIEF Koikov, V.
22 S3 p. S793
 artikel
1828 PNS123 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE IN INDONESIA Wasir, R.
22 S3 p. S782
 artikel
1829 PNS16 IMPROVING ACCESS TIME IN NUCLEAR CARDIOLOGY TOWARDS QUALITY DELIVERY OF HEALTHCARE SERVICES Arasaratnam, P.
22 S3 p. S765
 artikel
1830 PNS337 IMPROVING ON CYCLE CORRECTIONS FOR TIME-HOMOGENEOUS MARKOV MODELS Srivastava, T.
22 S3 p. S821
 artikel
1831 PNS302 IMPROVING THE PERFORMANCE OF PATIENT-LEVEL SIMULATION MODELS USING MULTI-THREADING AND SINGLE INSTRUCTION MULTIPLE DATA (SIMD) OPERATIONS Pollock, R.F.
22 S3 p. S814
 artikel
1832 PNS114 IMPROVING THE TRANSPARENCY OF MARKETING AUTHORISATION DECISIONS: TOWARDS A FRAMEWORK FOR MANAGING UNCERTAINTIES Janssens, R.
22 S3 p. S780
 artikel
1833 PNS260 INCLUSION OF NEW STRATEGIES IN THE UK'S CANCER DRUG FUND: WHAT WAS DECIDED IN FRANCE? Trancart, M.
22 S3 p. S806
 artikel
1834 PNS254 INCLUSION OF PRODUCTIVITY LOSSES IN HTA ASSESSMENTS IN FUNCTION OF WHO BEARS PRODUCTIVITY LOSSES IN THE REAL WORLD - A QUALITATIVE ASSESSMENT Contente, M.
22 S3 p. S804-S805
 artikel
1835 PNS59 INCORPORATING THE PATIENT'S PERSPECTIVE IN ECONOMIC EVALUATIONS OF HEALTHCARE Jamadar, F.
22 S3 p. S772
 artikel
1836 PNS304 IN SEARCH OF A PAN-EUROPEAN VALUE SET; APPLICATION FOR EQ-5D-3L: THE PECUNIA PROJECT Sajjad, A.
22 S3 p. S815
 artikel
1837 PNS234 INTERNATIONAL HTA FRAMEWORKS AS ROADMAP TO REVISIT PHARMA ORGANISATION AND OPERATIONS He, W.
22 S3 p. S801
 artikel
1838 PNS359 INTERNATIONAL OBSERVATIONAL STUDIES: THE INCREASED NEED FOR A COMMON EUROPEAN REGULATION Comet, D.
22 S3 p. S825
 artikel
1839 PNS284 IS THERE A NEED FOR REAL WORLD EVIDENCE (RWE) IN HEALTH TECHNOLOGY ASSESSMENTS OF RARE DISEASES AND ONCOLOGY TREATMENTS? Forsythe, A.
22 S3 p. S811
 artikel
1840 PNS253 IS THERE STILL A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS? UPDATED ANALYSIS Ferreira, C.
22 S3 p. S804
 artikel
1841 PNS122 LONG-ACTING GENE THERAPIES: CURRENT DEVELOPMENT ACTIVITIES AND CHALLENGES FOR GERMANY'S STATUTORY HEALTH INSURANCE SYSTEM Berkemeier, F.
22 S3 p. S782
 artikel
1842 PNS231 MANAGED ENTRY AGREEMENTS FOR PRESCRIPTION DRUGS IN SWEDEN Gregorsson, M.
22 S3 p. S800
 artikel
1843 PNS354 MARKET ACCESS AS DEFINED BY MARKET ACCESS (MA), HEALTH ECONOMICS, AND OUTCOMES RESEARCH (HEOR) PROFESSIONALS Fatoye, C.
22 S3 p. S824
 artikel
1844 PNS173 MEASURING DELAYS IN THE AVAILABILITY OF NEW MEDICINES WITHIN EUROPE USING A TIME-TO-PRICE INDICATOR Milosic, R.
22 S3 p. S790
 artikel
1845 PNS136 MEDICAL DEVICES PRICE SETTING IN FRANCE: A RETROSPECTIVE ANALYSIS (2018-2019) De Joannis, P.E.
22 S3 p. S784
 artikel
1846 PNS308 METHODOLOGICAL APPROACHES FOR INCORPORATING INVESTIGATORS' CHOICE COMPARATOR ARMS INTO NETWORK META-ANALYSES Goring, S.
22 S3 p. S815-S816
 artikel
1847 PNS370 METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, CONTENT VALIDITY TESTING, AND EVALUATION OF PATIENT EDUCATION TOOLS (PETS) Bentley, S.
22 S3 p. S827
 artikel
1848 PNS267 MODELLING OF LIFECYCLE PRICING IN HTA: METHODOLOGICAL CONSIDERATIONS Curry, A.
22 S3 p. S807
 artikel
1849 PNS180 MONITORING OF DRG-BASED PAYMENT FOR IN-PATIENT AND DAY CARE IN RUSSIAN HOSPITALS IN 2016-2018 Lazareva, M.
22 S3 p. S791-S792
 artikel
1850 PNS153 MOVING TOWARD UNIVERSAL HEALTH COVERAGE IN JORDAN Muhidat, H.
22 S3 p. S787
 artikel
1851 PNS387 MULTI-CRITERIA DECISIONAL ANALYSIS ON NON-EMERGENCY MEDICAL TRANSPORT IN HONG KONG CONTEXT Cheuk Wai, N.
22 S3 p. S830
 artikel
1852 PNS265 MULTI-CRITERIA DECISION ANALYSIS AS A SUPPORTIVE TOOL FOR EFFICIENCY MEASURING IN HEALTH CARE Araja, D.
22 S3 p. S807
 artikel
1853 PNS35 MULTI-NATIONAL NORDIC PHARMACOEPIDEMIOLOGIC STUDIES: OPPORTUNITIES AND CHALLENGES Svanström, H.
22 S3 p. S768
 artikel
1854 PNS210 NATIONAL HEALTH TECHNOLOGY SYSTEM (SINATS) IN PORTUGAL: 4-YEAR LANDMARK ANALYSIS Ferreira, C.
22 S3 p. S796
 artikel
1855 PNS259 NATIONAL HTA IMPLEMENTATION IN MIDDLE-INCOME COUNTRIES, THE CASE OF JORDAN Almomani, E.
22 S3 p. S806
 artikel
1856 PNS222 NEEDS AND RISKS ASSESSMENT IN CREATION OF HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE Romanenko, I.
22 S3 p. S798-S799
 artikel
1857 PNS129 NET PRICES OF GENERICS IN GREECE DUE TO PAYBACKS: UPDATING THE FACTS Papadopoulos, K.
22 S3 p. S783
 artikel
1858 PNS318 NETWORK META-ANALYSES COMBINING RANDOMIZED AND NON-RANDOMIZED EVIDENCE; A NICE HTA REVIEW Gebregergish, S.
22 S3 p. S817-S818
 artikel
1859 PNS336 NETWORK META-ANALYSIS (NMA) WITH TIME-VARYING HAZARD: A COMPARATIVE ANALYSIS OF SURVIVAL OUTCOMES Jootun, M.
22 S3 p. S821
 artikel
1860 PNS126 NEW DRUG BUDGET AND REIMBURSEMENT POLICY IN TAIWAN Chan, Y.Y.
22 S3 p. S783
 artikel
1861 PNS213 NICE FAST TRACK APPRAISALS: A DESCRIPTIVE OVERVIEW Dawoud, D.
22 S3 p. S797
 artikel
1862 PNS216 NICE HIGHLY SPECIALISED TECHNOLOGY ASSESSMENT: HOW ARE SELECTION CRITERIA APPLIED IN PRACTICE? Child, A.
22 S3 p. S797
 artikel
1863 PNS66 NON-INFERIORITY TRIALS IN HEALTH TECHNOLOGY ASSESSMENT - DO THEY NECESSITATE A COST-MINIMISATION APPROACH? Jacob, I.
22 S3 p. S773
 artikel
1864 PNS24 NORDIC COLLABORATIONS ON PROCUREMENT AND HEALTH TECHNOLOGY ASSESSMENT: CONCEPTS, COMPONENTS, AND OUTLOOK Stephens, T.
22 S3 p. S767
 artikel
1865 PNS315 ON THE USE OF DISCOUNT RATES IN ONE-WAY SENSITIVITY ANALYSIS Malmberg, C.
22 S3 p. S817
 artikel
1866 PNS43 ORGANISING THE LITERATURE IN A SYSTEMATIC LITERATURE REVIEW USING FACTOR ANALYSIS Mikkelsen, Y.
22 S3 p. S769-S770
 artikel
1867 PNS137 ORPHAN DRUGS: WHAT FACTORS IMPACT THE PRICE IN FRANCE? De Joannis, P.E.
22 S3 p. S784-S785
 artikel
1868 PNS244 PAN-EU CLINICAL HTA – A NON-UNIFORM IMPACT? Campbell, J.
22 S3 p. S802-S803
 artikel
1869 PNS202 PARALLEL SCIENTIFIC ADVICE FROM NICE AND CADTH: WHAT'S IN IT FOR MANUFACTURERS? Vania, D.K.
22 S3 p. S794-S795
 artikel
1870 PNS287 PATIENT-CENTRICITY FOR PHARMACEUTICAL COMPANIES: NEW MODELS IN THE ERA OF CONNECTED HEALTH Rahardjani, M.
22 S3 p. S811-S812
 artikel
1871 PNS7 PATIENT INPUT TO COST-UTILITY ANALYSES: A REVIEW FROM THE UK, CANADA AND AUSTRALIA Lee, J.M.
22 S3 p. S764
 artikel
1872 PNS364 PATIENT INVOLVEMENT IN EUNETHTA PHARMACEUTICAL JOINT CLINICAL ASSESSMENTS Willemsen, A.
22 S3 p. S826
 artikel
1873 PNS305 PATIENT-LEVEL SIMULATION MODELS: THE POWER OF PARALLEL WORLDS Cook, J.
22 S3 p. S815
 artikel
1874 PNS386 PATIENT PREFERENCES IN THE MEDICAL PRODUCT LIFECYCLE: INITIAL RESULTS FROM THE IMI PREFER PUBLIC-PRIVATE PROJECT Whichello, C.
22 S3 p. S830
 artikel
1875 PNS395 PATIENT-REPORTED OUTCOME INSTRUMENTS IN ARABIC-SPEAKING POPULATIONS: A SYSTEMATIC REVIEW Alaqeel, S.
22 S3 p. S832
 artikel
1876 PNS407 PATIENT SELECTION PROCESS IN REAL-WORLD DATA FROM ELECTRONIC HEALTH RECORDS - SUGGESTED STANDARDISED PROCESS FOR SELECTING PATIENTS Carlucci, C.
22 S3 p. S834
 artikel
1877 PNS397 PATIENTS' PERCEPTION OF THE QUALITY OF CONSULTATIONS MODELLED BY PATIENT-REPORTED EXPERIENCE AND HEALTH-RELATED QUALITY OF LIFE MEASURES Brito Fernandes, Ó.
22 S3 p. S832
 artikel
1878 PNS356 PAYERS RELATED ISSUES ARISING FROM THE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS AT PRE-LAUNCH Fatoye, C.
22 S3 p. S824
 artikel
1879 PNS402 PERCEIVED BARRIERS TO ENSURING THE EFFECTIVE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS Fatoye, C.
22 S3 p. S833
 artikel
1880 PNS109 PERCEPTIONS AND PRACTICES OF SELF- MEDICATION IN AN INDIAN URBAN COMMUNITY Swaroop, A.M.
22 S3 p. S780
 artikel
1881 PNS257 PERCEPTIONS ON THE PHARMACISTS' ROLE IN HTA DECISION MAKING IN GREECE Naoum, V.
22 S3 p. S805
 artikel
1882 PNS298 PER-MEMBER PER-MONTH (PMPM) EXPENDITURE VALUE IN ONCOLOGY: A QUICK LITERATURE REVIEW AND OPINION Tremblay, G.
22 S3 p. S814
 artikel
1883 PNS169 PERSONAL MEDICAL HEALTH RECORDS REGULATION IN THE UNITED STATED, EUROPEAN UNION AND ISRAEL Dubinsky, R.
22 S3 p. S789-S790
 artikel
1884 PNS269 PERSPECTIVES ON PRICING AND REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE GREEK HEALTHCARE SETTING: A QUALITATIVE STUDY Karampli, E.
22 S3 p. S808
 artikel
1885 PNS119 PHARMACEUTICAL POLICY REFORM UNDER SOCIAL HEALTH INSURANCE IN INDONESIA: DOES ACCESS TO QUALIFIED MEDICINE GET BETTER? Soewondo, P.
22 S3 p. S781
 artikel
1886 PNS107 PHARMACISTS KNOWLEDGE OF PROJECT MANAGEMENT PROPOSAL OR CHART Alomi, Y.A.
22 S3 p. S779-S780
 artikel
1887 PNS112 PHARMACIST’S PRIVILEGE IN SAUDI ARABIA: PHARMACIST PRESCRIBING AND THERAPEUTIC INTERCHANGE Alomi, Y.A.
22 S3 p. S780
 artikel
1888 PNS164 PHARMACOECONOMIC ASSESSMENT AND DRUG COSTS OF TREATMENTS FOR CANCER AND RARE DISEASES IN IRELAND Kennedy, C.
22 S3 p. S788-S789
 artikel
1889 PNS159 PHARMACOECONOMICS AND HEALTH OUTCOME STUDIES IN TURKEY: ISPOR DATABASE SEARCH Oguzhan Ergın, G.
22 S3 p. S788
 artikel
1890 PNS198 PHARMACY COST OF PREVENTING ADVERSE DRUG EVENTS BY PHARMACISTS' INTERVENTIONS ON PRESCRIBING ERRORS Robinson, E.G.
22 S3 p. S794
 artikel
1891 PNS103 PHARMACY RESEARCH BASIC KNOWLEDGE IN THE KINDOM OF SAUDI ARABIA Alomi, Y.A.
22 S3 p. S779
 artikel
1892 PNS46 POISSON REPRESENTATION OF MARKOV COHORT STATE-TRANSITION MODELS Iskandar, R.
22 S3 p. S770
 artikel
1893 PNS393 POPULATION NORMS WITH THE ICECAP-A AND ICECAP-O CAPABILITY MEASURES IN HUNGARY Péntek, M.
22 S3 p. S831-S832
 artikel
1894 PNS140 POTENTIAL IMPACTS OF THE U.K. VOLUNTARY SCHEME FOR BRANDED MEDICINES PRICING AND ACCESS: A REVIEW OF STAKEHOLDER OPINION Walker, A.
22 S3 p. S785
 artikel
1895 PNS240 POTENTIAL INFLUENCE OF HTA ON PRICE OUTCOMES OF NON-ORPHAN PHARMACEUTICALS IN THE GERMAN AMNOG PROCESS Pointner, J.
22 S3 p. S802
 artikel
1896 PNS311 PREDICTIVE-ADJUSTED INDIRECT COMPARISON (PAIC): A NOVEL METHOD FOR POPULATION-ADJUSTED INDIRECT COMPARISON Remiro Azocar, A.
22 S3 p. S816
 artikel
1897 PNS353 PRICING AND MARKET ACCESS LAUNCH EXCELLENCE: WHAT ARE THE KEY CHALLENGES FACING COMPANIES TODAY? Craddy, P.
22 S3 p. S823-S824
 artikel
1898 PNS143 PRIORITIZATION OF DRUGS FOR REIMBURSEMENT IN THE MALTESE HEALTH SYSTEM. Abraham, K.
22 S3 p. S785
 artikel
1899 PNS121 PRIVATE HEALTH INSURANCE COLLABORATION WITH PHARMACEUTICAL COMPANIES IN EGYPT Abouelmaged, E.
22 S3 p. S782
 artikel
1900 PNS178 PRIVATE HEALTH INSURANCE PERCEPTION OF THEIR ROLE AFTERWARD UNIVERSAL HEALTH INSURANCE IN EGYPT Abouelmaged, E.
22 S3 p. S791
 artikel
1901 PNS75 PROPER INCORPORATION OF ADVERSE EVENTS FROM MEDICAL TREATMENTS (AEMT) IN HEALTH TECHOLOGY ASSESSMENTS (HTA) Phelps, C.
22 S3 p. S775
 artikel
1902 PNS38 PROPOSING AND EVALUATING A DESIGN FOR GDPR-COMPLIANT, SCALABLE TECHNOLOGY FOR AUTOMATIC ADJUDICATION OF RISK-SHARING AGREEMENTS Hinkel, J.M.
22 S3 p. S769
 artikel
1903 PNS33 PUBLICATION TREND AND CITATION ANALYSIS OF ARTICLES PUBLISHED IN "VALUE IN HEALTH” BETWEEN 1998-2019 Janodia, M.
22 S3 p. S768
 artikel
1904 PNS92 PUBLIC AWARENESS OF NURSING REFORM IN THE REPUBLIC OF KAZAKHSTAN Bekbergenova, Z.
22 S3 p. S777-S778
 artikel
1905 PNS256 PUBLIC VIEWS ON PRIORITY-SETTING CRITERIA FOR LIMITED HEALTHCARE RESOURCE Bae, E.Y.
22 S3 p. S805
 artikel
1906 PNS415 PUBLISHING OBSERVATIONAL STUDIES VS RANDOMIZED CONTROLLED TRIALS - A PUBMED REVIEW Simoni, L.
22 S3 p. S836
 artikel
1907 PNS331 QUANTIFYING THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES USING THE EQ-5D-3L INSTRUMENT Zrubka, Z.
22 S3 p. S820
 artikel
1908 PNS167 QUANTITATIVE AND QUALITATIVE ANALYSIS OF DIFFERENCES IN AMNOG OUTCOMES BETWEEN IQWIG AND G-BA BETWEEN 2011-2018 Dehnen, J.
22 S3 p. S789
 artikel
1909 PNS312 QUANTITATIVE AND QUALITATIVE ANALYSIS OF THE AMNOG ARBITRATION BOARD DECISION FACTORS FOR THE PRICING OF NEW ACTIVE SUBSTANCES IN GERMANY Kempf, L.
22 S3 p. S816
 artikel
1910 PNS128 READY FOR PRIME TIME? HAVE EMA PRIME DESIGNATIONS SUPPORTED ACCELERATED REGULATORY APPROVAL AND PATIENT ACCESS? Cieply, B.
22 S3 p. S783
 artikel
1911 PNS328 REAL OPTIONS ANALYSIS FOR MORE OPTIMALLY INFORMED REIMBURSEMENT DECISIONS Geenen, J.W.
22 S3 p. S819
 artikel
1912 PNS21 REAL WORLD EVIDENCE (RWE) IN PARTITION SURVIVAL MODELLING: IS IT THE REAL DEAL? Ramjee, L.
22 S3 p. S766
 artikel
1913 PNS391 REAL WORLD USE OF VEHICLES BY OLDER PATIENTS TAKING SOLID ORAL MEDICATIONS: A SURVEY IN THE ONLINE HEALTH NETWORK PATIENTSLIKEME. Borthwick, E.
22 S3 p. S831
 artikel
1914 PNS20 RECENT ADVANCES IN THE EUROPEAN CROSS-BORDER COLLABORATIONS IN JOINT DRUG PROCUREMENT LANDSCAPE Pisarczyk, K.
22 S3 p. S766
 artikel
1915 PNS369 RECOMMENDATIONS FOR CONDUCTING COGNITIVE INTERVIEWS REMOTELY TO DEVELOP CLINICAL OUTCOME ASSESSMENTS Macey, J.
22 S3 p. S827
 artikel
1916 PNS78 RECONCILING ACEA AND MCDA: IS THERE A WAY FORWARD FOR MEASURING COST-EFFECTIVENESS IN THE U.S. HEALTHCARE SETTING? Zamora Talaya, M.B.
22 S3 p. S775
 artikel
1917 PNS168 REFERENCE PRICE GROUPS (RPG) DEFINED FROM 2008 TO 2018 IN GERMANY - A DETAILED OVERVIEW AND DISCUSSION Kuchenbecker, U.
22 S3 p. S789
 artikel
1918 PNS31 REIMBURSEMENT IN GERMANY: THE IMPACT OF G-BA RECENTLY REVISED REQUIREMENTS FOR AMNOG DOSSIERS Duerr, H.P.
22 S3 p. S768
 artikel
1919 PNS185 RELATIONSHIP BETWEEN PARTIAL VALUES AND SCORING SCALE FOR EACH CRITERION OF THE EVIDEM 10TH EDITION CORE MODEL IN JAPAN Funagoshi, M.
22 S3 p. S792-S793
 artikel
1920 PNS5 RELATIVE EFFECT OF INTERVENTIONS IN ACTINIC KERATOSIS: FINDINGS FROM METHODOLOGICAL ASSESSMENT AND NETWORK META-ANALYSES Ezzedine, K.
22 S3 p. S763
 artikel
1921 PNS314 RELAXING THE MEMORYLESS PROPERTY WITHIN A MARKOV MODEL Mahajan, S.
22 S3 p. S817
 artikel
1922 PNS294 REVIEW OF ANALYTICAL METHODS FOR ANALYSIS OF PATIENT REPORTED OUTCOME (PRO) DATA IN THE PRESENCE OF CENSORING DUE TO DEATH O'Kelly, M.
22 S3 p. S813
 artikel
1923 PNS322 REVIEW OF METHODOLOGICAL APPROACHES TO ANALYSE LONGITUDINAL UTILITY DATA Majewska, R.
22 S3 p. S818
 artikel
1924 PNS53 REVIEW OF METHODOLOGICAL QUALITY OF BUDGET IMPACT ANALYSES FOR ORPHAN DRUGS Abdallah, K.
22 S3 p. S771
 artikel
1925 PNS71 ROLE OF INFORMATION IN DEMAND FOR HEALTH SERVICES: AN INSTRUMENTAL VARIABLE APPROACH Jha, S.
22 S3 p. S774
 artikel
1926 PNS351 ROLE OF MARKET ACCESS (MA), AND HEALTH ECONOMIC AND OUTCOMES RESEARCH (HEOR) PROFESSIONALS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS. Fatoye, C.
22 S3 p. S823
 artikel
1927 PNS334 SCIENTIFIC MISCONDUCT AND SYSTEMATIC LITERATURE REVIEWS (SLRS): THE IMPACT OF FRAUDULENT CLINICAL STUDIES ON EVIDENCE-BASED MEDICINE Thompson, J.C.
22 S3 p. S820
 artikel
1928 PNS347 SCIENTIFIC OUTCOME OF ISPOR CONFERENCES: AN ANALYSIS OF 44,390 ABSTRACTS PRESENTED AT 38 ISPOR CONFERENCES BETWEEN 2002-2018 Boncz, I.
22 S3 p. S823
 artikel
1929 PNS85 SELF-MEDICATION PRACTICES AMONG PATIENTS IN SAUDI ARABIA: A SYSTEMATIC REVIEW Aljumah, K.
22 S3 p. S776-S777
 artikel
1930 PNS218 SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: ESTABLISHING A EUROPEAN PICO Schreuder-Morel, C.
22 S3 p. S798
 artikel
1931 PNS163 SHIFTING PARADIGM OF INTERNATIONAL REFERENCE PRICING. IS IT BENEFICIAL TO PAYERS, MANUFACTURERS OR PATIENTS? Pushkarna, D.
22 S3 p. S788
 artikel
1932 PNS51 SHIFTING THE MARKET ACCESS FRAMEWORK TO INVESTMENT DECISIONS IN EARLY ASSETS Felizzi, F.
22 S3 p. S770-S771
 artikel
1933 PNS125 SHOULD DRUG PRICES DIFFER BY INDICATION? RESULTS OF A CONSULTATION Cole, A.
22 S3 p. S782-S783
 artikel
1934 PNS275 SHOULD LIFECYCLE PRICING BE CONSIDERED IN HTA? PRACTICAL CONSIDERATIONS FOR INCORPORATION INTO HTA POLICY Ralston, S.
22 S3 p. S809
 artikel
1935 PNS224 SHOULD THE PATIENT VOICE HAVE AN ACTIVE ROLE IN HTA DECISION-MAKING? A PAG CONSENSUS ANALYSIS IN GREECE Naoum, V.
22 S3 p. S799
 artikel
1936 PNS37 SHOULD WE CONSTANTLY BE COUNTING WITH CONSTANT DISCOUNTING? Redig, J.
22 S3 p. S769
 artikel
1937 PNS245 SNAPSHOT OF EARLY ACCESS PROGRAMMES IN PORTUGAL: A NEW ACCESS HURDLE? Amorim, M.
22 S3 p. S803
 artikel
1938 PNS360 SOCIETAL PREFERENCES IN THE HEALTH CARE RESOURCE ALLOCATION Lim, M.K.
22 S3 p. S825
 artikel
1939 PNS149 STATUS OF COMPASSIONATE USE PROGRAMMES (CUP) IN THE EU-5 (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM) De Cock, E.
22 S3 p. S786
 artikel
1940 PNS283 STATUS QUO OF CLAIMS DATA ANALYSES IN THE GERMAN AMNOG HTA PROCESS - DID QUALITY IMPROVE? Seidel, K.
22 S3 p. S811
 artikel
1941 PNS214 STEPS OF THE CREATION OF A HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE Piniazhko, O.
22 S3 p. S797
 artikel
1942 PNS220 SUBMISSION PROCESS AND REQUIREMENTS OF NORDIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AUTHORITIES FOR HOSPITAL DRUGS: IMPLICATIONS FOR MARKET ACCESS STRATEGY Aronsson, M.
22 S3 p. S798
 artikel
1943 PNS181 SUBMISSIONS TO A NATIONAL HTA AGENCY IN IRELAND: DRUGS WITH DESIGNATED ORPHAN STATUS Lee, A.
22 S3 p. S792
 artikel
1944 PNS379 SUFFERING ALONE: UNMET NEEDS FOR INFORMAL CARE IN HUNGARY, POLAND AND SLOVENIA Péntek, M.
22 S3 p. S829
 artikel
1945 PNS205 SURROGATE VALIDATION IN GERMAN AMNOG BENEFIT ASSESSMENTS Gingrich, A.
22 S3 p. S795
 artikel
1946 PNS211 SWOT ANALYSIS FOR CREATION OF HTA ECOSYSTEM IN UKRAINE Piniazhko, O.
22 S3 p. S796
 artikel
1947 PNS6 SYSTEMATIC LITERATIVE REVIEW AND QUALITATIVE ANALYSIS ASSESSING EFFICACY AND SAFETY OF INTERVENTIONS IN ACTINIC KERATOSIS Ezzedine, K.
22 S3 p. S763-S764
 artikel
1948 PNS286 SYSTEMATIC REVIEW ON THE ECONOMIC EVALUATION OF THE NON-INVASIVE PRENATAL TESTING Zisis, K.
22 S3 p. S811
 artikel
1949 PNS182 SYSTEMIC ADMINISTRATION OF GLUCOCORTICOIDS IN GUIZHOU PROVINCE, CHINA: A SURVEY AMONG HOSPITAL PHARMACIES. Zhang, J.
22 S3 p. S792
 artikel
1950 PNS219 TARGETED LITERATURE REVIEW AND PAYERS' PERSPECTIVES ON THE CURRENT PROGRESS OF HTA SYSTEM IMPLEMENTATION IN THE MENA REGION Vollmer, A.
22 S3 p. S798
 artikel
1951 PNS96 TATTOO PREVALENCE, PERCEPTION AND REGRET IN US ADULTS: A 2017 CROSS-SECTIONAL STUDY Morlock, R.
22 S3 p. S778
 artikel
1952 PNS271 TESTING OF A QUESTIONNAIRE FOR ASSESSMENT OF RELATIVE WEIGHTS OF MEDICINES VALUE CRITERIA Tolkushin, A.
22 S3 p. S808
 artikel
1953 PNS93 THE ACTUAL NUTRITIONAL STATUS OF SCHOOLCHILDREN IN NUR-SULTAN, KAZAKHSTAN Bekbergenova, Z.
22 S3 p. S778
 artikel
1954 PNS365 THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING: A LITERATURE REVIEW Chachoua, L.
22 S3 p. S826
 artikel
1955 PNS398 THE ASSOCIATION BETWEEN EHEALTH-LITERACY, SHARED DECISION-MAKING AND HEALTH RISK BEHAVIOURS IN AN ONLINE SAMPLE OF THE HUNGARIAN GENERAL POPULATION Zrubka, Z.
22 S3 p. S832-S833
 artikel
1956 PNS238 THE CHANGING DYNAMICS OF PATIENT ACCESS SCHEMES IN ENGLAND El Ghannam, M.
22 S3 p. S801-S802
 artikel
1957 PNS307 THE COMBINED USE OF TREEAGE SOFTWARE TO ACCELERATE MARKOV MODEL CONSTRUCTION WITHIN AN EXCEL USER INTERFACE Pollit, V.
22 S3 p. S815
 artikel
1958 PNS343 THE COMPLETENESS OF CLINICALTRIALS.GOV. - WHAT IS THE RATE OF PUBLISHED CLINICAL TRIALS REGISTERED ON THE WEBSITE? Smela-Lipińska, B.
22 S3 p. S822
 artikel
1959 PNS55 THE COST OF MEDICATION ERRORS IN PUBLIC HEALTH FACILITIES OF EASTERN REGION, GHANA. Vanderpuije, L.N.O.
22 S3 p. S771
 artikel
1960 PNS127 THE DEVELOPMENT OF CHIMERIC ANTIGEN RECEPTOR (CAR-T) CELL THERAPY IN CHINA Qiu, T.
22 S3 p. S783
 artikel
1961 PNS70 THE EFFECT OF OUT-OF-POCKET HEALTHCARE PAYMENT ON THE FINANCES OF NIGERIAN FAMILIES Ben-Umeh, K.
22 S3 p. S774
 artikel
1962 PNS368 THE EVOLVING ROLE OF PATIENT ADVOCACY IN DRUG APPRAISAL AND COMMISSIONING: PERSPECTIVES FROM ENGLAND Montani, L.
22 S3 p. S826-S827
 artikel
1963 PNS401 THE FIRST PARALLEL EQ-5D-3L AND EQ-5D-5L COMPOSITE TIME TRADE-OFF VALUATION STUDY IN EUROPE Rencz, F.
22 S3 p. S833
 artikel
1964 PNS261 THE HEALTH ECONOMIC DOMAIN WITHIN HEALTH TECHNOLOGY ASSESSMENTS IN GERMANY — FIRST RESULTS AND ENSUING CONSEQUENCES OF THEMENCHECK MEDIZIN Gibbert, J.
22 S3 p. S806
 artikel
1965 PNS23 THE IMPACT OF EARLY CENSORING ON THE PFS BY A MULTI-STATE MODEL Vincken, T.
22 S3 p. S766-S767
 artikel
1966 PNS175 THE IMPACT OF RE-PRICING POLICY ON THE PRICE OF ANTI-CANCER DRUGS FROM 2007 TO 2017 IN SOUTH KOREA: A RETROSPECTIVE STUDY Kwon, S.H.
22 S3 p. S790-S791
 artikel
1967 PNS247 THE IMPLICATIONS OF EUROPEAN JOINT CLINICAL ASSESSMENT FOR MEMBER STATE PRICING & MARKET ACCESS Satherley, A.
22 S3 p. S803
 artikel
1968 PNS299 THE INCREASING USE AND ACCEPTANCE OF ALTERNATIVE STATISTICAL APPROACHES TO INDIRECT COMPARISON IN THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSION PROCESS Pooley, N.
22 S3 p. S814
 artikel
1969 PNS145 THE MALTESE EXCEPTIONAL MEDICINAL TREATMENT ROUTE: A BYPASS TO HEALTHCARE? Abraham, K.
22 S3 p. S785-S786
 artikel
1970 PNS367 THE NATIONAL HEALTH COUNCIL PATIENT ENGAGEMENT RUBRIC: A GUIDE TO INCORPORATING THE PATIENT VOICE INTO THE HEALTHCARE ECOSYSTEM Perfetto, E.M.
22 S3 p. S826
 artikel
1971 PNS19 THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE'S HIGHLY SPECIALISED TECHNOLOGIES PROCESS: A REVIEW OF PAST SUBMISSIONS AND RECOMMENDATIONS FOR THE FUTURE Hellmund, C.
22 S3 p. S766
 artikel
1972 PNS227 THE NOT-NICE ACCESS PATHWAY: NHS ENGLAND SPECIALISED COMMISSIONING Roibu, C.
22 S3 p. S799
 artikel
1973 PNS88 THE "REHAB MAP” FOR INTERACTIVE PLANNING OF AMBULATORY REHABILITATION SERVICES Miksch, F.
22 S3 p. S777
 artikel
1974 PNS204 THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS Borchert, K.
22 S3 p. S795
 artikel
1975 PNS381 THE RISE OF THE SOCIAL MEDIA MACHINE: A REVIEW OF PATIENT-CENTERED RESEARCH UTILIZING SOCIAL MEDIA RESEARCH METHODS PRESENTED AT ISPOR (2010 -2018) Crawford, S.R.
22 S3 p. S829
 artikel
1976 PNS277 THE ROLE OF EARLY VALUE FRAMEWORK IN A SUCCESSFUL REIMBURSEMENT JOURNEY Tomaras, D.
22 S3 p. S809
 artikel
1977 PNS392 THE ROLE OF PATIENTS IN THE UPTAKE OF PHARMACEUTICAL PRODUCTS BY PATIENTS AS PERCEIVED BY PROFESSIONALS Fatoye, C.
22 S3 p. S831
 artikel
1978 PNS151 THE ROLE OF REGULATORY GUIDANCE AND INFORMATION DISSEMINATION FOR BIOSIMILAR MEDICINES - THE PERSPECTIVE OF HEALTHCARE PROFESSIONALS AND INDUSTRY Barbier, L.
22 S3 p. S786-S787
 artikel
1979 PNS263 THE ROLE OF SURROGATES FOR PATIENT-RELEVANT ENDPOINTS IN THE EARLY BENEFIT ASSESSMENT IN GERMANY Ring, C.
22 S3 p. S806-S807
 artikel
1980 PNS340 THE THEORY OF CONTRACTS AND WARRANTIES: IMPLICATIONS FOR OUTCOMES-BASED CONTRACTING Schneider, J.
22 S3 p. S822
 artikel
1981 PNS361 THE TSQM: 15 YEARS OF USE Gemmen, E.
22 S3 p. S825
 artikel
1982 PNS165 THE USE OF MANAGED ENTRY AGREEMENTS FOR ADVANCED THERAPIES IN EU5 Hanna, E.
22 S3 p. S789
 artikel
1983 PNS184 THE VALUE OF BLOOD IN SUB-SAHARAN AFRICA Magutu, V.
22 S3 p. S792
 artikel
1984 PNS228 TIME FOR REIMBURSEMENT AND PRICING FOR DRUGS DEPENDING ON THE EARLY ACCESS STATUS IN FRANCE (WITH OR WITHOUT ATU) Le Tohic, D.
22 S3 p. S799-S800
 artikel
1985 PNS14 TOWARDS CONSISTENCY AND COHERENCE IN UNDERSTANDING THE ECONOMIC IMPACT OF DISEASE Ng'ambi, P.G.
22 S3 p. S765
 artikel
1986 PNS42 TO WHAT EXTENT DOES SEEKING CLINICAL EXPERT OPINION FOR MODEL INPUTS REDUCE THE COST OF UNCERTAINTY? A CONCEPTUAL APPROACH USING EXPECTED VALUE OF PERFECT PARAMETER INFORMATION (EVPPI) van Hest, N.
22 S3 p. S769
 artikel
1987 PNS138 TRANSNATIONAL COLLABORATIONS AMONG DRUG REGULATORY AGENCIES: TRENDS AND FUTURE PERSPECTIVES Vladimirova, A.
22 S3 p. S785
 artikel
1988 PNS400 TREND IN STUDIES ON PATIENT REPORTED OUTCOMES Janodia, M.
22 S3 p. S833
 artikel
1989 PNS310 TRENDS IN CLINICAL TRIALS FOR DIGITAL HEALTH TECHNOLOGIES Orkisz, A.
22 S3 p. S816
 artikel
1990 PNS243 TRENDS IN DECISIONS BY THE SCOTTISH MEDICINES CONSORTIUM OVER THE PAST 10 YEARS - AN ANALYSIS OF KEY FACTORS DRIVING ACCEPTANCE Belsey, J.
22 S3 p. S802
 artikel
1991 PNS172 TRENDS IN PRESCRIPTION MONITORING PROGRAM PATIENT QUERIES AND DELEGATE ACCESS Fleming, M.
22 S3 p. S790
 artikel
1992 PNS366 UNDERSTANDING THE ROLE OF ANCHOR CORRELATIONS IN THE CALCULATION OF MEANINGFUL CHANGE THRESHOLDS FOR HEALTH-RELATED QUALITY OF LIFE RESEARCH Griffiths, P.
22 S3 p. S826
 artikel
1993 PNS183 UNIVERSAL HEALTH INSURANCE COVERAGE FOR CHILDREN UNDER AGE 6: FACTORS ASSOCIATED WITH THE USE OF PRIVATE OVER PUBLIC HEALTH SERVICES IN VIETNAM Nguyen, M.
22 S3 p. S792
 artikel
1994 PNS319 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF COST-EFFECTIVENESS MODELS Smela-Lipińska, B.
22 S3 p. S818
 artikel
1995 PNS306 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF RANDOMIZED CONTROLLED TRIALS Smela-Lipińska, B.
22 S3 p. S815
 artikel
1996 PNS203 USE OF DISCRETE CHOICE EXPERIMENTS TO INFORM HTA DECISION MAKING. Lenny, A.
22 S3 p. S795
 artikel
1997 PNS316 USE OF GENERALISED FLUCTUATION TEST TO OPTIMISE PIECEWISE FITTING IN IMMUNO-ONCOLOGY (IO) SURVIVAL MODELLING Jootun, M.
22 S3 p. S817
 artikel
1998 PNS417 USE OF INSULIN GLARGINE-300 AND INSULIN DEGLUDEC-100 IN TYPE 2 DIABETES: A COMPARATIVE ECONOMIC ANALYSIS IN THE ITALIAN CONTEXT BASED ON THE BRIGHT STUDY. Napoli, R.
22 S3 p. S836
 artikel
1999 PNS404 USING DATA WAREHOUSES TO OPTIMIZE HEALTHCARE DECISION MAKING Brodinova, S.
22 S3 p. S834
 artikel
2000 PNS335 USING MACHINE LEARNING FOR EFFICIENCY IMPROVEMENTS IN SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EFFICACY AND SAFETY Halfpenny, N.
22 S3 p. S821
 artikel
                             2413 gevonden resultaten
 
<< vorige    volgende >>
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland